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Abstract 
 
The high mutation rate of influenza virus results in antigenic drift, meaning that 
each of the three components in the trivalent influenza vaccine are updated 
regularly so that the vaccine antigen closely matches the predominant or 
emerging strain. The production of influenza vaccines from the chosen seed has 
relied on embryonated chickens eggs for more than 40 years. Recent 
technological advances have resulted in the evaluation of several cell lines as 
alternative substrates for influenza vaccine production. Reverse genetics of 
influenza viruses allows the creation of viruses at will from cDNA. However, 
licensed cell lines have so far proved unpermissive for virus rescue and 
permissive lines remain largely unlicensed. A reverse genetics system for the 
production of influenza vaccines in PER.C6 cells has been developed and 
optimised. Many recent clinical isolates do not grow in eggs and hence require 
reassortment with a high growth, egg permissive backbone. Adventitious 
agents aside, cell lines able to support growth of clinical isolates could be used 
directly included in the vaccine, without the need for reassortment. However, 
this could lead to year on year variation in the quality and characteristics of the 
vaccine. Particularly pertinent, is the variation in the amount of IFN a clinical 
isolate can induce, which could severely limit yields. Yields and effects of IFN 
for a panel of high and low inducing viruses are investigated in a number of 
potential vaccine cell lines. The mechanisms behind virus IFN induction have 
been investigated. Using a panel of high and low inducing viruses the 
differences in growth and viral protein expressions, and activation of PRR has 
been analysed. The IFN response in PER.C6 cells has been characterised. 
Through an improved understanding of the mechanisms of IFN induction and 
inhibition, antagonists could be introduced into the vaccine cell line to improve 
yields.  
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Chapter 1 Introduction 
1.1 General Introduction 
 
Influenza is a highly contagious, acute respiratory disease, which causes 
significant mortality and morbidity worldwide. According to the World Health 
Organisation (WHO) it causes between three and five million cases of severe 
illness and 250,000 to 500,000 deaths every year around the world 
(http://www.who.int/mediacentre/factsheets/fs211/en/). The elderly, young 
children and those with chronic medical disorders such as asthma, diabetes and 
the immune-compromised are most at risk. It has a range of symptoms 
including rhinitis, cough, weakness, febrile illness and headache. Most infections 
are self-limiting however, they can occasionally progress to pneumonia and 
rare complications include encephalopathy, myocarditis, and myositis. 
 
Influenza is caused by infection with a single stranded, negative sense, RNA 
virus with a segmented genome (figure 1.1.1). The virus encodes 12 known 
proteins, encoded on 8 segments. The viral envelope contains the 
glycoproteins haemagglutinin (HA) and neuraminidase (NA) and matrix 
protein (M2) in host derived lipids. This encloses a matrix of M1 protein, 
around the virion core containing nuclear export protein (NEP) and each of 
the 8 RNA segments. Each segment is coated with nucleoprotein (NP) and 
complexed with the RNA-dependent RNA polymerase (RdRp), composed of 
two polymerase basic and one polymerase acidic subunits (PB1, PB2, and PA), 
and is known as an RNP. NS1 and PB1-F2 are non-structural proteins that help 
the virus control the host cell immune responses and N40 is a recently 
described N terminal product of the PB1 open reading frame which affects 
replication (Wise, Foeglein et al. 2009). 
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Figure 1.1.1 Schematic of an influenza virion 
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HA mediates virus binding to the host cell receptor, sialic acid. The virus is 
internalised by receptor mediated endocytosis (Lakadamyali, Rust et al. 2004). 
Internalized viruses are trafficked along the endocytic pathway to late 
endosomes. Exposure to the low pH results in a conformational change in the 
HA which exposes the HA2 fusion peptide and triggers HA-mediated fusion 
between the viral and endosomal membranes (Skehel and Wiley 2000). M2 
forms an ion channel which results in the acidification of the virus interior, 
triggering disassembly of the core and release the vRNPs from the matrix 
proteins (reviewed in (Betakova 2007). vRNPs are imported into the nucleus 
via nuclear localisation signals which direct cellular proteins to import the RNPs 
and viral proteins into the host cell nucleus (Wu, Sun et al. 2007). 
 
RdRp synthesizes viral mRNA and cRNA (copy RNA) from the same vRNA 
(viral RNA) template (figure 1.1.2). The 3′ and 5′ non-coding regions are highly 
conserved among each of the segments and partially complementary 
(Desselberger, Racaniello et al. 1980). They base pair to form a helical hairpin 
panhandle (figure 1.1.3), with which the RdRp associates (Gonzalez and Ortin 
1999) The conserved non coding nucleotides function as the promoter (Luytjes 
et al. 1990). The replication of vRNA is primer-independent and is terminated 
by run-off transcription of the vRNA template to form a full-length cRNA, an 
exact positive sense copy of the genome, which acts as a template for the 
synthesis of subsequent vRNA. Initiation of viral mRNA synthesis requires 
capped RNA fragments derived from host mRNA. PA has endonuclease activity 
and “steals” or  “cap snatches” 5′ capped primers from cellular RNA 
polymerase II (Pol II) activity (Dias, Bouvier et al. 2009). PB2 subunit then 
binds the 5' cap and is responsible for the initiation of transcription (Guilligay, 
Tarendeau et al. 2008). PB1 subunit plays a central role in polymerase 
elongation (Biswas and Nayak 1994). The non-coding regions also include the 
mRNA polyadenylation signal and termination occurs following reiterative 
copying of a sequence of uridine residues to generate a poly(A) tail (Luo, 
Luytjes et al. 1991). 5′ capped, poly (A) mRNA can be exported and translated
22 
 
Figure 1.1.2 Schematic of influenza replication, depicting v, c and mRNA 
synthesis, and 3‟ and 5‟ non coding regions. 
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Figure 1.1.3 Schematic of influenza virus vRNP, depicting vRNA complexed 
with NP and RdRp (PB2, PB1 and PA).  
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like host mRNA. Nuclear export of vRNA segments is mediated by the viral 
proteins M1 and NEP via a CRM1-dependant pathway (Neumann, Hughes et 
al. 2000; Elton, Simpson-Holley et al. 2001; Watanabe, Takizawa et al. 2001). 
The mechanism controlling the synthesis of mRNA or cRNA from the same 
template has been long debated. Most recently Brownlee and co-workers have 
shown that both products are generated at the same time during infection but 
that cRNA is unstable in the absence of associating NP and polymerases and 
therefore only accumulates later in infection when intracellular viral protein 
levels are high (Vreede and Brownlee 2007). This hypothesis is in line with a 
much older theory that NP accumulation triggers the switch from transcription 
to replication (Beaton and Krug 1984).  
 
The envelope proteins HA, NA, and M2 accumulate at the cell membrane 
(Nayak, Hui et al. 2004). M1 is thought to chaperone the RNPs to the cell 
membrane for packaging, where it interacts with cytoplasmic tails of envelope 
proteins HA, NA and M2, leading to assembly and budding of virions (Chen, 
Leser et al. 2008; Nayak, Balogun et al. 2009). Virus budding may be initiated 
by the accumulation of M1 matrix protein at the cytoplasmic side of the lipid 
bilayer. The HA spikes continue to bind the virions to the sialic acid on the cell 
surface until virus particles are released by the sialidase activity of the NA 
protein (Barman, Adhikary et al. 2004).  
 
The incorporation of the eight segments that comprise the genome into virus 
particles has also long been a matter of debate. There is evidence for random 
packaging whereby virions could contain more than eight segments and a 
proportion would have the correct combination. However, recent elegant 
work from Kawaoka has shown both genetically and by electron microscopy 
that there are eight RNPs per virion because of the existence of segment 
specific packaging signals that extend across both non-coding and coding 
regions of each of the eight RNA segments (Fujii, Fujii et al. 2005; Noda, 
Sagara et al. 2006). Interestingly this knowledge may lead to new strategies to 
generate attenuated viruses suitable for vaccines (Gao, Brydon et al. 2008).  
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There are three serologically distinct types of the virus; A, B, and C- of which A 
and B cause widespread outbreaks. Influenza A virus causes most severe 
disease, whilst B causes significant epidemic outbreaks approximately every 
three years. Influenza A viruses are further classified into subtypes based on the 
surface glycoproteins; there are 16 haemagglutinin (HA) and 9 neuraminidase 
(NA) subtypes. Three subtypes are known to infect and transmit within the 
human population (H1N1, H2N2 and H3N2). Both, but particularly HA, are 
major antigenic determinants and antibodies directed against HA and NA, are 
crucial in current vaccine strategy.  
 
New strains appear from gradual accumulation of point mutations in the 
surface glycoproteins. This “antigenic drift” allows the virus to evade immune 
recognition and forms the basis for the seasonal epidemics which occur each 
year. Because influenza A is able to infect multiple organisms, occasionally a 
“new” virus emerges, which is unrelated to the circulating strains and arises not 
from mutation, but from reassortment between 2 different subtypes of the 
virus, one of which was previously circulating only in an animal reservoirs. This 
is called antigenic shift and can result in strains to which most adults do not 
have pre-existing immunity. Antigenic shift can lead to influenza pandemics 
such as the infamous 1918 “Spanish flu”- which killed 40 million, the Asian flu 
1957, and Hong Kong flu 1968, and recently the swine-origin 2009 H1N1 
pandemic. Despite the devastating effects of a pandemic, the cumulative deaths 
during intervening years have been far greater than those associated with 
pandemics. Influenza B virus infects only humans and therefore is only able to 
undergo antigenic drift. Although most influenza virus infections are self-
limiting, few other diseases have such an effect on absenteeism, hospital 
admission and economic loss. 
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1.2 Influenza Vaccines 
 
Vaccination is the primary measure available to control influenza. The most 
widely available vaccines are based on technology over 50 years old and give 
inadequate protection to the most in need- the young and the elderly. Current 
vaccine production could be considered somewhat archaic- involving 
manufacture in chicken‟s eggs. With the threat of highly pathogenic avian 
influenza (HPAI) gaining the ability to transmit between humans, the need to 
develop new vaccine strategies is essential. Vaccine manufacturers need to be 
able to respond quickly to new emerging strains, which will probably 
necessitate an egg free system such as cell culture. Depending on the viruses 
included in the vaccine and the method of vaccine generation, egg based 
production may in any case be inappropriate for avian virus based vaccines 
which could be pathogenic to eggs. New vaccines will need to be highly 
immunogenic and provide protection to all age groups. This may demand the 
addition of adjuvants, few of which are currently licensed. The first part of this 
introduction will discuss at the current state of influenza vaccination and new 
advances in the field. 
 
1.2.1 Antiviral drugs 
 
In the case of an influenza outbreak, there are two classes of antiviral drugs 
available. Amantadine and rimantadine (only effective against influenza A) 
block M2 ion channels, which regulate the internal pH of the virion and are 
crucial during early virus replication. Amantadine has several adverse side 
effects including insomnia, headaches and dizziness which can lead to falls 
especially in the elderly. Although rimantadine has fewer side effects, it is not 
widely available. Furthermore, viruses can rapidly acquire resistance to both 
these drugs through single non-synonymous nucleotide changes in the 
membrane spanning domain of M2.  
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The other antiviral agents available are NA inhibitors. These drugs are effective 
against both influenza A and B. Zanamivir (Relenza) is administered by 
inhalation (which is less desirable for elderly use but more convenient for 
children), and may cause bronchospasm. Oseltamivir (Tamiflu) is administered 
orally and can induce vomiting if not taken after food. These drugs can reduce 
infection on average between 0.8-1.3 days. Resistance can occur but seems to 
be strain and subtype specific (Meijer, Lackenby et al. 2009).  
 
The National institute for Clinical Excellence (NICE) has issued guidance on the 
use of antivirals; Amantadine is not recommended, whilst Zanamivir and 
Oseltamivir are not recommended in adults or children unless they are at risk, 
can start therapy within 48 hrs of the onset of symptoms, and it is known that 
influenza is circulating. There is clearly scope for improvement to available 
anti-influenza treatments, and effective vaccination should be both maintained 
and improved in order to deal with the threat of an avian pandemic and to 
alleviate morbidity in the interpandemic period. 
 
1.2.2 Current Vaccines 
 
1.2.2.1 Vaccine content 
 
The emergence of new strains by antigenic drift demands the annual 
reformulation of the vaccines. Retrospective analysis of variants from past 
major epidemics shows that typically only 3 or 4 mutations in HA molecule are 
all that is required for a new epidemic strain to emerge (Smith, Lapedes et al. 
2004). New variants are identified from epidemiological surveillance studies 
coordinated by WHO. A panel convenes in February in the northern 
hemisphere, September in the south, to predict the circulating strains likely to 
give most the most protection in the coming influenza season. Currently, two 
influenza A virus strains, representing both subtypes that currently circulate in 
humans (H1N1, H3N2) and one B strain are selected for inclusion in the 
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seasonal vaccine. Vaccine manufacturers then have approximately 6 months to 
produce and register the vaccine. Approximately 50 countries have 
government funded immunisation programmes (Nicholson, Wood et al. 2003) 
and approximately 350 million doses are available to some 1.2 billion people 
worldwide who are at risk  
(http://www.who.int/vaccine_research/diseases/ari/en/index.html).  
The industry is dominated by only a few manufacturing companies. In 2007, 
Sanofi Pasteur supplied 180 million doses of seasonal influenza vaccine, an 
estimated 40 percent of the world influenza vaccine market. 
 
Vaccination results in a 30% reduction of mortality among elderly persons 
during influenza epidemics (Groenwold, Hoes et al. 2009). Recommendations 
for vaccination vary; and tend to be founded on rates of morbidity and 
mortality. Therefore annual vaccination of at risk groups; the elderly, those 
with chronic medical disorders, asthma, diabetes, immune-suppressed and 
carers is generally recommended (Zimmerman and Middleton 2007). 
 
1.2.2.2 Inactivated vaccines 
 
The segmented nature of the influenza genome means a vaccine seed can be 
generated from the reassortment of the WT epidemic strain and a high yield, 
laboratory adapted strain such as A/Puerto Rico/8/34 (PR8). The reassortant 
generally contains the six internal genes from PR8 and the surface antigen 
genes, HA and NA, from the selected vaccine strains. PR8 has been used as the 
recipient genetic backbone of the influenza A virus vaccine for more than 30 
years (Kilbourne 1969). 
 
No such lab adapted high growth master strains exists for influenza B viruses 
and these viruses are simply strain selected each year. Often yields of influenza 
B virus are lower than for influenza A as a result. 
 
  
29 
 
Trivalent inactivated vaccine (TIV) is the oldest licensed vaccine, its 
effectiveness was first evaluated in 1938 (Francis 1953) and contains partially 
purified HA and NA, from formaldehyde or β-propiolactone inactivated 
virions, detergent treated to give a split product. It is administrated by 
intramuscular injection. When there is a good match between the selected 
vaccine strains and the circulating strains, the vaccine can confer up to 80% 
immunity in healthy adults less than 65 years of age (Nicholson, Wood et al. 
2003; Subbarao and Katz 2004) and is usually well tolerated with very few 
adverse side effects. Protection is largely mediated by induction of neutralising 
serum Ab against HA. Substantial but not complete protection is seen in the 
elderly population. In young, naïve children, multiple injections are required 
for high immunity. The split vaccines, delivered intramuscularly, are poor 
inducers of local IgA in respiratory secretions and of cell mediated immunity, 
important in protection against airborne pathogens and recovery respectively. 
 
1.2.2.3 Live attenuated vaccines 
 
Whole, live vaccine, administered intranasally is potentially a better alternative 
to the split, intramuscular vaccine, as it should induce superior immunity more 
analogous to a natural virus infection. To reduce virulence these vaccines are 
designed to have limited replication in the upper respiratory tract. As with TIV, 
a master backbone strain is generated. However, in the case of live attenuated 
influenza vaccine (LAIV) the backbone confers an attenuated phenotype from 
internal genes. Vaccines are made from 6:2 reassortants of attenuated 
backbone and circulating HA and NA. There have been several strategies used 
to attenuate the backbone strains (Reviewed in (Subbarao and Katz 2004)). 
 
Some non-human viruses are naturally attenuated in humans, for example, 
some avian viruses have restricted replication in primates and master backbone 
strains have been developed from these (Snyder, Clements et al. 1986). This 
overcomes the need for derivation or passage to attain attenuation. 
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A/Mallard/New York/6750/78 (H3N2) exhibited restricted replication in both 
nonhuman primates and human adults and was shown to be safe, genetically 
stable and immunogenic. However, in further clinical trials of vaccine strains 
based on avian master backbones possessed some residual virulence in infants 
and children, so use of host restricted attenuation has not been pursued 
(Steinhoff, Halsey et al. 1991). 
 
Another approach was to generate temperature sensitive (ts) viruses in 
presence of the mutagen 5-fluorouracil, which showed restricted growth at 
37°C (Mills, Chanock et al. 1971). They consequently have restricted replication 
in the lower respiratory tract of animals (37-38°C) but are able to replicate in 
the upper respiratory tract (32-33°C) and induce a humoral response that 
protects against lethal virus challenge in mice. Two master strains were 
developed but these proved genetically unstable and reverted to virulent 
phenotypes in clinical trials (Tolpin, Massicot et al. 1981). 
 
The last method involves adaptation of the virus for growth at sub-optimal 
temperatures resulting in decreased virulence. This strategy has been used 
independently by both American and Russian investigators, to generate highly 
stable master strains, which have proved good candidates for LAIV. 
 
In the US, A/Ann Arbor/6/60 (H2N2) and B/Ann Arbor/1/66 were used as 
master strains (Maassab 1967). Viruses were isolated on chick kidney cells and 
then adapted for growth at 25°C by 32 stepwise passages at successively lower 
temperatures. They replicate efficiently between 25°C and 33°C but not 37°C, 
thus they not only have a cold adapted (ca) but also a ts phenotype. In ferrets, 
there is no replication in the lungs and attenuation in the upper respiratory 
tract, with lower titres and decreased infection times compared to WT. A dose 
of 10
7
 TCID50 administered intranasally, is typically safe and immunogenic in all 
age groups. 
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In Russia, A/Leningrad/134/57 (H2N2) was passaged 20 times in eggs followed 
by a further 17 or 47 passages at reduced temperature 25-26°C (Ghendon, 
Klimov et al. 1981). The mutants again, are ts as well as ca, being unable to 
replicate in eggs at 37°C. A/Leningrad/134/17/57 is used in vaccines for adults, 
whilst A/Leningrad/134/47/57 is used for children 3-14 yrs, in a trivalent 
vaccine formation with B/USSR/60/69. 
 
US and Russian strains have similar rates of infectivity in humans (Nicholson, 
Tyrrell et al. 1987). The attenuating mutations (ca) are found mostly in NP and 
the polymerase subunits, PB1 PB2 and PA (Jin, Lu et al. 2003; Hoffmann, 
Mahmood et al. 2005; Chen, Aspelund et al. 2006) (see table 1.2.1). 
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Table 1.2.1 Attenuating mutation in cold adapted viruses. 
 
Adapted from (Subbarao and Katz 2004). For B/Ann Arbor/1/66 only cold adapting mutations are shown 
 
Gene Product A/Ann Arbor/6/60 A/Leningrad/137/57 B/ Ann Arbor/1/66 
 Amino acid   Amino acid    Amino acid   
 Residue WT Ca Residue WT Ca 17 Ca 47 Residue WT Ca 
PB2 265 N S 478 V L L 630 S R 
    490 S - R    
PB1 391 K E 265 L N N -   
 457 E D 317 M - I    
 581 E G 591 V I I    
 661 A T        
PA 613 K E 28 L P P 431 V M 
 715 L P 341 V L L 497 Y H 
NP 23 T N 341 I - I 114 V A 
 34 N G     410 P H 
        509 A T 
M1 -   15 I V V 159 H Q 
        183 M V 
M2 86 A S 86 A T T    
BM2 -   -    -   
NS1 153 A T -       
NS2 -   100 M I I    
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LAIVs have been in use in Russia >50 years. MedImmune Vaccines Inc licensed 
and marketed Flumist in US in 2002. There have been several evaluations of 
the efficacy of LAIV (Palker, Kiseleva et al. 2004; Huber and McCullers 2006; 
Belshe, Ambrose et al. 2008) and comparisons with inactivated vaccine. Serum 
antibody titres are generally lower and mucosal IgA elevated, although in some 
trials protection was conferred without detectable serum or nasal antibody 
implying a CTL response. Generally, trials indicate that in adults LAIV is as 
effective at eliciting a protective response as inactivated vaccine. In the elderly 
it can be less immunogenic, possibly due to the limited replication of the 
vaccine virus, which may be a result of higher levels of pre-existing antibodies 
to influenza (Powers, Fries et al. 1991). Conversely, in naïve children a 
substantial level of protection can be elicited after just one dose (Arvin and 
Greenberg 2006) and children experienced more than 50% fewer cases of 
influenza illness when vaccinated with LAIV compared to TIV (Ashkenazi, 
Vertruyen et al. 2006; Belshe, Edwards et al. 2007; Rhorer, Ambrose et al. 
2009). However in younger children 6–11 months, a small increase in the 
number of hospitalizations (1% increase) and wheezing (2.1%) were noted 
weeks to months after receiving the live vaccine. Although these are not 
thought to be related specifically to influenza or temporally related to LAIV, 
LAIV is not approved for use in children <2 years of age (Belshe, Ambrose et 
al. 2008).  
 
Since LAIV contains live virus there exists the possibility of reassortment with 
native virus to produce new strains with unpredictable traits. Reassortants from 
avirulent strains have previously been able to produce pathogenic strains 
(Scholtissek, Vallbracht et al. 1979). Concerns have also been raised about the 
potential for the virus to transmit from vaccinated to non-vaccinated 
individuals and contact with immune-suppressed individuals is not advised. A 
recent study investigated the duration and extent of virus shedding following 
vaccination (Block, Yogev et al. 2008) and concluded that the amount of 
shedding depended on the specific vaccine strains and the level of pre-existing 
immunity in vaccine recipients. However, transmission was possible particularly 
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from younger children (<9 years old). The findings support the Advisory 
Committee on Immunization Practices recommendation that LAIV recipients 
should avoid contact with severely immunosuppressed. Despite this, ferrets 
immune compromised by treatment with dexamethasone and cytarabine, 
elicited improved responses (Huber and McCullers 2006) and a study in HIV 
infected children showed equivalent responsiveness between groups with 
different immunological status (Levin, Song et al. 2008). Also to be considered 
are the benefits of herd immunity due to virus shedding and transmission, 
which could increase the benefits of LAIV. Due to higher acquisition costs, LAIV 
costs more per dose than TIV; however, as a result of increased protection and 
reduced burden of disease, LAIV vaccination of children results in a net saving 
(Luce, Nichol et al. 2008). 
 
1.2.3 The cell substrate 
 
Although the existing vaccines are comparatively successful in inducing immune 
responses, there is evidently scope for improvement. Importantly, dependence 
on eggs is a major limitation for current production procedure. It takes 
between 3 and 6 months to develop the vaccines in eggs and efficiency is low, 
requiring 1-2 eggs per dose of vaccine. Careful planning is needed each year to 
ensure millions of fertile, embryonated eggs are available for vaccine 
production, and this is often unable to take into account calls for increased 
production. Furthermore, diseases in laying flocks can affect availability and 
variation in the quality of the embryos can effect vaccine production. Some 
highly pathogenic avian influenza (HPAI) strains such as H5N1 are lethal to 
chicken embryos, and insufficient yields are obtained, making eggs an 
inadequate method for production of vaccines against these viruses. 
Furthermore, in the event of a pandemic many birds may be killed by the virus 
or culled to limit the spread. 
 
The SARS outbreak demonstrated that with increased air travel and 
globalisation, a pandemic could spread in weeks or days and highlights the 
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need for a system which can respond rapidly, should HPAI gain the ability for 
human-human transmission. Cell lines are the obvious alternative to egg based 
vaccine production. Cell cultures can be used to manufacture vaccine at any 
time of year, pertinent during the current H1N1 pandemic which emerged 
outside of the typical winter influenza season in the northern hemisphere. Since 
they are maintained in a strictly monitored and sterile environment, the risk of 
contamination, and thus bio burden and end toxin content, is greatly reduced. 
Consequently, the use of preservatives like thiomersal, which can cause 
potential side effects, can be decreased. Cell lines are strictly monitored by 
WHO, and licensed lines are free from contaminants. Moreover, cells can be 
grown in serum free media, eliminating the potential for allergic reaction to 
serum or chick embryo proteins. This is particularly relevant to whole, live 
vaccine production, which does not involve the complex purification process 
used for inactivated vaccine, and the virus is not purified away from cell 
proteins. Egg derived vaccines are contraindicated for those with egg allergies. 
 
Many recent clinical isolates, while becoming more adapted to the human host 
exhibit altered receptor binding characteristics compared to strains that 
circulated shortly after the emergence of the H3 or H1 subtype more than 40 
years ago (Medeiros, Escriou et al. 2001; Mochalova, Gambaryan et al. 2003; 
Thompson, Barclay et al. 2004). Since the receptor used for cell entry in eggs 
differs from that in the human respiratory tract, this has the consequence that 
fewer isolates are able to grow in eggs, and unless they acquire mutations in 
HA (Schild, Oxford et al. 1983). These can, confer changes to glycosylation 
patterns (Chen, Aspelund et al. 2008) and can give rise to mismatches in 
antigenicity between the egg grown human influenza strains and the circulating 
clinical virus (Mochalova, Gambaryan et al. 2003). 
 
Cell cultures are easy to handle and scale-up and readily adjust to market 
needs. However, licensed cell lines have largely proved unpermissive for 
production of high yield influenza virus product, and many permissive lines 
used in the laboratory are refractory to licensing.  
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The efficiency of a cell culture depends upon its ability to generate high yields, 
and requires a well-optimised purification process. In the case of LAIV the 
capacity of cell line to produce infectious particles is also very important.  
 
The most common cell lines used in the laboratory for the amplification and 
isolation of influenza viruses are Madin-Darby canine kidney (MDCK) or Vero 
(African Green Monkey Kidney). These are adherent cell lines and can be 
expanded for large scale manufacturing in a number of ways including fixed 
bed reactors, fluidised bed reactors and microcarrier culture.  
 
1.2.3.1 MDCK cells 
 
Although in most published comparisons fluid from embryonated eggs yields 
the highest virus titres (e.g. 3.9x10
9
  PFU/ml (Tree, Richardson et al. 2001), 
yields from MDCKs remain respectable ranging from 3 to 10 fold less (Tree, 
Richardson et al. 2001; Audsley and Tannock 2005). Often these comparisons 
are carried out using the laboratory strain PR8 which has been specifically 
adapted to be high yield in eggs. If a cell culture adapted backbone strain was 
generated, equivalent yields could conceivably be achieved. Indeed, MDCKs 
may well prove a better substrate for more recent clinical isolates which grow 
less well in eggs. MDCK derived split vaccines have been tested in clinical trials 
for efficacy. There were no statistical differences between the immunogenicity 
(e.g. HAI titres) and post immunisation symptoms between subjects who were 
immunised with either egg and cell derived vaccine (Halperin, Nestruck et al. 
1998). As mentioned above recent clinical isolates have a decreased tropism for 
egg propagation. In 2003/04 season the strain A/Fujian/411/02 was selected for 
inclusion in the trivalent vaccine. However, following generation of the 
vaccine seed the reassortant was unable to grow in eggs and an alternative had 
to be sought, resulting in delays to vaccine issue. Recent research shows that 
MDCK cells would have supported growth of the Fujian strain (Makizumi, 
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Kimachi et al. 2008). In terms of virus yield and vaccine efficacy, MDCKs pose 
a truly viable alternative to eggs. However, there are concerns about the safety 
of MDCKs due to the non-human origin, lack of documentation about their 
transformation history and oncogenic potential. The line has consequently 
been extensively characterised, shown to be free from detectable infectious 
agents (viral or microbial) and highly unlikely to induce tumours in humans 
(Kistner, Barrett et al. 1998; Genzel, Olmer et al. 2006). An assessment of the 
risk of inclusion of adventitious agents in the vaccine product demonstrated 
that MDCK cells are restricted in the number of mammalian viruses for which 
they support growth (Gregersen 2008), and testing by infection with >20 virus 
families and other pathogens, such as Mycoplasma and Chlamydia has shown 
the manufacturing process capable of reducing adventitious agents to non 
infectious level (Gregersen 2008).  As such, Novartis, Solvay, GlaxoSmithKline 
and MedImmune have all developed and characterised proprietary cell banks. 
Moreover, Novartis and Solvay have extensively tested and characterized their 
cell banks according to USA, EU and ICH requirements. These vaccines are not 
inferior to those generated in eggs and some have been taken to clinical trials 
and licensed. In 2001 Influvac-TC, Solvay Pharmaceuticals, was approved in the 
Netherlands; Novartis have developed an MDCK based vaccine that is now on 
the market (Gregersen 2008; Doroshenko and Halperin 2009). The high 
permissivity of MDCKs makes the cell line an attractive prospect for vaccine 
manufacture. However, MDCKs are difficult to transfect; as such, they are less 
expedient for the generation of reverse genetics vaccines (see section 1.2.4.1). 
They have also been evaluated for generation of reassortant vaccine seeds and 
fell short of the yields attained in eggs. MDCK cells have also been shown to 
support the growth of an efficacious LAIV (Ghendon, Markushin et al. 2005; 
Liu, Hossain et al. 2008), an inactivated H5N1 vaccine (Hu, Weng et al. 2008) 
and an equine vaccine (Genzel, Olmer et al. 2006). 
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1.2.3.2 Vero cells 
 
Vero cells are an African green monkey kidney cell line, which are already 
licensed for a range of other human vaccines including poliovirus, rabies and 
even an inactivated influenza vaccine from Baxter healthcare corp. The 
influenza vaccine generated in Vero cells is fully immunogenic (Youil, Su et al. 
2004; Audsley and Tannock 2005; Ghendon, Markushin et al. 2005). A 
whole, formalin and UV inactivated, H5N1 vaccine has been developed from 
wt virus, which has proved immunogenic in both mice and guinea pigs 
(Kistner, Howard et al. 2007; Howard, Kistner et al. 2008). In clinical trials 
(against A/Vietnam/1203/2004), a relatively high dose (7.5-15 µg) was able to 
induce neutralising and cross protecting antibodies to clades 1, 2 and 3 (Ehrlich, 
Muller et al. 2008). The addition of alum adjuvant did not induce a dose 
spearing effect. Generally, titres are at least a log lower than MDCKs, and 
maximum yields are achieved in 4 rather than 2 days. A key advantage in the 
use of Vero cells is their primate origin; since the cells are more human the 
number of cell line specific mutations are reduced (Romanova, Katinger et al. 
2003). Furthermore, glycosylation of HA has been implicated in the 
antigenicity and immunogenicity of viral glycoproteins (Skehel, Stevens et al. 
1984), and the infectivity of macrophages (Reading, Miller et al. 2000), this 
could be particularly relevant for LAIV and could decrease the efficacy of a 
vaccine. 
 
The UK government has a sleeping contract with Baxter (now active) for 72 
million doses of a whole, inactivated pandemic vaccine (Kistner, Howard et al. 
2007) which will be produced in Vero cells  
(http://www.parliament.uk/documents/upload/postpn331.pdf).  
 
An LAIV was developed that is attenuated by inclusion of a truncated NS-1. 
This vaccine is attenuated in most cell culture substrates via the induction of 
IFN-β (Steel, Lowen et al. 2009). However, since Vero cells are IFN 
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incompetent IFN response they would represent a suitable cell line for vaccines 
of this type. 
 
1.2.3.3 PER.C6 cells 
 
For commercial interest, a cell line to needs to be well characterised. 
Developed by the Dutch company Crucell N.V., PER.C6 cells are a recently 
derived cell line originating from the primary culture of foetal human 
retinoblasts immortalised with an E1A minigene from type 5 adenovirus. They 
can be grown in suspension, which eliminates the need for microcarriers, 
making scale-up easier than for adherent MDCK and Vero cells (Fallaux, Bout 
et al. 1998). PER.C6 cells support growth of a variety of influenza A and B 
strains and produce high titres (10
10
 TCID50/ml) of virus in 4 days, in roller 
bottles and bioreactors (Pau, Ophorst et al. 2001). Preliminary data, suggests 
that passage of virus could result in higher yields of HA antigen. PER.C6 cells 
are licensed for the use of a variety of vaccines and therapeutics, including a 
West Nile virus vaccine (Samina, Havenga et al. 2007), a rabies vaccine 
(Marissen, Kramer et al. 2005), recombinant adenovirus vectors for gene 
delivery (Subramanian, Kim et al. 2007), production of recombinant proteins 
such as an HIV-1 gag protein vaccine (Ledwith, Lanning et al. 2006) and 
neutralizing monoclonal antibodies, e.g. SARS-CoV (SARS-AB) (Havenga, 
Holterman et al. 2008). Sanofi Pasteur purchased an exclusive license from 
Crucell N.V. in 2003 to research, develop, manufacture and market cell-based 
human influenza vaccines using PER.C6 cell line. Crucell retains the commercial 
rights for human vaccines in Japan and pandemic vaccine.  
 
1.2.3.4 PBS-1 
 
A recently developed cell line derived from 11 day old immortalized chick 
embryo cell line, termed PBS-1, is especially novel because it can support the 
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replication of influenza in the absence of exogenous trypsin. PBS-1 cells support 
the growth of recent isolates of human influenza A and B viruses as well as 
avian viruses to high titres (up to 10
7.5
 PFU/ml). The authors claim that PBS-1 
cells outperformed other licensed cell lines: CEK cells, MDCK cells and Vero 
(Smith, Colvin et al. 2008). PBS-1 cells are free of exogenous agents, are non-
tumorigenic, and are readily adaptable to a variety of culture conditions, 
including growth on microcarrier beads. 
 
1.2.4 Vaccine content 
 
1.2.4.1 The use of reverse genetics to generate the vaccine seed 
 
The strains of virus used in the vaccine are updated every year. High growth 
6:2 reassortants with the backbone strain need to be generated and selected. 
The process can be time consuming and unpredictable. In 1990 a technique to 
generate designer influenza viruses was developed. At this time, the „reverse 
genetic‟ technique used helper viruses and exchanged synthetic segments 
derived from cDNAs one at a time into the influenza genome. RNA was 
transcribed in vitro from cDNA and contained RNP proteins purified from virus 
particles. The reconstituted RNPs were transfected into cells simultaneously 
infected with „helper‟ virus. Reassortants containing the novel segment were 
then selected from the progeny which also contained abundant titres of helper 
virus progeny. Even with the use of tight selection markers such as antigenic 
differences or ts/ca mutations, the technique was laborious. Still, some 
candidate vaccines were generated using this technique (Li et al 1997). 
 
Two laboratories independently came up with a procedure to “rescue” whole 
virus genomes entirely from viral cDNAs (Fodor, Devenish et al. 1999; 
Neumann, Watanabe et al. 1999). Cells are co-transfected with 8 plasmids 
encoding each of the viral genomic RNAs and 4 helper plasmids directing 
expression of viral mRNAs (fig 1.2.1). The 8 viral RNAs are under the control 
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of an RNA polymerase I (pol I) promoter; a hepatitis delta virus (HDV) 
genomic ribozyme or a polymerase terminator, downstream of the vRNA-
coding region ensures that RNA is processed correctly from 3' end of the 
vRNA. The helper plasmids typically express proteins from a viral promoter 
such as that of CMV, which directs transcription by the host pol II apparatus, a 
poly A tail is added via a 3‟ polyadenylation site. The helper plasmids encode 
the three subunits of the viral RNA-dependent RNA polymerase complex (PB1, 
PB2, and PA) and the nucleoprotein (NP), and compromise the minimal set of 
viral proteins required for encapsidation, transcription and replication of the 
viral genome (Parvin, Palese et al. 1989). More recently, an 8 plasmid 
expression system was developed. The cDNA of each of the 8 influenza virus 
segments was inserted between the pol I promoter and the pol I terminator. 
The pol I transcription unit is flanked by the pol II promoter of the human 
cytomegalovirus and the polyadenylation signal of the gene encoding bovine 
growth hormone. After transfection of the eight expression plasmids, two types 
of molecules are synthesized. From the human pol I promoter, negative-sense 
vRNA is synthesized by cellular pol I. The synthesized vRNA contains the 
noncoding regions (NCR) at the 5' and 3' ends. Transcription by pol II yields 
mRNAs with 5' cap structures and 3' poly (A) tails; these mRNAs are translated 
into viral proteins. The ATG of the viral cDNA is the first ATG downstream of 
the pol II transcription start site. The orientation of the two transcription units 
allows the synthesis of both negative-sense viral RNA and positive-sense mRNA 
from one viral cDNA template (Hoffmann, Krauss et al. 2002). More recently 
still all the viral cDNAs have been combined onto a single plasmid for ease of 
transfection (Neumann, Fujii et al. 2005). The efficiency of recovery of virus 
may be enhanced by reducing the number of plasmids required for the 
transfection.  
 
Due to the species specificity of the pol I promoter the earliest reverse genetics 
systems were ineffective in MDCK cells. Two labs cloned the canine RNA 
polymerase I (pol I) promoter from MDCK cells and exchanged the promoter 
regions of the respective reverse genetics systems; a human pol I promoter in a  
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Figure 1.2.1 Schematic of reverse genetics systems. 
 
There are several reverse genetics systems available. Plasmids from each system 
are transfected into cells and virus recovered. 
 
In the 12 plasmid system 8 plasmids encode each of the viral genomic RNAs 
and 4 helper plasmids directing expression of viral mRNAs of the minimal set 
of virus proteins required to drive virus replication (PB2, PB1, PA and NP). The 
viral RNAs are under the control of an RNA polymerase I (pol I) promoter; a 
hepatitis delta virus (HDV) genomic ribozyme or a polymerase terminator, 
downstream of the vRNA-coding region ensures that RNA is processed 
correctly from 3' end of the vRNA. The helper plasmids typically express 
proteins from a viral promoter such as that of CMV, which directs transcription 
by the host pol II apparatus. A poly A tail is added via a 3‟ polyadenylation 
site. This system has been adapted for use in both human and canine cells 
(MDCK) by using a species specific pol I promoters. 
 
The 10 plasmid system (described in chapter 3) encodes the helper plasmids on 
just two plasmids, one carrying PB1 and PB2 separated by an internal 
ribosomal entry site (IRES) sequence of EMCV (Clontech) and another carrying 
NP and PA also separated by an IRES sequence. These double constructs are 
cloned between a CMV promoter and BGH polyadenylation site. The vRNA 
plasmids are of a similar design to the 12 plasmid rescue system. 
 
The T7 system directs vRNA transcription from a T7 promoter. The T7 RNA 
polymerase is co-transfected with 8 vRNA plasmids. 
 
The 8 plasmid system is bidirectional, the human pol I promoter, synthesizes 
vRNA. Proteins are expressed from a pol II promoter. 
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Figure 1.2.1 Schematic of reverse genetics.  
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cold adapted backbone (Wang and Duke 2007) or the chicken pol I promoter 
in a PR8 backbone (Murakami, Horimoto et al. 2008). Thus, providing MDCK 
cells can be transfected efficiently, they can be used to generate the vaccine 
seed, and represent a single cell suitable for all stages of vaccine manufacture. 
Both these labs report rescue titres in the range of 10
6
 PFU/ml, equivalent to 
titres achieved by co-culture with 293T cells. 
 
An alternative reverse genetics system based on the T7 promoter rather than 
pol I has also been described (de Wit, Spronken et al. 2007). The vector 
contains the T7 RNA polymerase promoter, hepatitis delta virus ribozyme 
sequence and T7 RNA polymerase terminator sequence. The system is not 
species specific since the T7 RNA polymerase is provided in the form of 
plasmid DNA that is co-transfected with the vRNA and has been used in cell 
lines from a variety of species including 293T, MDCK and QT6 cells. vRNA is 
transcribed from the T7 promoter in a negative-sense orientation and efficiency 
is improved when a T7 RNA polymerase with the inclusion of a nuclear-
localization signal was used. 
 
1.2.4.2 Novel reverse genetics strategies 
 
Reverse genetics not only permits the generation of 6:2 reassortants but also 
has the potential for easy genetic modification of viruses. Individual segments 
can be manipulated to investigate the role of viral proteins on replication and 
dissemination, to generate higher growth, higher yielding viruses or perhaps 
viruses more immunogenic to humans, all of which have scope for improving 
vaccine production and efficacy. It also makes possible the generation of safer 
vaccine strains from HPAI strains by removing known pathogenicity 
determinants by genetic engineering. For example, the replication cycle of the 
virus requires cleavage of HA by host proteases to activate fusion and infect 
cells. Natural cleavage of the HA protein is performed by the trypsin-like 
enzyme Clara tryptase which is secreted from the Clara cells of the respiratory 
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tract. This restricts virus replication to sites in the host where such enzymes are 
found. HPAI viruses possess multiple, basic amino acids (arginine and lysine) at 
their cleavage sites and these are cleavable by a ubiquitous protease, furin (fig 
1.2.2) These viruses are thus able to replicate throughout the host, damaging 
vital organs and tissues causing more severe disease and death. These highly 
pathogenic HA are unsuitable for inclusion in a vaccine strain since they may 
confer pathogenicity to the backbone strain and pose the risk of recombination 
with other circulating human strains. For H5 and H7 vaccines, designed to 
protect against HPAI, viruses bearing HAs with the multibasic site deleted have 
been constructed (Stieneke-Grober, Vey et al. 1992; Li, Liu et al. 1999; 
Subbarao, Chen et al. 2003; Subbarao, Chen et al. 2003; Horimoto, Takada et 
al. 2006; Whiteley, Major et al. 2007). 
 
A whole, live HA attenuated vaccine has been designed in which the HA 
cleavage site has been modified to be dependent on elastase for cleavage 
(Stech, Garn et al. 2005). The virus is a conditional mutant, attenuated in vivo 
where elastase like enzymes are not present naturally, but able to grow as well 
as wild type in vitro, in the presence of exogenous elastase. This means an 
epidemic strain can be converted to a live attenuated vaccine. The chief 
difference between this live attenuated vaccine strategy and the cold adapted 
strains is the self-limiting replication. Ca virus can cause shedding up to 11 days 
pi which increases the probability of reversion and recombination.  
 
Initial elastase dependant mutants were made in a lab-adapted virus, 
A/WSN/33 (WSN). Replication was restricted to very few cycles and there 
were no revertants after five passages. Inactivation of elastase dependant 
mutants (WSN-E) with formalin abrogated the ability of the vaccine to protect 
against a wt challenge, so minimal replication of the WSN-E mutant is essential 
for protection. One intranasal dose was sufficient to generate HA inhibiting 
titres, serum IgG and mucosal IgA. However a high dose of WSN-E (10
6
 PFU) is 
required to protect against challenge.  
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Figure 1.2.2 Schematic of multibasic cleavage. 
 
High pathogenic avian influenza (HPAI) viruses possess multiple, basic amino 
acids (arginine and lysine) at their cleavage sites and these are cleavable by a 
ubiquitous protease, furin. 
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Reverse genetics has also been used to develop an attenuated virus which 
could serve as a LAIV against classical swine influenza virus (SIV) (Masic, Babiuk 
et al. 2009). The HA cleavage site was mutated from arginine to valine at 
amino acid 345, which like the WSN-E mutant removes sensitivity to trypsin 
cleavage but retains elastase sensitivity. The resultant virus was attenuated in 
both mice and swine. 
 
Reverse genetics has been used to assess growth determinants of the PR8 
backbone in eggs compared to MDCK cell culture (Murakami, Horimoto et al. 
2008). There are several different strains of PR8 maintained in laboratories 
across the world. Certain strains contain amino acids which confer higher 
growth characteristics in MDCKs which could be important if this cell line were 
used for the manufacture of vaccines. Two amino acid positions were found to 
be important for the MDCK high yield phenotype, S360 on PB2 and E55 on 
NS1. Only the PR8 (Cambridge) strain possesses S360 in PB2, all the others 
strains possess Y360. E55 NS1 is expressed in several strains and seems to confer 
improved IFN antagonism.  
 
1.2.4.3 Baculovirus expression systems 
 
Cell culture has been used for the production of whole virus, with similar 
inactivation and downstream processing steps, effectively replacing eggs 
directly with cell culture; however, this still requires generation of high yield re-
assorted virus. Novel approaches to vaccine manufacture, presentation and 
delivery are also being developed. Recombinant protein technology, the 
cloning of virus subunits into DNA vectors, enables the production of pure 
viral antigens such as HA and NA, in cell culture, as the  active ingredient in 
vaccine (Wang, Holtz et al. 2006). Recombinant DNA vaccines have been 
shown to be highly effective inducers of both humoral and cellular immunity, 
most notably in the development of HIV vaccines (Barouch, Santra et al. 2000; 
Barouch, Santra et al. 2001). Several have been tested in clinical trials, and 
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indications are that they are safe to use, immunogenic and may confer more 
cross-reactivity than inactivated viruses.  
 
Indeed a plethora of biotech companies have been investing in developing 
different cell lines, vectors, influenza strains and fusion proteins (Crawford, 
Wilkinson et al. 1999; Treanor, Wilkinson et al. 2001; de Wit, Munster et al. 
2005; Wang, Holtz et al. 2006; Huber and McCullers 2008; Huber, Thomas et 
al. 2009). The protein-based approach represents a safe alternative to egg-
based technology for pandemic vaccines; since it uses HA proteins as antigens, 
it does not require the large-scale production of potentially dangerous live 
virus. Purification is rapid- fermentation to 95% purity can be achieved in 6 
hrs, with a yield of 57% (Wang, Holtz et al. 2006). Following the H5 
influenza outbreak in Hong Kong in 1997, a vaccine based on a recombinant 
baculovirus, was prepared 4 months after isolation of etiological virus and was 
ready for trial before any other vaccine candidates (Treanor, Wilkinson et al. 
2001).  
 
Baculovirus DNA vectors have been applied to the development of influenza 
vaccines production and have been particularly employed in development of 
HPAI H5 vaccines. They can also be fused with other proteins with adjuvant or 
immune stimulatory effects. 
 
A trivalent epidemic vaccine of full length, recombinant HA (rHA) H1N1, 
H3N2 and a flu B, marketed as FluBlØk has been developed by Protein 
Sciences Corp and UMN Pharma Inc (Huber and McCullers 2008). It has been 
developed in a high-yield SF9-derived insect cell line, expresSF+, in serum-free 
conditions (McPherson 2008). FluBlØk has recently been through phase III 
clinical trials which are awaiting publication. Phase II clinical trials showed that 
although high concentrations of protein were required (45 µg) to induce serum 
antibody response, even higher doses were well tolerated and were more 
immunogenic than the H3 component of an inactivated TIV, 15 µg Fluzone 
(Sanofi Pasteur) (Treanor, Schiff et al. 2006). 
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Chickens were effectively protected against H5N1 (Crawford, Wilkinson et al. 
1999) and mice against H7N7 (de Wit, Munster et al. 2005) following 
inoculation with rHA vaccines, and these to some extent also conferred 
heterosubtypic immunity. The main drawback to rHA is the high doses 
required to induce neutralising antibody (two 90 µg doses) and indeed thus far 
have proved less immunogenic than conventional virus based vaccines 
(Treanor, Wilkinson et al. 2001). 
 
This has partly been explained by the conformation of the recombinant HA 
(rHA). HAs derived from insect cells are monomeric, whereas they naturally 
exists as trimers. Development of a trimeric and oligomeric HA has improved 
the immunogenicity (Wei, Xu et al. 2008). 
 
A vaccine strategy combining rHA with LAIV, in a prime-boost approach shows 
promise for wide cross protection (Huber, Thomas et al. 2009). Priming with 
rHA followed by an LAIV boost, strengthened and broadened the antibody 
response, such that it elicited immunity against multiple strains within the H3 
subtype. Although not a universal vaccine, since protection is limited to 
circulating viruses within a two-decade period, full protection within a subtype 
may be possible with the inclusion of multiple HAs from current and predicted 
future influenza strains. 
 
rHA can be stored in PBS without the need for preservatives such as thiomersal 
(a mercury derivative which is required in egg-based vaccines), or antibiotics. 
The vaccine contains no live virus, and so does not require any 
biocontainment, nor chemical inactivating treatments, and could be the reason 
for decrease in observed in side effects compared with licensed vaccines (Wang, 
Holtz et al. 2006). If the problems with immunogenicity can be resolved, 
perhaps by delivery with adjuvants, this vaccine strategy could be a reliable, 
affordable and effective alternative.  
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1.2.4.4 Recombinant viruses 
 
A number of other recombinant viruses have been used to direct expression of 
HA and generate live attenuated vaccines for influenza.  
 
Parainfluenza 5 (PIV5) (formerly SV5) infects humans but is not associated with 
any known human illness. The HA gene from A/Udorn/72 (H3N2) was 
inserted into the PIV5 genome, as an extra gene between the haemagglutinin-
neuraminidase (HN) gene and the large (L) polymerase gene. Infection with 
this recombinant was able to protect mice against infection with WSN-H3, a 
7:1 reassortant virus containing all of the genome segments from A/WSN/33 
virus except the HA from A/Udorn/72 (Tompkins, Lin et al. 2007). Vesicular 
stomatitis virus (VSV) expressing H5 has been used as an experimental vaccine 
vectors (Schwartz, Buonocore et al. 2007). A recombinant fowlpox virus co-
expressing HA and NA (H5N1) genes was evaluated for its ability to protect 
chickens against intramuscular challenge with a lethal dose of HPAI (Qiao, Yu 
et al. 2003). 
 
An adenovirus vector with E1/E3 deletion, expressing the HA gene from 
A/Vietnam/1203/2004, protected mice and chickens from wt H5N1 with broad 
and potent HA specific humoral and cellular immune response (Gao, Soloff et 
al. 2006),  and pigs were protected from swine influenza virus by 
immunisation with an adenovirus H3N2 (Wesley, Tang et al. 2004). Studies in 
pigs and mice reveal adenovirus vaccines can afford cross protection in the 
absence of neutralising humoral immunity. Phase 1 clinical trials indicate 
Adenovirus vaccines to be safe (Van Kampen, Shi et al. 2005).  
 
An important consideration for the use of vector based vaccines is vector-
specific immunity, which could reduce the overall efficiency of a vaccine and 
poses a major drawback for the use of vectors in vaccination. However, in 
spite of the presence of pre-existing anti-adenovirus antibodies, these vaccines 
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have still proved efficient, suggesting vector directed immunity can be 
overcome. Should vector immunity become an issue, a wide range of human 
and simian adenovirus serotypes are being developed as alternative vectors 
(Bangari and Mittal 2006). 
 
1.2.4.5 Influenza M2 protein 
 
Since the origin of the next human pandemic is impossible to predict, the holy 
grail of the vaccine industry would be to produce a universal vaccine which 
cross-protects against all strains of influenza (Kaiser 2006; Hellemans 2008). 
The vaccines discussed above, still require sufficient homology between 
circulating and selected strains to give adequate protection. In 2003-4 season 
the vaccine strain A/Panama/2007/99 did not match circulating strain 
A/Fujian/411/2002, and vaccine protection was decreased by 50% (De Filette, 
Min Jou et al. 2005). 
 
HA and NA are highly immunogenic, but antigen drift means new epidemic 
strains arise every 1-2 years and any HA based vaccine will need to be updated 
in response. An ideal vaccine candidate is one which gives full heterosubtypic 
protection between strains of influenza. The membrane protein, M2, is an 
integral membrane protein like HA and NA but is much smaller- only 97 amino 
acids. The M2 extracellular domain (M2e) is extremely highly conserved 
among human viruses, although there is more variation among the avian 
strains sequenced (Buckler-White, Naeve et al. 1986; Obenauer, Denson et al. 
2006). Amino acid changes have been recorded in only two human influenza 
viruses sequenced since the first virus sequence in 1933 (A/WSN/33- H1N1)- 1 
amino acid in PR8, 2 amino acids in A/Fort Monmouth/1/47 (Lamb and Lai 
1981). Segment 7 encodes for both M1 and M2. Since M2 shares its first 9 
amino acids directly with M1, and the next 15 in a different reading frame, this 
could constrain possible mutations and maintain conservation. M2 tetramers 
are present in low abundance on the virus particle and since it has a small 
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external domain may be shielded from interaction with antibodies and effector 
cells (Black, Rota et al. 1993). 
 
The most prominent M2 vaccine is a recombinant vaccine derived from M2e 
fusion to hepatitis B core protein (M2eHBc) designed by Walter Fiers at Ghent 
University, Belgium (Neirynck, Deroo et al. 1999) which has recently been 
tested in phase I clinical trials as ACAM-FLU-ATM, in collaboration with 
Acambis, Cambridge, although the results are yet to be published. The authors 
claim it is highly immunogenic and provides protection against a potentially 
lethal virus challenge in mice (Neirynck, Deroo et al. 1999), especially in the 
presence of adjuvants and confers full protection when administered 
parenterally or intranasally (De Filette, Min Jou et al. 2005). The mechanism 
of protection from M2e vaccines is still unclear, but since protective immunity 
is transferred in serum it suggests that the humoral response confers protection 
(Neirynck, Deroo et al. 1999).  
 
However, despite the apparent success of M2e vaccines in mice there has been 
limited evidence of testing in other animal models. An M2eHBc vaccine was 
tested in pigs. Surprisingly no protection was conferred when challenged with 
classical swine influenza virus (Heinen, de Boer-Luijtze et al. 2001; Heinen, 
Rijsewijk et al. 2002). Clinical signs and virus excretion were not reduced in 
vaccinated group compared to the control and vaccinated pigs showed more 
severe clinical signs, suggesting that M2e antibodies may exacerbate disease. 
Side by side testing of two M2 vaccine in mice provided equivalent protection 
(Fan, Liang et al. 2004), however differences in the level of protection were 
seen in rhesus monkeys (Fu, Grimm et al. 2009). Pigs are a natural reservoir for 
influenza and the pathology of disease in pigs and monkeys is more similar to 
humans than the pathology in mice. This highlights the need for stringent 
analysis and the use of adequate controls in assessing vaccine efficacy.  
 
The M2e is currently well conserved in human influenza however this could be 
partly due to a poor M2e-specific Ab response and thus the absence of pressure 
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for change. Evolutionary pressure from vaccination against could induce 
mutations, rendering the vaccine ineffective. SCID mice were infected in the 
presence or absence of passive M2e-specific monoclonal antibodies (mAbs) 
(Zharikova, Mozdzanowska et al. 2005). Escape mutants emerged following 
weekly treatment with M2e mAbs, suggesting that M2e may not prove to be 
the universal vaccine its creator‟s desire. 
 
1.2.5 Adjuvants 
 
Intramuscular injection of inactivated vaccine does not elicit a strong immune 
response and nasopharyngeal administration of soluble antigen to mucosal 
surfaces is inefficient. Vaccination often result in a poor response in those with 
poor susceptibility, particularly the elderly who have had been repeatedly 
infected or vaccinated with influenza. The decline of the immune system 
related to impaired immunity in elderly is a growing problem with the global 
rise in the ageing population. Early  H5N1 vaccine  trials required 2 high doses 
(95 µg compared to 15 µg of annual trivalent vaccines to elicit an adequate 
serum antibody response (Treanor, Campbell et al. 2006). This could in part 
be due to immunological naivety of humans to avian subtypes of influenza. 
The newer generation of vaccines such as recombinant proteins and synthetic 
peptides, yield purer products which although considered safer, often prove 
less immunogenic. Unsurprisingly, attention has focused on ways to improve 
the immunogenicity and enhance the immune response to these vaccines. In 
the event of a pandemic, large quantities of vaccine need to be made available, 
and dose-sparing measures will greatly facilitate vaccine distribution 
(Radosevic, Rodriguez et al. 2008). Recent developments involving the use of 
adjuvants has generated increased confidence in the ability to vaccinate against 
pandemic influenza.  
 
Adjuvants have an important role to play in the efficacy of vaccines. Many 
substances have adjuvant properties, although their mechanisms of action are 
often still unknown and most are unlicensed due to their potential toxicity and 
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side effects. The type of adjuvant employed depends upon a number of factors 
ranging from the target species, type of antigen presented, route of 
inoculation, and type and duration of immune response required. Hence, there 
is currently no “universal” adjuvant, able to fulfil all requirements. 
 
1.2.5.1 Aluminium hydroxide 
 
Aluminium hydroxide generically called alum, was first described as an 
adjuvant 1926 by Glenny et al (as cited in (Singh, Ugozzoli et al. 2006). 
Aluminium hydroxide and aluminium phosphate have since been used as the 
preferred adjuvant in a number of human vaccines, although this tendency is 
perhaps more a result of its long-standing history, than its suitability. Alum is a 
good adjuvant for bacterial toxins e.g. diphtheria and tetanus, but has had 
limited success with newer vaccine antigens. It stimulates IgE, a Th2 dependant 
response and is a poor inducer of Th1, MHC class 1 restricted, cellular immune 
responses, in influenza vaccination this corresponds to high IgG1 levels and a 
low number of IFN-γ producing T cells. Th1 responses are favourable for most 
infectious diseases (e.g. TB, HIV, HCV and influenza) which benefit from IL-2 
induction and antiviral IFN activity. Mice vaccinated with inactivated vaccine 
plus alum adjuvant had higher antibody titres than unadjuvanted vaccinated 
mice. However, they suffered more severe weight loss and had significantly 
higher virus loads in their lung tissue than mice receiving TIV alone (Bungener, 
Geeraedts et al. 2008). The major difference between these groups of mice was 
the type of immune response induced, Th2 instead of Th1, indicating that a Th1 
response plays a major role in viral clearance. Alum adjuvants are therefore not 
well suited to the new generation of influenza vaccines, and yet they continue 
to be used (e.g. (Ehrlich, Muller et al. 2008; Nolan, Richmond et al. 2008; 
Cox, Madhun et al. 2009). 
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1.2.5.2 MF59 
 
Emulsions have proved highly effective adjuvants however many are not well 
tolerated. A proprietary squalene based oil in water emulsion adjuvant MF59 
(4.3% squalene, 0.5% tween, 0.5% span 85), has been developed by Novartis 
(Podda 2001). MF59 has been licensed for use in an influenza vaccine, FLUAD 
(Novartis), in 20 countries. In clinical trials it has been shown to be safe and 
tolerable, and stimulates both humoral and cellular immune responses (Gupta 
and Siber 1995). The systemic reaction between adjuvanted and non 
adjuvanted vaccines were similar, there were reports of pain, erythema and 
induration, at site of injection but these were short lived and self limiting and 
in most cases described as mild.  
 
Trials comparing adjuvanted and non-adjuvanted licensed vaccines found both 
vaccines to be effective. In one trial (Frey, Poland et al. 2003) the adjuvanted 
vaccine gave rise to a fourfold increase in haemagglutination titres against the 
influenza B antigen component of the vaccine after 28 days and a fourfold 
increase in the H3N2 component titres 28 days after the second dose, although 
this effect was minimal after 180 days. Importantly the adjuvanted vaccine was 
more immunogenic in elderly recipients (≤75 years of age (Squarcione, Sgricia 
et al. 2003) (<64 years of age (Puig-Barbera, Diez-Domingo et al. 2004). 
 
As mentioned previously avian viruses are poor immunogens in humans 
(Nicholson, Colegate et al. 2001) and have even proved poor in vaccination of 
poultry (Stephenson, Nicholson et al. 2003). Antibody responses in a number 
of cases to vaccines containing avian derived HA have been low. As an 
example, responses to A/Duck/Singapore (H5N3) were poor, even with two 
30 µg HA doses; but when adjuvanted with MF59, two 7.5 µg doses were 
sufficient to give levels of antibody associated with protection. In further trials 
in humans (Stephenson, Bugarini et al. 2005), adjuvanted A/Duck/Singapore 
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(H5N3) induced antibodies against H5N1 viruses, having significant 
implications for potential avian influenza outbreaks.  
 
Addition of MF59 to a subunit H5N1 vaccine A/Vietnam/1203/2004(H5N1) 
was  able to significantly reduce the dose required, 15 µg of adjuvanted vaccine 
elicited a better response than 45 µg vaccine alone (Bernstein, Edwards et al. 
2008). Two 7.5 µg doses of a subunit H5N1 vaccine (A/Vietnam/1194/2004) 
(clade 1) elicited high antibody titres and induced heterologous Abs to a clade 
2 virus, H5N1/turkey/Turkey/05 (Banzhoff, Gasparini et al. 2009). This 
response is sustained, priming subjects with MF59-adjuvanted H5 vaccine 
induces cross reactive B-cell memory responses that can be rapidly mobilized 
many years later by a single booster dose (Galli, Hancock et al. 2009). The 
data is encouraging for the priming strategy currently being considered by the 
WHO, which have previously been dismissed due to the lack of cross-reactivity 
of antibodies. 
 
Use of MF59 is not limited to H5N1; it has also been shown to improve 
antigenicity of an H9N2 vaccine (Radosevic, Rodriguez et al. 2008). Much 
publicity surrounds the pandemic potential of H5N1, yet other influenza 
viruses circulate in bird or swine populations have equal potential for zoonosis 
as recently seen with pandemic H1N1 2009. 
 
Senescence of the immune system means the ability to mount novel immune 
responses may be compromised in the elderly who often don‟t respond well to 
vaccination (Puig-Barbera, Diez-Domingo et al. 2004). The ability of MF59 to 
improve the immune responses of the elderly has also been widely tested (de 
Bruijn, Meyer et al. 2007). The addition of MF59 increased the 
immunogenicity of the influenza vaccines in the elderly but was particularly 
pronounced in those with low pre-vaccination titres, who are at greatest risk of 
developing severe influenza disease and vaccine failure (De Donato, Granoff et 
al. 1999; Banzhoff, Nacci et al. 2003). Systemic reactions were more common 
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in those receiving the adjuvanted vaccine, however, these were predominantly 
mild and transient, and none were serious. 
 
MF59 adjuvanted vaccine (FLUAD, Novartis) also exhibited better 
immunogenicity in HIV patients than non adjuvanted vaccine (Agrippal, 
Novartis) in an analysis that compared the geometric mean antibody titres 
(Durando, Fenoglio et al. 2008). 
 
1.2.5.3 AS03 
 
GSK has also produced a proprietary oil in water emulsion adjuvant (5% DL-α-
tocopherol and squalene, 2% Tween 80 in the aqueous phase) as an antigen-
sparing strategy (Leroux-Roels, Borkowski et al. 2007). Two doses of an 
inactivated split NIBRG-14 (A/Vietnam/1194/2004) vaccine were well tolerated 
and no serious adverse events were reported during the trial. There were no 
more participants reporting unsolicited symptoms in adjuvanted or non-
adjuvanted vaccine groups. Adjuvantation substantially improved both 
seroconversion and seroprotection rates; after the second dose 86% of 
participants administered 3.8 µg HA adjuvanted vaccine had neutralising 
antibody responses compared to only 65% of participants vaccinated with the 
highest dose of unadjuvanted vaccine (30 µg) (Leroux-Roels, Borkowski et al. 
2007; Sambhara and Poland 2007). The vaccine also induced heterosubtypic 
protection; the neutralising seroconversion rate was 77% after the second dose 
of adjuvanted vaccine, whereas in the non-adjuvanted groups, rates were just 
9%. Interestingly, the two dose prime-boost regime was found to be more 
effective when the second dose was administered 6 months after the first rather 
than the typical 21 days (Schwarz, Horacek et al.). 
 
Vaccine adjuvanted with AS03 was approved for use in Europe in May 2008 as 
Prepandrix and Pandemrix, to be administered as pre-pandemic and pandemic 
vaccines respectively (Jones 2009). Furthermore, 60 million doses of 2009 
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pandemic swine origin influenza vaccine being manufactured as a result of a 
sleeping contract between the government and GSK 
(http://www.parliament.uk/documents/upload/postpn331.pdf) is adjuvanted 
with AS03. 
 
1.2.6 Conclusions 
 
In the current swine-origin H1N1 2009 influenza pandemic, vaccines are being 
manufactured in both eggs and cell culture. Vaccine seeds have been produced 
by classical reassortment and reverse genetics  
(http://www.who.int/immunization/sage/4.Zhang_SAGE_vaccine_virus_reagen
ts_-_Final.pdf). In the UK, the government has activated two sleeping contacts 
with Baxter and GSK  
(http://www.parliament.uk/documents/upload/postpn331.pdf). These are for 
72 million doses from Baxter of a whole, inactivated Vero derived vaccine, 
and 60 million doses from GSK of egg grown, split vaccine. 
 
There are many new adjuvants being developed, those mentioned here are a 
small cross-section. An adjuvant of some kind is certainly required to enhance 
the immunogenicity of split pandemic and recombinant vaccines, to stretch the 
number of doses available, and to enhance the immunogenicity.  
 
The vaccine industry has the tools and techniques available to update the 
antiquated way in which influenza vaccines are made. Cell culture is a 
convenient alternative to eggs, and easy scale-up means the number of doses 
can be controlled as required. Reverse genetics means vaccines can be designed 
as and when new strains arise. The current pandemic has seen the fast tracking 
of new vaccines 
(http://www.emea.europa.eu/pdfs/human/press/pr/46856809en.pdf) and the 
use of reverse genetics, which is not covered by IP in the event of a pandemic, 
to generate vaccine seeds 
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 (http://whqlibdoc.who.int/hq/2009/WHO_IVB_09.05_eng.pdf). Hopefully, 
the experience will leave us well prepared in the event of a more pathogenic 
pandemic in the future. 
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1.3 The innate immune response to influenza viruses 
  
Multiple cytokines and chemokines are produced in response to a viral 
infection. The principal cytokines involved in the antiviral response are the 
interferons (IFN), a family of secreted cytokines which are grouped according 
to amino acid sequence into three classes; I, II and III. Type I IFNs comprising 
IFN-α and IFN-β were discovered in 1957 by Isaacs and Lindemann (Isaacs and 
Lindenmann 1957) in classic experiments performed at Mill Hill in London 
using influenza virus infected embryonated chicken eggs. There are multiple 
isoforms of IFN-α and between one and three forms of IFN-β plus other 
members such as -ε, -κ, -ω; type I IFNs are ubiquitously expressed by all 
nucleated cells in response to infection. IFN-γ is the only type II IFN isoform 
and is secreted by mitogenically activated T cells and natural killer (NK) cells. 
The type III IFN group (IFN-λ) have been described quite recently and were 
previously known as IL-29, IL-28A and IL-28B (Sommereyns, Paul et al. 2008). 
IFN-λ expression is prominent in the stomach, intestine and lungs but less in 
other organs, suggesting that IFN-λ may contribute to the prevention of viral 
invasion through skin and mucosal surfaces.  
 
IFN-α and -β activate a ubiquitously expressed heterodimeric type 1 IFN 
receptor, IFNAR, to initiate a signalling cascade which results in the induction 
of transcription of an assortment of IFN stimulated (IS) genes which set up an 
antiviral state in the cell. 
 
1.3.1 JAK/STAT positive feedback 
 
Activation of IFNAR induces the expression of antiviral response gene signals  
(Samuel 2001). STAT (signal transducer and activator of transcription) proteins 
are transcription factors that reside in the cytoplasm and become 
phosphorylated by JAK-1 (Janus kinase) and TYK-2 (tyrosine kinase) after 
IFNAR activation. Phosphorylated STAT-1 and -2 recruit IRF-9 (IFN response 
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factor) and translocate to the nucleus in a trimeric complex known as ISGF-3 
(IFN stimulated gene factor). This binds to the cis–acting DNA element 
designated the IFN stimulated response element (ISRE promoter) which up-
regulates the expression of many genes e.g. PKR (protein kinase R), Mx. 
 
Cells also express SOCS (suppressor of cytokine signalling) proteins which are 
potent endogenous inhibitors of JAK/STAT signalling. SOCS-1 and -3 levels 
were elevated in influenza virus infection and SOCS deficient cells had elevated 
expression of ISRE genes and reduced viral titres (Pauli, Schmolke et al. 2008; 
Pothlichet, Chignard et al. 2008). The mechanism of SOCS induction by 
influenza virus is still unclear since two groups have described different 
pathways. (Pauli, Schmolke et al. 2008) show that SOCS-3 but not SOCS-1 
mRNA induction is dependent upon NF-κB and is independent of IFN. 
(Pothlichet, Chignard et al. 2008) demonstrated that SOCS-1 and SOCS-3 are 
up-regulated during influenza infection in a manner independent of both the 
TLR-3, and of the RIG-I/MAVS pathways. They also show that SOCS-1 and 
SOCS-3 differentially modulate inflammatory signalling pathways.  
 
1.3.2 Pattern Recognition Receptors 
 
To mediate an antiviral response, a cell must first detect the virus or viral 
antigen in the cell. Cellular pattern-recognition receptors (PRRs) recognise 
specific molecular structures on viral particles or products of viral replication 
known as pathogen associated molecular patterns (PAMPs) (Mogensen and 
Paludan 2005).  
 
Toll receptors were first identified in Drosophila melanogaster as the major 
PRR involved in the innate immune response and this subject is 
comprehensively reviewed in (Koyama, Ishii et al. 2008; Randall and 
Goodbourn 2008). The mammalian homologue Toll-like receptors (TLRs) are 
membrane-bound PRRs and are extensively expressed on antigen presenting 
cells such as macrophages and dendritic cells. There are at least 11 TLRs which 
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are characterised by a Toll/IL-1 receptor (TIR) domain in the cytoplasmic tail 
and leucine rich repeats (LRR) in the extracellular domain which are believed 
to interact directly with their cognate ligands. TLRs are widely distributed on 
and in the immune cells and recognize and respond to a diverse range of 
molecules such as lipids, proteins, and nucleic acids derived from pathogens 
and damaged host cells (Ishii, Coban et al. 2005).  Many TLRs are expressed 
on the cell surface and so are not involved in virus recognition. TLR-3, -7, -8 
and -9 are expressed in endosomes. TLR-3 is able to detect dsRNA, TLR-7 
recognises ssRNA and TLR-9 recognizes unmethylated DNA with a CpG motif 
(CpG-DNA). 
 
1.3.3 TLR-3 signalling 
 
Tyrosine phosphorylation and dimerisation of TLR-3 following exposure to 
dsRNA initiates two distinct pathways (Sarkar, Peters et al. 2004) (fig 1.3.1). 
Upon TLR-3 activation the TRIF (TIR (Toll-interleukin 1 receptor) domain-
containing adapter inducing IFN-β) (also known as TIR domain-containing 
adapter protein TICAM-1) is recruited to the receptor and associates with 
TRAF-3, TRAF-6 (tumour necrosis factor (TNF) receptor-associated factors -3 
and -6) and RIP-1 and -3  (receptor interacting protein) (Yamamoto, Sato et al. 
2002; Meylan, Burns et al. 2004). Oligomerisation of TRAF-6 initiates its 
ubiquitin E3 ligase activity which polyubiquitinates itself and RIP-1. The 
polyubiquitin chains are recognized by TAB-2 and TAB-3 (TAK1-binding 
proteins -2 and -3) (Kanayama, Seth et al. 2004), which recruit TAK-1 
(transforming growth factor β-activated kinase 1) to the complex (Wang, Deng 
et al. 2001). Polyubiquitinated RIP-1 is also recognised by a subunit of IKK, 
NEMO (NF-κB essential modifier) (Ea, Deng et al. 2006; Li, Kobayashi et al. 
2006) which recruits IKK (Wu, Conze et al. 2006). TAK-1 is then able to 
phosphorylate the IKKβ subunit of the IKK complex (Wang, Deng et al. 2001), 
leading to the downstream phosphorylation of IκB. Following subsequent 
ubiquitination and degradation, NF-κB is translocated to the nucleus.  
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Figure 1.3.1 Schematic of TLR-3 signalling 
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The alternative signalling cascade involves the interaction of TRAF-3 with 
TANK (TRAF family member-associated NK-κB activator) which associates with 
TBK-1 (TANK-binding kinase 1) and inducible IκB kinase (IKK-i) (Sato, Sugiyama 
et al. 2003), which are able to phosphorylate IRF-3. Phosphorylated IRF-3 
homodimerises, and translocates to the nucleus. This recruits the transcriptional 
co-activators p300 and CBP (CREB-binding protein) and the synthesis of IFN-β 
is induced. IFN-β triggers the expression of IRF-7, which up-regulates the 
synthesis of IFN-α.  
 
Phosphorylation of TLR-3 also recruits and activates PI3K 
(phosphatidylinositol-3 kinase) (Sarkar, Peters et al. 2004), activating the 
downstream kinase Akt leads to full phosphorylation and dimerisation of IRF-
3.  
 
TLR-3 is more widely expressed than the other TLRs, being found in 
conventional dendritic cells (cDCs), macrophages and non-immune cells such as 
fibroblasts and epithelial cells. It recognises dsRNA, a predicted replication 
intermediate for ssRNA viruses, although it has yet to be detected in influenza 
virus infected cells (Weber, Wagner et al. 2006). 
 
1.3.4 TLR-7 signalling 
 
TLR-7 recognises ssRNA and signals through a TIR domain-containing adapter, 
MyD88 (myeloid differentiation factor 88). Upon exposure to its ligand, 
MyD88 forms a complex with IRAK-4 (interleukin-1-receptor (IL-1R)-associated 
kinase-4), IRAK-1, TRAF-3, TRAF-6, Ikkα and IRF-7 (Honda, Yanai et al. 2004; 
Kawai, Sato et al. 2004; Uematsu, Sato et al. 2005).  TRAF-6 can then initiate 
the NF-κB signalling pathway described for TLR-3. Alternatively  IRF-7 can be 
bound and ubiquitinated by TRAF-6 and then interacts with RIP-I (Huye, Ning 
et al. 2007). Recruited IRF-7 is phosphorylated by IRAK-1 and also possibly 
IKKα (Hoshino, Sugiyama et al. 2006), and is then able to translocate into the 
nucleus (still in association with MyD88, TRAF-6 and IRAK-1), where it binds to 
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the ISRE. Expression of TLR-7 is however, restricted to plasmacytoid dendritic 
cells (pDCs), thus their involvement in influenza antigen recognition is limited. 
 
1.3.5 RIG-Like Receptors 
 
Respiratory viruses, such as influenza, target airway epithelial cells which have 
limited expression of TLRs. These cells instead encode other PRR, such as the 
intracellular RNA helicases RIG-I (retinoic inducible gene I (Yoneyama, Kikuchi 
et al. 2004) and MDA-5 (melanoma differentiation-associated gene-5 
(Andrejeva, Childs et al. 2004) and the negative regulator, LGP2 (laboratory of 
genetics and physiology 2 (Murali, Li et al. 2008).  
 
LGP2 has homology to RIG-I and MDA-5 but lacks a caspase recruitment 
domain (CARD), and binds dsRNA but not ssRNA with a higher affinity 
(Murali, Li et al. 2008). LGP2 inhibits virus induction of ISRE genes and NF-κB-
dependent pathways, and as such acts as a dominant negative regulator of 
RIG-I/ MDA-5 signalling through competitive sequestering of dsRNA, 
suggesting a role in negative feedback (Rothenfusser, Goutagny et al. 2005; 
Yoneyama, Kikuchi et al. 2005; Komuro and Horvath 2006) 
 
The signalling pathways of RIG-I (figure 1.3.2) and MDA-5 are less well 
characterised than those of TLRs. Both RIG-I and MDA-5 have two N-terminal 
CARDs and a C-terminal DExD/H box RNA helicase, also known as the 
regulatory domain (RD). 
 
The helicase activity is essential for MDA-5 and RIG-I but not LGP-2 indicating 
a differential mode of action (Bamming and Horvath 2009). A single-point 
mutation (K270A) in the ATPase site rendered RIG-I inactive in antiviral 
signalling, despite retention of RNA binding. Helicases unwind duplex nucleic 
acids by translocating along one of the strands of nucleic acid by ATP 
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Figure 1.3.2 Schematic of RIG-I signalling 
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hydrolysis (Myong, Cui et al. 2009). This suggests that the ATP-dependant 
dsRNA translocation activity is linked to sensing of the PAMPs.  
 
Recently RIG-I has been the focus of intense research and the mechanisms of 
downstream activation are now more clearly defined than for MDA-5. RIG-I 
has been shown to associate  with the actin cytoskeleton via the CARDs 
although the significance has yet to be determined (Mukherjee, Morosky et al. 
2009). Engagement of the PAMP is thought to induce a conformational change 
(Yoneyama, Kikuchi et al. 2004), which exposes the CARDs and promotes the 
formation of homodimers (Childs, Andrejeva et al. 2009). Yeast 2-hybrid 
experiments showed no self-interaction suggesting that dimer formation does 
not occur via direct interaction and requires the binding of RNA to regulatory 
domain. 
 
Following activation, RIG-I is ubiquitinated by two proteins; ubiquitination is 
not required for MDA-5 activation (Gack, Shin et al. 2007). RIG-I CARDs 
interact with tripartite motif protein 25 (TRIM25), an E3 ubiquitin ligase which 
contains a RING finger domain. The first and second card domains have 
distinct roles in RIG-I signalling. TRIM25 binds the first CARD (Gack, Kirchhofer 
et al. 2008), the C-terminal SPRY domain of TRIM25 then delivers K63-linked 
ubiquitin moieties to the second CARD (Gack, Shin et al. 2007). Mutation of 
T55I in the first CARD abolishes TRIM25 interaction, whereas mutation of 
K172R in the second CARD eliminates polyubiquitin attachment. TRIM25 
expression did not result in ubiquitination of MDA-5 CARD. Polyubiquitination 
may facilitate the interaction of RIG-I with MAVS in a similar fashion to RIP 
and NEMO in TLR-3 signalling. 
 
Another E3 ubiquitin ligase, Riplet (RING finger protein leading to RIG-I 
activation), shares 60% sequence homology to TRIM25, but ubiquitinates the 
C-terminal RD of RIG-I via a PRY domain (Oshiumi, Matsumoto et al. 2009). 
Since RIG-I C-terminal RD region is a negative regulator of CARD activity, it is 
suggested that ubiquitination by Riplet stabilizes RIG-I by inhibiting conversion 
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from the active to inactive conformation and providing sufficient structure for 
RIG-I to maintain the accessibility to TRIM25.  
 
Upon ubiquitination of the CARD, RIG-I binds to MAVS (mitochondrial 
antiviral signalling molecule (Seth, Sun et al. 2005) (also known as IPS-1 (IFN-β 
promoter stimulator (Kawai, Takahashi et al. 2005)), VISA (virus-induced 
signalling adaptor (Xu, Wang et al. 2005) and Cardiff (CARD adaptor inducing 
IFN β (Meylan, Curran et al. 2005). MAVS localises to the mitochondrial 
membrane via its C-terminal, transmembrane domain. This localisation is 
essential for its function. The transmembrane domain mediates the dimerisation 
of MAVS which mediates association and subsequent activation of the E3 
ligase, TRAF-3 (Tang and Wang 2009). MAVS N-terminal CARD is required for 
the interaction with RIG-I, CARD-CARD interactions may allow the 
stabilisation and accumulation of active MAVS homodimers which interact with 
TRAF-3. 
 
Expression of a RIG-I splice variant (SV) is up-regulated upon viral infection 
and IFN-β pre-treatment. It carries a short deletion (amino acids 36–80) within 
the first CARD which renders it unable to bind TRIM25; CARD ubiquitination 
and downstream signalling ability is ablated. The RIG-I SV is detectable in a 
number of cell lines upon IFN-β treatment (Gack, Kirchhofer et al. 2008), and 
maintains the ability to bind MAVS, so competitively inhibits downstream RIG-
I signalling.  
 
Two novel proteins have recently been shown to interact with MAVS. NLRX1 
interacts with the CARD domain of MAVS, and may compete with RIG-I as a 
negative regulator of IFN induction (Moore, Bergstralh et al. 2008). STING 
(Bowzard, Ranjan et al. 2009) interacts with both MAVS and RIG-I and is 
essential for IFN induction. It is proposed that STING recruits TBK-1 to the 
mitochondria, where it phosphorylates IRF-3. IRF-3 can also be 
phosphorylated by another IκB kinase- IKKε (Fitzgerald, McWhirter et al. 
2003). IKKε and TBK1 differ functionally in DNA virus-mediated IFN responses; 
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however, they are redundant in RNA virus-mediated IFN responses (Miyahira, 
Shahangian et al. 2009).  
 
Alternative splicing of TBK-1 pre-mRNA which removes the kinase domain is 
induced by Sendai virus infection or priming with IFN-β (Deng, Shi et al. 2008) 
and results in negative regulation of IFN-β induction. Since binding to IRF-3 is 
maintained, an interaction with RIG-I that disrupts the subsequent interaction 
with MAVS is thought to occur, as opposed to prevention of IRF-3 activation.  
 
Ultimately RIG-I signalling results in the activation of IRF-3 by phosphorylation 
and homodimerisation. The dimers translocate to the nucleus and initiate the 
synthesis of IFN-β as described for TLR-3 signalling by recruitment of the 
transcriptional co-activators p300 and CBP.  
 
1.3.6 Pathogen Associated Molecular Patterns 
 
As cytoplasmic RLRs, RIG-I and MDA-5 seem to maintain both unique and 
redundant roles of RIG-I and MDA-5 in signalling (Loo, Fornek et al. 2007). 
Their signalling pathways converge on MAVS activation which is essential for 
signalling via IRF-3 activation by both RLRs.  
 
RIG-I is essential for IFN induction by negative sense single stranded RNA 
viruses such as influenza virus A and B, human respiratory syncytial virus (RSV), 
and Ebola virus. Whilst MDA-5 is required for the detection of PAMPS made 
by positive sense single stranded Picornaviridae such as Encephalomyocarditis 
(EMCV) (Gitlin, Barchet et al. 2006) and Paramyxoviruses (PIV5) (Childs, Stock 
et al. 2007). However, since both MDA-5 and RIG-I can transduce IFN 
triggered by dsRNA Reoviruses and the positive sense ssRNA Flavivirus, 
Dengue virus; it is not simply the species of RNA. Indeed the nature of the 
PAMPs still remains somewhat elusive. 
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The PAMP in an influenza infection was historically considered to be dsRNA, a 
predicted intermediate of viral replication, however detectable levels of dsRNA 
have yet to be observed in influenza infected cells by immunofluorescence or 
FACs (Pichlmair, Schulz et al. 2006; Weber, Wagner et al. 2006). One group 
(Kato, Takeuchi et al. 2006) suggested MDA-5 and RIG-I are differentially 
activated by different species of dsRNA; MDA-5 recognizing the dsRNA 
analogue, poly IC whilst RIG-I detects in vitro transcribed dsRNA. MDA-5 has 
been shown to be more readily activated by lower concentrations of poly IC 
than RIG-I in in vitro assays (Childs, Andrejeva et al. 2009), suggesting MDA-5 
may be more sensitive to poly IC ligand.  
 
RIG-I is activated by 5‟ triphosphate (5‟3P) ssRNA in influenza infection 
(Pichlmair, Schulz et al. 2006). ssRNA lacking a 5'3P can bind RIG-I in vitro but 
is not able to activate signal transduction (Ranjith-Kumar, Murali et al. 2009) 
and treatment with calf intestinal phosphatase (CIP) to remove the 5‟3P 
completely abrogated ssRNA IFN induction (Pichlmair, Schulz et al. 2006). 
More recent research suggests that short doubled stranded secondary structures 
may form within 5‟3P ssRNA, which are important for RIG-I  detection of the 
PAMP (Schlee, Roth et al. 2009; Schmidt, Schwerd et al. 2009). RIG-I -/- MEFs 
(Kato, Takeuchi et al. 2006; Loo, Fornek et al. 2007), dominant negative RIG-I 
(Matikainen, Siren et al. 2006; Siren, Imaizumi et al. 2006) and small 
interfering RNA (siRNA) knockdown of RIG-I (Guo, Chen et al. 2007; 
Mibayashi, Martinez-Sobrido et al. 2007) abrogate the response to influenza 
viruses suggesting that IFN induction by influenza PAMP is RIG-I dependant.  
 
Ligand specificity may also be a result of length, since poly IC can be converted 
to a RIG-I ligand following shortening (Kato, Takeuchi et al. 2008). Thus, RIG-I 
and MDA-5 may be differentially activated depending on the PAMP length, 
and RIG-I and MDA-5 may selectively recognize short and long dsRNAs, 
respectively.  
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RIG-I is also the RLR involved in the detection of dsRNA lacking 5'3P in 
infection with Vesicular stomatitis virus (Kato, Takeuchi et al. 2008) and SeV 
(Hausmann, Marq et al. 2008). It seems that RIG-I interacts with poly IC and 
dsRNA in different ways, indeed poly IC has been shown to activate RIG-I 
variants which lack the C-terminal regulatory domain (Hausmann, Marq et al. 
2008).  
 
At the moment there exists a certain amount of discrepancy in the field 
detailing the precise nature of the PAMPs and the redundancy and differential 
roles of each RLR.  
 
1.3.7 NS1 as an antagonist of IFN-β  
 
Many viruses encode proteins which can negatively regulate the IFN response. 
Influenza encodes the non-structural protein NS1, on the smallest influenza 
segment (segment 8) whose mRNA upon splicing also encodes nuclear export 
protein (NEP, previously known as NS2). The numerous functions of NS1 are 
extensively reviewed in (Hale, Randall et al. 2008). An influenza virus with the 
NS1 protein knocked out induces very high levels of IFN, the growth of these 
viruses is attenuated in most cell lines but restored in the IFN incompetent cell 
line Vero, although still reduced compared to WT virus. The ability of NS1 to 
antagonise IFN has been shown to be strain specific (Hayman, Comely et al. 
2006; Kochs, Garcia-Sastre et al. 2007). 
 
NS1 is a small protein of ~26 KD, which varies in length from 230 to 237 
amino acids, although some strains may encode further C-terminal deletions. 
There are two functional domains, an N-terminal RNA-binding domain 
(residues 1–73) and a C-terminal effector domain (residues 74–230) which 
mediates the interactions with host-cell proteins, and also stabilizes the RNA-
binding domain. NS1 has been shown to form homodimers (Xia, Monzingo et 
al. 2009). 
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NS1 contains one or two nuclear localisation signals (NLS) depending on strain, 
and is found predominantly in the nucleus although again this is strain 
dependant and can depend upon the time post infection. The N terminal NLS 1 
(residues 35-41) (Melen, Kinnunen et al. 2007) also contains the RNA binding 
domain (Arg-35, Arg-38 and Lys-41). Not all strains of influenza contain the 
second NLS in the C terminus (Lys-219, Arg-220, Arg-231 and Arg-232). There 
is also a third potential nucleolar localisation signal (Arg-224 and Arg-229). 
 
Pre transcriptional regulation, suppressing the activation of IRF-3 dependant 
signalling is dependent on the RNA binding domain of NS1 (Arg-35, Arg-38 
and Lys-41) and NS1 has been shown to interact with the dsRNA (Donelan, 
Basler et al. 2003) (Hatada and Fukuda 1992) (Wang, Riedel et al. 1999),  
Initially it was proposed that NS1 interacted with dsRNA sequestering it from 
PRR, but dsRNA has yet to be detected in infected cells (Weber, Wagner et al. 
2006). NS1 co-precipitates with the PRR, RIG-I (Pichlmair, Schulz et al. 2006), 
and the stability of the interaction is enhanced by the inclusion of RNA 
(Mibayashi, Martinez-Sobrido et al. 2006). Residues E96/E97 of NS1 mediate 
an interaction with the coiled-coil domain (CCD) of TRIM25, and so block 
TRIM25 multimerisation and subsequent ubiquitination of the RIG-I CARD 
(Gack, Albrecht et al. 2009) which binds to the SPRY domain of TRIM25 
(Gack, Shin et al. 2007). Thus NS1 and RIG-I do not compete for binding to 
TRIM25, instead the data suggest that a triple complex is formed in influenza 
virus-infected cells. The RNA binding residues R38 and K41 are important for 
the interaction with TRIM25, since the mutations R38A/K41A lack TRIM25 
binding perhaps as a result of changes to NS1 conformation that affects its 
dimerisation or stability. 
 
NS1 also prevents nuclear post-transcriptional processing and inhibits the 
nuclear export of mRNAs. The CPSF30 (C-terminal effector domain binds to 
cleavage and polyadenylation specificity factor) (Nemeroff, Barabino et al. 
1998) mediated by residues P103, M106, and interacts with PABPII (poly(A)-
binding protein II) via residues 223–237aa (Chen, Li et al. 1999). These 
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interactions interfere with CPSF30 binding of cellular pre-mRNAs; and thus 
inhibit the cleavage and polyadenylation of the 3'-end of host-cell mRNAs 
(Nemeroff, Barabino et al. 1998). Since the polyadenylation of influenza A 
virus mRNAs is independent of cellular 3'-end processing factors, viral mRNAs 
are not affected by CPSF30 inhibition. NS1 also forms an inhibitory complex 
with the host mRNA nuclear export machinery, NXF1/TAP, p15/NXT, 
Rae1/mrnp41, and E1B-AP5, which direct mRNAs through the nuclear pore 
complex (Satterly, Tsai et al. 2007) abrogating the export of cellular mRNAs, 
including those that encode anti-viral genes.  
 
NS1 is also involved in splicing of vRNAs and the temporal regulation of vRNA 
synthesis and translation. NS1 protein can enhance transcription or translation 
of viral RNAs although this may be strain specific. NS1 also interacts with the 
IFN induced protein, PKR (protein kinase R) (Wang, Riedel et al. 1999; 
Salvatore, Basler et al. 2002). 
 
1.3.8 Conclusion 
 
Incongruent induction of IFN may play an important role in pathogenesis. 
Infection with HPAI viruses (such as H5N1 and 1918) can elicit 
hypercytokaemia or “cytokine storm” (Cheung, Poon et al. 2002; Heui Seo, 
Hoffmann et al. 2002; Zambon and Barclay 2002; R Deng, M Lu et al. 2008). 
It has been suggested that this contributes to the highly pathogenic phenotype 
of these viruses. Unrestricted viral replication in the face of cytokine induction 
leads to exponential cytokine secretion and corresponds with acute respiratory 
distress, lymphopaenia, haemophagocytosis and eventually multiple organ 
failure. However, recent publications suggest that lack of hypercytokaemia in 
transgenic mice did not alter the pathogenicity of these viruses (Droebner, 
Reiling et al. 2008). The contribution of individual inflammatory cytokines to 
the morbidity and mortality was not apparent, and they may either not be 
involved in the destructive cytokine response or are redundant to other factors 
elicited during such a response (Salomon, Hoffmann et al. 2007). 
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Understanding the balance between cytokine induction and viral antagonism, 
and the mechanism of induction, will provide insight into their effects on both 
virus and host, including their role in pathogenicity and severity of infection. 
Importantly, a better understanding of IFN induction by influenza viruses may 
reveal further targets for drug use and vaccines. 
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Plasmids 
Construct Description Source 
pPol I  pPol I vector for reverse genetics 
containing human pol I promoter 
and hepatitis delta virus ribozyme 
Dr T. Zurcher 
GlaxoSmithKline 
pPol I PR8 PB2 pPol I vector containing PR8 
Segment 1 cDNA FluPAN backbone 
(Whiteley, Major et 
al. 2007) 
pPol I PR8 PB1 pPol I vector containing PR8 
Segment 2 cDNA FluPAN 
backbone 
(Whiteley, Major et 
al. 2007) 
pPol I PR8 PA pPol I vector containing PR8 
Segment 3 cDNA FluPAN 
backbone 
(Whiteley, Major et 
al. 2007) 
pPol I PR8 HA pPol I vector containing PR8 
Segment 4 cDNA FluPAN 
backbone 
(Whiteley, Major et 
al. 2007) 
pPol I PR8 NP pPol I vector containing PR8 
Segment 5 cDNA FluPAN 
backbone 
(Whiteley, Major et 
al. 2007) 
pPol I PR8 NA pPol I vector containing PR8 
Segment 6 cDNA FluPAN 
backbone 
(Whiteley, Major et 
al. 2007) 
pPol I PR8 M pPol I vector containing PR8 
Segment 7 cDNA FluPAN 
backbone 
(Whiteley, Major et 
al. 2007) 
pPol I PR8 NS pPol I vector containing PR8 
Segment 8 cDNA FluPAN 
backbone 
(Whiteley, Major et 
al. 2007) 
   
pPol I PR8 PB2 
Crucell 
pPol I vector containing PR8 
Segment 1 cDNA Crucell backbone 
(Koudstaal, 
Hartgroves et al. 
2009) 
pPol I PR8 PB1 
Crucell 
pPol I vector containing PR8 
Segment 2 cDNA Crucell backbone 
(Koudstaal, 
Hartgroves et al. 
2009) 
pPol I PR8 PA 
Crucell 
pPol I vector containing PR8 
Segment 3 cDNA Crucell backbone 
(Koudstaal, 
Hartgroves et al. 
2009) 
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Construct Description Source 
pPol I PR8 HA 
Crucell 
pPol I vector containing PR8 
Segment 4 cDNA Crucell backbone 
(Koudstaal, 
Hartgroves et al. 
2009) 
pPol I PR8 NP 
Crucell 
pPol I vector containing PR8 
Segment 5 cDNA Crucell backbone 
(Koudstaal, 
Hartgroves et al. 
2009) 
pPol I PR8 NA 
Crucell 
pPol I vector containing PR8 
Segment 6 cDNA Crucell backbone 
(Koudstaal, 
Hartgroves et al. 
2009) 
pPol I PR8 M 
Crucell 
pPol I vector containing PR8 
Segment 7 cDNA Crucell backbone 
(Koudstaal, 
Hartgroves et al. 
2009) 
pPol I PR8 NS 
Crucell 
pPol I vector containing PR8 
Segment 8 cDNA Crucell backbone 
(Koudstaal, 
Hartgroves et al. 
2009) 
   
pPol I/pPol II PR8 
PB2 
pPol I/pPol II vector containing 
PR8 Segment 2 cDNA 
(Whiteley, Major et 
al. 2007) 
pPol I/pPol II PR8 
PB1 
pPol I/pPol II vector containing 
PR8 Segment 3 cDNA 
(Whiteley, Major et 
al. 2007) 
pPol I/pPol II PR8 
PA 
pPol I/pPol II vector containing 
PR8 Segment 4 cDNA 
(Whiteley, Major et 
al. 2007) 
pPol I/pPol II PR8 
NP 
pPol I/pPol II vector containing 
PR8 Segment 5 cDNA 
(Whiteley, Major et 
al. 2007) 
   
pPol I Vic PB2 pPol I vector containing 
A/Victoria/3/75  segment 1 cDNA 
Dr T Zurcher 
GlaxoSmithKline 
pPol I Vic PB1 pPol I vector containing 
A/Victoria/3/75  segment 2 cDNA 
Dr T Zurcher 
GlaxoSmithKline 
pPol I Vic PA pPol I vector containing 
A/Victoria/3/75  segment 3 cDNA 
Dr T Zurcher 
GlaxoSmithKline 
pPol I Vic HA pPolI vector containing 
A/Victoria/3/75  segment 4 cDNA 
Dr T Zurcher 
GlaxoSmithKline 
pPol I Vic NP pPol I vector containing 
A/Victoria/3/75  segment 5 cDNA 
Dr T Zurcher 
GlaxoSmithKline 
   
pPol I Vic NA pPol I vector containing 
A/Victoria/3/75  segment 6 cDNA 
Dr T Zurcher 
GlaxoSmithKline 
pPol I Vic M pPol I vector containing 
A/Victoria/3/75  segment 7 cDNA 
Dr T Zurcher 
GlaxoSmithKline 
pPol I Vic NS pPol I vector containing 
A/Victoria/3/75  segment 8 cDNA 
Dr T Zurcher 
GlaxoSmithKline 
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Construct Description Source 
pPol II Vic PB2 pPol II vector containing 
A/Victoria/3/75  segment 1 cDNA 
Dr T Zurcher 
GlaxoSmithKline 
pPol II Vic PB1 pPol II vector containing 
A/Victoria/3/75  segment 2 cDNA 
Dr T Zurcher 
GlaxoSmithKline 
   
pPol II Vic PA pPol II vector containing 
A/Victoria/3/75  segment 3 cDNA 
Dr T Zurcher 
GlaxoSmithKline 
pPol II Vic NP pPol II vector containing 
A/Victoria/3/75  segment 5 cDNA 
Dr T Zurcher 
GlaxoSmithKline 
   
pPol II WSN PB2 pPol II vector containing WSN  
segment 1 cDNA 
Ervin Fodor, 
Oxford University 
pPol II WSN PB1 pPol II vector containing WSN  
segment 2 cDNA 
Ervin Fodor, 
Oxford University 
pPol II WSN PA pPol II vector containing WSN  
segment 3 cDNA 
Ervin Fodor, 
Oxford University 
pPol II WSN NP pPol II vector containing WSN  
segment 5 cDNA 
Ervin Fodor, 
Oxford University 
   
pPol I/pPol II PR8 
PB2 
pPol I/pPol II vector containing 
PR8 Segment 2 cDNA 
(Koudstaal, 
Hartgroves et al. 
2009) 
pPol I/pPol II PR8 
PB1 
pPol I/pPol II vector containing 
PR8 Segment 3 cDNA 
(Koudstaal, 
Hartgroves et al. 
2009) 
pPol I/pPol II PR8 
PA 
pPol I/pPol II vector containing 
PR8 Segment 4 cDNA 
(Koudstaal, 
Hartgroves et al. 
2009) 
pPol I/pPol II PR8 
NP 
pPol I/pPol II vector containing 
PR8 Segment 5 cDNA 
(Koudstaal, 
Hartgroves et al. 
2009) 
   
pPol I B PB2 pPol I vector containing 
B/Beijing/87 segment 1 cDNA 
(Jackson, Cadman 
et al. 2002) 
pPol I B PB1 pPol I vector containing 
B/Beijing/87 segment 2 cDNA 
(Jackson, Cadman 
et al. 2002) 
pPol I B PA pPol I vector containing 
B/Beijing/87 segment 3 cDNA 
(Jackson, Cadman 
et al. 2002) 
pPol I B HA PPol I vector containing 
B/Beijing/87 segment 4 cDNA 
(Jackson, Cadman 
et al. 2002) 
pPol I B NP pPol I vector containing 
B/Beijing/87 segment 5 cDNA 
(Jackson, Cadman 
et al. 2002) 
pPol I B NA pPol I vector containing 
B/Beijing/87 segment 6 cDNA 
(Jackson, Cadman 
et al. 2002) 
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Construct Description Source 
pPol I B M pPol I vector containing 
B/Beijing/87 segment 7 cDNA 
(Jackson, Cadman 
et al. 2002) 
pPol I B NS pPol I vector containing 
B/Beijing/87 segment 8 cDNA 
(Jackson, Cadman 
et al. 2002) 
pPol II B PB2 pPol II vector containing 
B/Beijing/87 segment 1 cDNA 
(Jackson, Cadman 
et al. 2002) 
pPol II B PB1 pPol II vector containing 
B/Beijing/87 segment 2 cDNA 
(Jackson, Cadman 
et al. 2002) 
pPol II B PA pPol II vector containing 
B/Beijing/87 segment 3 cDNA 
(Jackson, Cadman 
et al. 2002) 
pPol II B NP pPol II vector containing 
B/Beijing/87 segment 5 cDNA 
(Jackson, Cadman 
et al. 2002) 
   
pPol I A/Sydney/97 
HA 
pPol I vector containing 
A/Sydney/97/5 segment 4 cDNA 
(Hayman, Comely 
et al. 2006) 
pPol I A/Sydney/97 
NA 
pPol I vector containing 
A/Sydney/97/5 segment 6 cDNA 
(Hayman, Comely 
et al. 2006) 
pPol I A/Sydney/97 
NS 
pPol I vector containing 
A/Sydney/97/5 segment 8 cDNA 
(Hayman, Comely 
et al. 2006) 
   
pPol I Panama HA pPol I vector containing 
A/Panama/ segment 4 cDNA 
Dr Alison Whiteley, 
Reading University 
pPol I Panama NA pPol I vector containing 
A/Panama/ segment 6 cDNA 
Dr Alison Whiteley, 
Reading University 
pPol I New 
Caledonia HA 
pPol I vector containing A/New 
Caledonia/20/99 segment 4 cDNA 
Isabelle Legastalois, 
Sanofi Pasteur 
pPol I New 
Caledonia NA 
pPol I vector containing A/New 
Caledonia/20/99 segment 6 cDNA 
Isabelle Legastalois, 
Sanofi Pasteur 
   
pPol I RD3 HA pPol I vector containing 
A/Chicken/Italy/1347/99 segment 4 
cDNA 
(Whiteley, Major et 
al. 2007) 
pPol I RD3 NA pPol I vector containing 
A/Chicken/Italy/1347/99 segment 6 
cDNA 
(Whiteley, Major et 
al. 2007) 
pPol I HK/97 HA pPol I vector containing A/Hong 
Kong/156/97segment 4 cDNA 
(Koudstaal, 
Hartgroves et al. 
2009) 
pPol I HK/97 NA pPol I vector containing A/Hong 
Kong/156/97segment 6 cDNA 
(Koudstaal, 
Hartgroves et al. 
2009) 
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Construct Description Source 
pPol I DI 220 pPol I vector containing 225 ntd 
of 3' and 220 ntd of 5' from PB2 
A/equine/Newmarket/7339/79 
(Duhaut and 
Dimmock 2002) 
pPol I DI 317 pPol I vector containing 268 ntd 
of 3' and 317 ntd of PB2 from 
A/chicken/Dobson/27 
(Duhaut and 
Dimmock 2002) 
   
pCAGG 
A/Victoria/75 NS 
pCAGG vector containing 
A/Victoria/3/75 segment 8 cDNA 
(Hayman, Comely 
et al. 2006) 
pCAGG 
A/England/24/00 
NS 
pCAGG vector containing 
A/England/24/00  segment 8 
cDNA 
Dr. Anna Hayman, 
Reading University  
pCAGG 
A/England/492/95 
NS 
pCAGG vector containing 
A/England/492/95  segment 8 
cDNA 
Dr. Anna Hayman, 
Reading University 
pCAGG 
A/Equine/Sussex/89 
NS 
pCAGG vector containing 
A/Equine/Sussex/89 segment 8 
cDNA 
Sarah Linton, 
Reading University 
   
IFN-β luc Fire fly luciferase reporter gene 
under the control of IFN- β 
promoter 
Steve Goodbourn, 
St. Georges, 
London 
ISRE LUC Fire fly luciferase reporter gene 
under the control of ISRE promoter 
Steve Goodbourn, 
St. Georges, 
London 
β-gal β-galactosidase reporter with a rat 
actin promoter and a 3‟ SV40 T Ag 
splice /polyadenylation site 
Steve Goodbourn, 
St. Georges, 
London 
Up-luc A/Victoria/75/3 segment 7 with 
fire fly luciferase reporter gene 
under the control of 358 up 
promoter  
Dan Brookes, ICL 
pEGFP Green fluorescent protein Clontech 
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2.1.2 Primers 
 
Primer Name Sequence  Description 
PB2-BsmBI F 
5‟ TAT TGG CGT CTC ACC CAG CGA 
AAG CAG GTC 3‟ 
cloning 
segment 1 
PB2-BsmBI R 
5‟ ATA TCG CGT CTC TTA TTA GTA 
GAA ACA AGG TCG TTT 3‟ 
cloning 
segment 1 
PB1-BsmBI F 
5‟ TAT TGG CGT CTC ACC CAG CGA 
AAG CAG GCA 3‟ 
cloning 
segment 2 
PB1-BsmBI R 
5‟ ATA TGC CGT CTC TTA TTA GTA 
GAA ACA AGG CAT TT 3‟ 
cloning 
segment 2 
PA-BsmBI F 
5‟ TAT TGG CGT CTC ACC CAG CGA 
AAG CAG GTA C 3‟ 
cloning 
segment 3 
PA-BsmBI R 
5‟ ATA TGC CGT CTC TTA TTA GTA 
GAA ACA AGG TAC TT 3‟ 
cloning 
segment 3 
HA-BsmBI F 
5‟ TAT TGG CGT CTC ACC CAG CGA 
AAG CAG GGG 3‟ 
cloning 
segment 4 
HA-BsmBI R 
5‟ ATA TGC CGT CTC TTA TTA GTA 
GAA ACA AGG GTG TTT T 3‟ 
cloning 
segment 4 
NP-BsmBI F 
5‟ TAT TGG CGT CTC ACC CAG CGA 
AAG CAG GGT A 3‟ 
cloning 
segment 5 
NP-BsmBI R 
5‟ ATA TGC CGT CTC TTA TTA GTA 
GAA ACA AGG GTA TTT TT 3‟ 
cloning 
segment 5 
NA-BsmBI F 
5‟ TAT TGG CGT CTC ACC CAG CGA 
AAG CAG GAG T 3‟ 
cloning 
segment 6 
NA-BsmBI R 
5‟ ATA TGC CGT CTC TTA TTA GTA 
GAA ACA AGG AGT TTT TT 3‟ 
cloning 
segment 6 
M-BsmBI F 
5‟ TAT TGG CGT CTC ACC CAG CGA 
AAG CAG GTA G 3‟ 
cloning 
segment 7 
M-BsmBI R 
5‟ ATA TGC CGT CTC TTA TTA GTA 
GAA ACA AGG TAG TTT TT 3‟ 
cloning 
segment 7 
NS-BsmBI F 
5‟ TAT TGG CGT CTC ACC CAG CGA 
AAG CAG GGT G 3‟ 
cloning 
segment 8 
NS-BsmBI R 
5‟ ATA TGC CGT CTC TTA TTA GTA 
GAA ACA AGG GTG TTT T 3‟ 
cloning 
segment 8 
   
Universal 
primer 4a 
5‟ TAT TGG CGT CTC ACC CAG CGA 
AAG 3‟ 
cDNA RT 
PCR 
Universal 
primer 4g 
5‟ TAT TGG CGT CTC ACC CAG CGA 
AAA 3‟ 
cDNA RT 
PCR 
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Primer Name Sequence Description 
T7 Flu G F 
5‟ GCA TCC TAA GAC TCA CTA TGG 
AGC GAA GAC AGG 3‟ 
dsRNA 
T7 Flu R 
5‟ GGA TCC TAA TAC GAC TCA CTA 
TGG AGT AGA AAC AAG 3‟ 
dsRNA 
   
RIG-I F 
5‟ TGT TTC CAG GGA TCC CAG CAA 
TGA 3‟ 
RT PCR 
RIG-I R 
5‟ ACT TCA CAT GGA TCC CCC AGT 
CAT GGC 3‟ 
RT PCR 
MDA-5 F 
5‟ GCT CAC AGT GGA TCC GGA GTT 
ATC AA 3‟ 
RT PCR 
MDA-5 R 
5‟ CAC CAT CAT GGA TCC CCA AGC 
CTG GCC 3‟ 
RT PCR 
SOCS-3 F 
5‟ TCA CCC ACA GCA AGT TTC CCG C 
3‟ 
RT PCR 
SOCS-3 R 
5‟ GTT GAC GGT CTT CCG ACA GAG 
ATG C 3‟ 
RT PCR 
 
Primers were synthesised by eurofins MWG operon. 
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2.1.3 Virus Preparations 
 
Virus Comments Source 
A/PR8/34 Wild type virus H1N1 Dr Alison Whiteley, 
University of Reading  
A/Victoria/3/7
5 
Wild type virus H3N2 Dr Wendy Barclay,  
Reading University 
A/Sydney/5/9
7 
Wild type virus H3N2- high 
inducer 
Dr. Maria Zambon, 
HPA CfI 
A/England/41/
96 
Wild type virus H3N2- high 
inducer 
Dr. Maria Zambon, 
HPA CfI 
A/England/91
9/99 
Wild type virus H3N2- low 
inducer 
Dr. Maria Zambon, 
HPA CfI 
A/England/37
0/02 
Wild type virus H3N2- high 
inducer 
Dr. Maria Zambon, 
HPA CfI 
   
Vic +Syd NS 7:1 Recombinant virus 
A/Victoria/3/75 + A/Sydney/5/97 
NS 
(Hayman, Comely et 
al. 2006) 
Vic +Syd HA 7:1 Recombinant virus 
A/Victoria/3/75 + A/Sydney/5/97 
HA 
(Hayman, Comely et 
al. 2006) 
Vic +Syd NA 7:1 Recombinant virus 
A/Victoria/3/75 + A/Sydney/5/97 
NA 
(Hayman, Comely et 
al. 2006) 
Vic +Syd HA 
+NS 
6:2 Recombinant virus 
A/Victoria/3/75 + A/Sydney/5/97 
HA +NS 
(Hayman, Comely et 
al. 2006) 
   
PR8P  6:2 Recombinant virus PR8 
A/Panama HA NA 
(Hayman, Comely et 
al. 2006) 
PR8 +Syd HA 
NA 
6:2 Recombinant virus PR8 + 
A/Sydney/5/97 HA NA 
(Hayman, Comely et 
al. 2006) 
PR8 +Syd NS 7:1 Recombinant virus PR8 + 
A/Sydney/5/97 NS 
(Hayman, Comely et 
al. 2006) 
PR8P +Syd 
HA +NS 
5:2:1 Recombinant virus PR8 + 
A/Panama NA + A/Sydney/5/97 
HA +NS 
(Hayman, Comely et 
al. 2006) 
PR8P +Syd 
HA  
5:2:1 Recombinant virus PR8 + 
A/Panama NA + A/Sydney/5/97 
HA  
(Hayman, Comely et 
al. 2006) 
PR8P +Syd 
NA 
5:2:1 Recombinant virus PR8P + 
A/Panama HA + A/Sydney/5/97 
HA NA 
(Hayman, Comely et 
al. 2006) 
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Virus Comments Source 
PR8P +Syd 
NS 
5:2:1 Recombinant virus PR8P + 
A/Sydney/5/97 NS 
(Hayman, Comely et 
al. 2006) 
   
RD3 6:2 A/PR/8/34 + 
A/Chicken/Italy/1347/99 HA & 
NA
 
H7N1  
(Koudstaal, Hartgroves 
et al. 2009) 
RG14 6:2 A/PR/8/34 + A/Hong 
Kong/156/97 HA & NA
 
H5N1  
(Koudstaal, Hartgroves 
et al. 2009) 
 
 
2.1.4 Cell Lines 
 
Cell line Description Source 
PER.C6  Human retina cell line immortalised 
with adenovirus 
Crucell N.V. 
Vero  African Green Monkey Kidney cell line ATCC 
MDCK Madin Darby canine kidney cell Glaxo 
Smithkline 
MDCK-SIAT Madin Darby canine kidney cell over-
expressing 2-6 sialidase 
HPA, 
(Matrosovich, 
Matrosovich 
et al. 2003) 
293 T Human embryonic kidney cell line Glaxo 
Smithkline 
Huh-7 Human hepatoma cell line Dr. Michael 
McGarvey, IC 
Huh-7.5 Human hepatoma cell line containing a 
point mutation in RIG-I TRIM25 
binding domain 
Dr. Michael 
McGarvey, IC 
A549 Human lung cell line ATCC 
A549 IFN-luc Human lung cell line stably expressing 
Fire fly luciferase reporter gene under 
the control of IFN-β promoter 
(Hayman, 
Comely et al. 
2006) 
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2.1.5 Antibodies 
 
Antibody Description Dilution for 
Western 
blot 
Dilution 
for IF 
Source 
-NP Mouse monoclonal 
antibody raised 
against Influenza A 
H7 NP clone 2F6.C9 
1/300 1/300 Dr. Maria 
Zambon, 
HPA CfI 
-NS1 Rabbit polyclonal 
raised against A/PR/8 
NS1 clone V29 
1/300 NA Dr. Paul 
Digard, 
Cambridge 
University 
-M1 Mouse monoclonal 
antibody raised 
against Influenza A 
matrix protein 
1/1000 NA Oxford 
Biotechnolo
gicals 
-IRF3 Rabbit polyclonal 
raised against IRF-3 
NA 1/300 Santa Cruz 
-Stat-1 P Goat polyclonal 
antibody raised 
against Stat-1 Tyr 701 
1/500 NA Santa Cruz 
-vinculin Goat polyclonal 
antibody raised 
against vinculin 
1/1000 NA Santa Cruz 
Goat -
rabbit 
FITC 
FITC conjugated 
antibody used in 
confocal microscopy 
and flow cytometry 
NA 1/500 Immunologi
cals Direct 
Goat -
mouse 
Texas Red 
Texas Red conjugated 
antibody used in 
confocal microscopy 
NA 1/500 Oxford 
Biotechnolo
gicals 
Sheep -
rabbit 
HRPO 
Horse radish 
peroxidase 
conjugated antibody  
1/1000 NA AbD Serotec 
Goat -
mouse 
HRPO 
Horse radish 
peroxidase 
conjugated antibody  
1/1000 NA AbD Serotec 
donkey -
sheep/goat 
HRPO 
Horse radish 
peroxidase 
conjugated antibody  
1/1000 NA AbD Serotec 
Goat -
mouse -
gal 
-galactosidase 
conjugated antibody, 
used in blue cell assay 
NA 1/400 AbD Serotec 
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2.1.6 Buffers, diluents and culture media 
 
Unless otherwise stated, all reagents were obtained from Sigma 
 
2.1.7 Virus and cell culture reagents 
2.1.7.1 Virus diluent 
 
3% FCS (Bio Sera International) 
0.1% Pen/Strep (Gibco) 
PBS 
2.1.7.2 Plaque assay overlay  
 
0.7x EMEM (Gibco)  
0.303 % BSA (fraction V) (Gibco) 
0.7xL-Glutamine (Gibco) 
0.2% NaHC02 (Gibco) 
0.7M HEPES (Gibco) 
0.007% dextran DEAE (Sigma)  
0.7x Pen/Strep (Gibco) 
 
2.1.7.3 Agarose for plaque assay 
 
2% purified agar in ddH2O, Oxoid Ltd 
2.1.7.4 RIPA buffer 
 
50 mM Tris HCl pH 8 
150 mM NaCl 
1% NP-40 
0.5% sodium deoxycholate 
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0.1% SDS  
10% sodium deoxycholate stock solution (protected from light) 
5 mM Iodoacetamide 
 
2.1.8 Bacterial culture and cloning 
2.1.8.1 LB 
 
1% Oxoid tryptone  
0.5% Oxoid yeast extract 
0.5% NaCl  
0.1% glucose 
2.1.8.2 SOCS 
 
2% Oxoid tryptone  
0.5% Oxoid yeast extract  
10 mM NaCl  
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM glucose 
2.1.8.3 TAE Buffer 
 
4 mM Tris acetate 
1 mM EDTA 
2.1.8.4 6 x DNA loading buffer 
 
0.25% bromophenol blue 
30% glycerol 
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2.1.9 Assays 
 
2.1.9.1 6 x SDS sample buffer 
 
300 mM Tris HCl 
600 mM DTT 
2% SDS 
0.1% bromophenol blue 
50% glycerol 
 
2.1.9.2 Tris-glycine SDS-Polyacrylamide Gel running buffer (10X)  
 
25 mM Tris base  
250 mM Glycine  
0.1% SDS   
pH 8.3 
 
2.1.9.3 Transfer buffer 
 
0.037 % (w/v) SDS  
48 mM Tris   
39 mM Glycine  
20% (v/v) Ethanol added just before use 
2.1.9.4 X-gal 
 
10% in DMF 
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2.1.9.5 10X CN buffer 
 
3 mM Potassium Ferricyanide 
3 mM Potassium Ferrocyanide 
1 mM MgCl2  
PBS 
 
2.1.9.6 X-gal substrate 
 
8.75 ml PBS 
1 ml CN buffer 
0.25 ml 10% X-gal 
 
2.1.9.7 Molviol 
 
6g glycerol 
2.4g Molviol 4-8 Hoechst 
6 ml ddH2O 
12 ml 0.2M TRIS pH 8 
DAPI 1000x stock 
DABCO final concentration 2.5% 
 
Glycerol, Molviol and ddH2O were dissolved O/N rotating. Tris was added 
and allowed to dissolve for 2-3 hours alternating between 50°C and rotation. 
Following centrifugation 2500 RPM x 5 minutes, the supernatant was 
transferred, DAPI and DABCO were added as required, aliquotted and stored -
20°C up to 6 months. 
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2.1.9.8 Lac Z buffer 
 
60 mM Na2HPO4.7H2O 
40 mM NaH2PO4. H2O 
10 mM KCl 
1 mM MgSO4 7.H2O 
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2.2 Methods 
 
2.2.1 Viral and cell culture techniques 
2.2.1.1 Standard cell culture  
 
Cells were passaged in Dulbecco‟s modified Eagle‟s medium (DMEM) (Gibco 
BRL) supplemented with 10% FCS (v/v) and 1% penicillin streptomycin and 
were maintained at 37°C, 5% CO2.  
 
Media for A549 luc cells was supplemented with 2 mg/ml Genetcin (G418).  
 
Media for MDCK-SIAT cells was supplemented with 0.4 mg/ml Genetcin 
(G418). 
 
2.2.1.2 PER.C6 cell culture  
 
PER.C6 cells were passaged in DMEM +10% FCS, 1% penicillin streptomycin 
and 10 mg/ml MgCl2 and were maintained at 37°C, 10% CO2. 
 
2.2.2 Production of virus stocks 
 
Viruses were grown in MDCK or MDCK-SIATs cells. All viruses were 
propagated at the 33°C, except A/Victoria/3/75 and A/Sydney/5/97, at 37°C. 
Cells were infected at an MOI of 0.01 in serum free DMEM (SF DMEM) for 1 
hour. Media was replaced with SF DMEM containing 2.5g/ml of porcine 
trypsin (Sigma). Viruses were harvested 2-3 days post infection by collecting 
supernatants. These were clarified by centrifugation at 2,500 RPM for 10 
minutes, aliquotted and stored at –80°C. 
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2.2.3 Infection of cell lines with influenza viruses 
 
PER.C6, Huh-7, Huh-7.5 and A549 cell lines were infected with influenza virus 
at the relevant MOI in SF DMEM. After 1 hour incubation at 34°C or 37°C the 
media was removed and cells washed with PBS, the media was replaced with 
2% DMEM. 
 
2.2.4 Haemagglutinin assay 
 
Haemagglutination assays were performed by mixing two-fold dilutions of 
virus in PBS with equal volumes of 0.5% chicken, turkey or guinea pig red 
blood cell suspensions in PBS in 96 well V-bottom plates. These were incubated 
for 1 hour, at RT. The HA titre of the virus was determined as the well prior to 
the first well displaying a red blood cell pellet. 
 
2.2.5 Plaque assay 
 
Plaque assays were carried out in 12 well plates. Serial 10-fold dilutions of 
samples were created. 200 l of diluted virus was incubated on MDCK 
monolayers for 1 hour at 34°C or 37°C depending on the virus. Media was 
then removed and 1 ml semisolid agar overlay media (17.5 ml plaque assay 
overlay, 2.1.7.2 plus 7.5 ml Oxoid agar, 2.1.7.3) containing 0.4 g/ml trypsin 
(Worthington Biochemical Corporation) was added to each well. These were 
incubated at 34°C or 37°C for 3 to 4 days and then visualised by staining with 
crystal violet stain. Plaques were counted and used to determine viral titres in 
terms of PFU/ml. 
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2.2.6 Transfections 
 
2.2.6.1 PER.C6 cell transfection  
 
Adherent PER.C6 cells in a 6 well plate in 2% DMEM were transfected with at 
a 2:1 ratio reagent (µl): µg DNA, poly IC or RNA. Generally 0.5 µg plasmid 
(e.g. IFN luc) and 0.25 µg b-gal was used. Lipofectamine was added to 250 µl 
Optimem and the plasmids added to 250 µl Optimem. These were incubated 5 
minutes RT, combined and incubated a further 20 mins, then added drop wise 
to cells, and incubated for 24-48 hours. Volumes and concentrations were 
scaled appropriately for smaller wells. 
 
2.2.6.2 A549 cell transfection 
 
A549 cells in a 6 well plate in 1.5 ml/well of 2% DMEM media were 
transfected with plasmids. Generally 0.5 µg LUC reporter and 0.25 µg b-gal 
reporter. These were combined in a total volume of 100 µl/reaction of serum 
free DMEM, in a 1.5 ml Eppendorf. 12 µl of Polyfect (QIAGEN) was added, 
vortexed for 15 seconds, and incubated for 10 minutes at RT. 600 µl of 10% 
DMEM added to the Eppendorf and pipetted gently twice. The transfection 
mix was added directly to each well and incubated at 37°C for 24-48 hours. 
Volumes and concentrations were scaled appropriately for smaller wells. 
 
2.2.6.3 Huh-7 cell transfection 
 
Huh-7 cells were transfected following the same protocol used for PER.C6 
cells. 
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2.2.7 Virus rescue 
 
2.2.7.1 Co-culture virus rescue 
 
293T cells in DMEM+ 3% FCS in 12 well plates, 70-80% confluent were 
transfected with 12 plasmids for virus rescue and a ratio of 3:1 Fugene reagent: 
DNA. 20 µl Fugene was added to 200 µl SF DMEM. Incubated 5 minutes, RT. 
Plasmids required for virus rescue as below were added and incubated a further 
15 mins, then added drop wise to cells. These were incubated overnight at 
37°C. Confluent MDCK cells were detached using trypsin and cells resuspended 
in 20 ml DMEM +10% FCS + pyruvate/75 cm
2
 flask. 4 ml MDCK cell 
suspension was transferred to a 25 cm
2
 flask. Transfected 293T cells were 
washed in PBS and detached by adding 5 drops of PBS, EDTA, trypsin. 1 ml 
MDCK cell suspension was added to the detached 293T cells, mixed and 
transferred to 25 cm
2
 flask. These were allowed to adhere for 6 hours at 37°C. 
Cells were washed in serum-free DMEM and then incubated 5 ml serum-free 
media + pyruvate with 2.5 µg/ml trypsin, 37°C (A/Victoria/75 backbone 
viruses) or 33°C (A/PR/8 backbone viruses and influenza B) until cytopathic 
effect was observed. Samples were clarified by centrifugation, 3000 RPM for 3 
minutes, and stored -80°C. 
 
The amounts of each plasmid used for the rescue are as follows:  
 
vRNA Plasmids: 
 
pPol I PB1   0.5 µg 
pPol I PB2   0.5 µg 
pPol I PA   0.5 µg 
pPol I HA   0.5 µg 
pPol I NP   0.5 µg 
pPol I NA   0.5 µg 
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pPol I M   0.5 µg 
pPol I NS   0.5 µg 
 
Helper Plasmids: 
 
pCMV PB1   0.5 µg 
pCMV PB2   0.5 µg 
pCMV PA   0.05µg  
pCMV NP   1 µg 
 
2.2.7.2 PER.C6 virus rescue 
 
For rescue in PER.C6, adherent cells in DMEM +2% FCS in 6 well plates were 
transfected with 12 plasmids for virus rescue. Lipofectamine 2000 2:1 ratio 
reagent: DNA. 26 µl Lipofectamine was added to 250 µl Optimem and double 
the amount of the plasmids described above added to 250 µl Optimem. These 
were incubated 5 mins RT, combined and incubated a further 20 minutes, then 
added drop wise to cells. The transfection reagent was removed after 3 hrs and 
cells resuspended in 2 ml virus growth media (2/3 adenovirus expression 
media-AEM, 1/3 VPSF) +3 µg/ml trypsin. Cells were then shaken 80 RPM 
(Shaker flask table IKA KS 260). Samples were clarified by centrifugation, 3000 
RPM for 3 minutes, and stored -80°C. 
 
2.2.8 Molecular biology techniques 
 
2.2.8.1 vRNA extraction 
 
vRNA was extracted using the QIAamp viral RNA mini kit (QIAGEN) or TRIzol 
LS (Invitrogen) according to manufacturer‟s instructions. For the QIAamp kit 
280 µl of virus stock was lysed using the AVL buffer containing Raisin 
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(Promega). This was bound to silica membrane, washed and eluted in 30 µl of 
AVE elution buffer. vRNA was stored at -20°C. For TRIzol LS protocol 250 µl 
virus preparation was combined with 750 µl TRIzol LS. 200 µl of chloroform 
was added, shaken 15 seconds, incubated RT for 2-3 minutes and centrifuged 
at 12,000g, 4°C, for 15 minutes. The supernatant was removed using RNase 
free tips, and transferred to a clean Eppendorf. An equal amount of 
isopropanol was added and incubated RT for 10 minutes, then centrifuged 
12,000 RPM, 4°C, for 15 minutes. The supernatant was removed and the pellet 
washed in pre-chilled -20°C 75% ethanol, and centrifuged 7,500g, 4°C, for 5 
mins. The pellet was air dried for 10 minutes and dissolved in 50-100 l 
nuclease free water.  
 
RNA was quantified by spectrophotometry by measurement of absorbance at 
260 nm. Concentration (µg/ml) = A260 X  where for RNA = 44.19  
 
2.2.8.2 RNA extraction 
 
Total cellular RNA was extracted using TRIzol (Invitrogen) according to 
manufacturer‟s instructions. Cells were washed with PBS, lysed in 1 ml TRIzol, 
transferred to an RNase free Eppendorf tube. Following addition of 200 µl of 
chloroform, the protocol is the same as for TRIzol LS RNA extraction. 
 
2.2.8.3 Reverse Transcription 
 
Generation of cDNA by reverse transcription of RNA was performed using 
Promega reagents. A reaction mix consisting of 2 g of RNA, 0.5g of oligo dT 
primers (Promega), nuclease free water to 15l. The mix was incubated 70°C x 
5 minutes, then 5 µl 5x RT buffer, 1.25 l of 10 mM dNTP mix (Promega), 200 
units M-MLV RT 200 U/l (Promega), 25 units RNasin (Promega) was added 
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and mixed by flicking. This was incubated 42°C for 1 hour, then stored -20°C 
until required for PCR. 
 
2.2.8.4 PCR amplification 
 
PCR was performed with KOD Taq (Novagen) or GoTaq green master mix 
(Promega). For cDNA amplification, 2 l was used, for plasmid amplification 
200 ng was used. 
 
For KOD, a 25 µl PCR mix was made consisting of 2.5 µl 10X Buffer for KOD 
DNA Polymerase, 0.4 µM forward and reverse primers, 2.5 l dNTPs 2 mM, 
0.2l KOD polymerase (2.5 U/µl), nuclease free water to 25 l. 
 
30 cycles of: 95° C for 15 seconds, optimised annealing temperature for 5 
seconds/ 1 Kb DNA, 72° C for 30 seconds. 
  
For GoTaq, 12.5 µl 2X GoTaq® Green Master Mix, forward and reverse 
primers, 0.25 µM, nuclease free water to 25 µl. 25 cycles was sued for semi-
quantitative RT-PCR  
 
Cycling conditions were: 95° C for 2 minutes, 30 cycles of 95° C for 30 
seconds, optimised annealing temperature for 1 minute/ Kb DNA, 72°C for 30 
seconds, followed by a final extension of 72° C 5 minutes 
 
2.2.8.5 In vitro transcribed dsRNA synthesis 
 
In vitro transcribed dsRNA was synthesised using T7 RiboMAX Express RNAi 
System (Promega). Two complementary RNA strands were synthesized from 
DNA templates, in this instance a plasmid encoding an influenza DI (kindly 
provided by Nigel Dimmock). T7 RNA polymerase promoters were added at 
the 5´ ends of both DNA strands with amplification by PCR with primers 
containing the T7 promoter sequence at the 5´ end. Generating the two DNA 
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templates requires two separate PCR amplifications, each containing one gene 
specific primer and the converse T7 primers. PCR was performed with KOD as 
section 2.2.8.4; the first 10 cycles were performed at an annealing temperature 
5°C above the melting temperature of the gene-specific sequences, followed by 
25 cycles of annealing approximately 5°C above the melting temperature of 
the entire primer, including the T7 promoter. A 20 µl reaction was set up at RT 
included: Express T7 2X Buffer 10, linear DNA template (~1 µg total; 1-8 µl, 
nuclease free water 0-7 µl, T7 Express Enzyme Mix, 2 µl to a final Volume of 
20 µl. the reaction was mixed gently and incubated at 42°C, since the RNA 
contains a high level of secondary structure, for 30 minutes. The RNA strands 
were annealed by mixing equal volumes of complementary RNA reactions 
together and incubated at 70°C for 10 minutes, then slowly cooled to room 
temperature (~20 minutes). The DNA template was removed by digestion 
with RQ1 RNase-Free DNase. The RNase Solution was diluted 1:200 in 
nuclease free water. 1 µl freshly diluted RNase Solution was added to 1 µl RQ1 
RNase-Free DNase per 20 µl reaction volume, and incubated for 30 minutes at 
37°C. 0.1 volume of 3M Sodium Acetate (pH 5.2) and 1 volume of 
isopropanol was added and incubated on ice for 5 minutes, then centrifuged 
for 10 minutes, 13,000 RPM. The supernatant was aspirated and the pellet 
washed with 2 volumes of cold 70% ethanol. The pellet was air dried for 
approximately 15 minutes RT, and resuspended in nuclease free and stored -
20°C.  
 
2.2.8.6 Site directed mutagenesis 
 
Site directed mutagenesis was performed using the Quikchange XL site directed 
mutagenesis kit (Stratagene), following the manufacturers protocol. The PCR 
reaction mixtures comprised of 10 ng of DNA template, 125 ng of each of 
forward and reverse primers, 1 µl 10 M dNTPs, 1x reaction buffer, 3 µl 
Quikchange solution, 2.5 units of Pfu turbo DNA polymerase and made up to 
50 µl with sterile water. The PCR was carried out using an initial denaturation 
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stage of 1 minute at 95°C, followed by 18 cycles of denaturation at 95°C for 50 
seconds, annealing at 60°C for 50 seconds and elongation at 68°C for 8 
minutes. The final elongation step occurred at 68°C for 7 minutes. The PCR 
products were digested with 10 U of DpnI restriction enzyme to remove the 
methylated parental (non-mutated) DNA prior to transformation. Plasmids 
were transformed into XL10-Gold ultracompetent cells (Stratagene) following 
manufacturers‟ instructions, and plated out onto L Agar + 100 µg/ml ampicillin 
plates. 
 
2.2.8.7 Restriction digest 
 
Restriction enzymes were from New England Biosciences (NEB) unless 
otherwise stated. They were used according to manufacturers‟ instructions in 
the buffers suggested. pPol I constructs were digested with EcoRI and HindIII. 
 
2.2.8.8 Transformation 
 
Plasmids were transformed into One Shot TOP 10 chemically competent cells 
(Invitrogen) according to manufacturers‟ instructions. 100 µl of cells were 
plated onto LB plates containing 100 µg/ml ampicillin and incubated inverted 
overnight at 37°C. 
 
2.2.8.9 Small scale plasmid purification 
 
A single bacterial colony was picked from selection plates and grown up 
overnight in LB + 100 µg/ml ampicillin at 37°C, shaking Bacteria were pelleted 
from 1.5 ml of the bacterial suspension in a 1.5 ml Eppendorf using a 
microcentrifuge at 13,000 RPM for 3 minutes. The supernatant was discarded, 
1.5 ml fresh bacterial suspension added and the process repeated. Plasmids 
were recovered using the QIAprep spin miniprep kit (QIAGEN) according to 
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manufacturer‟s instructions. This involves alkaline lysis of bacterial cells 
followed by neutralisation and binding of plasmid DNA to a silica membrane. 
The membrane is then washed and plasmids eluted in 30 µl of sterile water 
and stored at -20°C. 300 µl of the original suspension were mixed with 300 µl 
of sterile glycerol and stored at -80°C as a glycerol stock. 
 
2.2.8.10 Large scale plasmid purification 
 
A single bacterial colony was picked from selection plates and grown in LB plus 
100 g/ml ampicillin at 37°C for 8 hours, shaking. 100 l of this was inoculated 
into 100 ml of LB plus 100 g/ml ampicillin. This was grown overnight at 37°C, 
shaking. Plasmids were recovered using the high-speed plasmid purification 
maxi kit (QIAGEN) according to the manufacturer‟s instructions. Briefly, 
bacterial cells were pelleted by centrifugation at 6000 RPM for 15 minutes at 
4°C using a Sorval GSA rotor. The supernatant was discarded and cells 
resuspended in 10 ml of resuspension buffer containing RNaseA. Alkaline lysis 
buffer containing SDS was added to lyse the cells and denature the 
chromosomal DNA. The suspension was neutralised, precipitating 
contaminants, and passed through a resin containing column that binds plasmid 
DNA. The columns were washed and plasmid DNA eluted. Isopropanol was 
added to desalt and precipitate plasmid DNA, which was then ethanol washed 
and eluted in 500 µl of nuclease free water. Plasmid preparations were stored 
at -20°C. 
 
2.2.8.11 Agarose gel electrophoresis 
 
DNA fragments were separated on 1% agarose gels diluted with TAE and 
supplemented with 1x gel red (Cambridge Bioscience). Gels were made and run 
in TAE buffer. Samples were run alongside commercially available DNA size 
markers at 80-100V until the bands had sufficiently separated. DNA was 
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visualised using a UV transilluminator. Where required bands were purified 
using a QIAquick gel extraction kit (QIAGEN), following manufacturer‟s 
instructions. PCR products were eluted in 30 µl nuclease free water and stored 
at -20°C. 
 
2.2.8.12 DNA Sequencing 
 
Constructs were sequenced using the in-house sequencing service. 
Reactions were sequenced using the ABI Prism 3100 (ABI), a fluorescence based 
automated capillary electrophoresis system. 
 
2.2.9 Assays 
 
2.2.9.1 Blue cell assay 
 
Cells were infected with virus at serial dilutions incubated at 37°C for 1 hour. 
The infection media was replaced with DMEM plus 2% FCS for 8 hours 37°C. 
Cells were fixed and permeabilised using ice-cold methanol: acetone (50:50 
v/v) for 10 minutes, RT. NP was detected by incubation with mouse -NP 
antibody (1/300) for 1 hour at room temperature, washed 3 times with PBS, 
followed by goat -mouse antibody conjugated to -galactosidase (1/400) for 
1 hour RT. Infected cells were visualised by incubation with CN buffer (X-Gal 
substrate) which changes from yellow to blue in the presence of -
galactosidase, for 2 hours- overnight at 37°C depending on cell type. 
 
2.2.9.2 SDS-PAGE  
 
A549 or Huh-7 cells were infected with virus at a relevant MOI or left 
uninfected for 8 hours. Cells were washed in PBS, then lysed in an appropriate 
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volume of RIPA buffer for 10 minutes, centrifuged at 1000 RPM, for 1 minute, 
and stored -80°C. Lysates were mixed with 6x loading buffer containing 2% -
mercapto-ethanol. Samples were heated at 55°C for 5 minutes. Proteins were 
separated by denaturing SDS-PAGE on polyacrylamide gels at 100V for 15 mins, 
followed by 180V. 
 
2.2.9.3 Western blotting 
 
Proteins were transferred onto ethanol activated PVDF at 200 mA for 1 hour. 
Membranes were blocked in blocking solution: 5% Marvel milk powder in PBS 
+ 0.1% Tween20 (PBST) except NS1 antibody 5% Marvel milk powder, 10% 
horse serum, in PBS, for 1 hour, RT rocking. Membranes were incubated 
primary antibodies at appropriate dilution (see 2.1.5) in blocking solution for 1 
hour at RT. Membranes were washed 3 times 5 minutes in PBST, then 
incubated with the appropriate secondary antibody conjugated to horseradish 
peroxidase for 1 hour at RT. Membranes were washed 3 times as before then 
incubated with enhanced chemiluminescence (ECL) reagents (Amersham 
Biosciences) according to manufacturer‟s instructions for 1 minute and 
developed using autorad film (Kodak). 
 
2.2.9.4 Immunofluorescence 
 
A549 cell monolayers grown on poly-L-lysine coated coverslips, were infected 
with influenza virus at the relevant MOI in serum free DMEM for 1 hour, then 
replaced with 2% DMEM for the desired time. Coverslips were washed with 
PBS and fixed with freshly made 4% paraformaldehyde for 20 minutes at RT. 
After fixing, cells were blocked with blocking buffer (3% BSA in PBS, 0.02% 
azide) for 30 minutes. cells were permeabilised in 0.1% Triton, PBS for 30 
mins. Antibodies were diluted in blocking buffer and incubated for 1 hour, RT, 
rocking, followed by 3 washes with PBS. Coverslips were washed in water and 
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mounted with Molviol. Cells were visualised using a Pascal confocal 
microscope and analysed using Leica software. 
 
2.2.9.5 Flow cytometry 
 
Cells were transfected with eGFP for 8 hrs, washed once with PBS, suspended 
in PBS containing 2% FCS and 0.02% Azide and analysed by flow cytometry 
using a Becton Dickinson flow cytometer. 
 
2.2.9.6 Mini replicon assay 
 
Cells were transfected with 0.5g of PB2 pol II, PB1 and PA, 1 g of NP and s 
reporter construct: CAT (chloramphenicol acetyltransferase) reporter construct, 
or M-luc (segment 7 UTRs flanking a luciferase reporter). After 48 hours, cells 
were washed with PBS. For CAT, production was quantified using a CAT ELISA 
kit (Roche) following manufacturers‟ instructions. Briefly, cells were lysed and 
diluted appropriately in sample buffer provided. Samples and standards were 
loaded onto a 96 well plate pre-coated with -CAT antibodies and incubated 
at 37°C for 1 hour. Wells were washed and incubated with a DIG labelled -
CAT antibody for 1 hour at 37°C. Following washing, wells were incubated 
with an -DIG antibody conjugated to peroxidase, followed by washing and 
visualisation using the peroxidase substrate ABTS. The absorbance at both 405 
and 490 nm was measured and the value for 405 nm subtracted from the 
value at 490 nm. The levels of CAT present in the samples were determined by 
reading off a standard curve. For Luciferase reporter, cells were washed in PBS, 
lysed in CCLR. Luciferase was measured using a luminometer. 
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2.2.9.7 IFN Luciferase assays 
 
Cells transiently or stably expressing IFN luc reporter construct were infected 
with influenza virus at MOI 2 (unless otherwise stated) in SF DMEM. After 1 
hour incubation at 34°C or 37°C the media was removed, cells were washed 
with PBS, and the media replaced with 2% DMEM. After 8 hours or 
appropriate incubation cells were lysed in CCLR for 5 minutes, centrifuged 
1,000 RPM for 1 minute, supernatants were transferred to clean Eppendorf and 
stored -20°C. Luciferase was measured using a luminometer. 
 
2.2.9.8 ISRE Luciferase assays 
 
Cells transiently expressing ISRE luc reporter construct were treated with 1U/ml 
IFN for 16 hours at 37°C media. Cells were lysed in CCLR for 5 minutes, 
centrifuged 1000 RPM for 1 minute transferred to clean Eppendorf. Luciferase 
was measured using a luminometer. 
 
2.2.9.9 Up luc assay 
 
Cells transiently expressing the up luc reporter construct were infected with 
influenza virus at the MOI 2 (unless otherwise stated) in SF DMEM. After 1 
hour incubation at 34°C or 37°C media was removed and cells washed with 
PBS, replaced with 2% DMEM. After 8 hours or appropriate incubation cells 
were lysed in CCLR for 5 minutes, centrifuged 1000 RPM for 1 minute 
transferred to clean Eppendorf. Luciferase was measured using luminometer. 
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2.2.9.10 β-galactosidase assay 
 
In a 96 well plate CCLR lysates (20 µl PER.C6, 2 µl 293T, 20 µl A549, 20 µl 
Huh-7), plus 800 µl lacZ buffer and 200 µl ONPG (4 mg/ml) were incubated 
37°C until lemon yellow. Absorbance measured at 420 nm. If reactions are 
very fast (2 hours or less), stopped by addition of 500 µl of 1M Na2CO3. 
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Chapter 3 Rescue of recombinant influenza virus 
in PER.C6 cells  
 
3.1 Introduction 
 
Influenza vaccines of the future will be manufactured in cell cultures rather than 
eggs. Future influenza vaccines may be generated from recombinant proteins 
purified from insect cells infected with engineered baculoviruses (Cox, Patriarca 
et al. 2008; He, Madhan et al. 2009), or from mammalian cells infected with 
other viral vectors (adenovirus (Hoelscher, Singh et al. 2008; Holman, Wang 
et al. 2008), modified vaccinia virus Ankara (MVA) (Kreijtz, Suezer et al. 2009; 
Rimmelzwaan and Sutter 2009)). However, it is likely that the bulk of doses 
manufactured during the next few decades will be derived from whole 
influenza viruses, as they are today. Thus, whether further processed to 
become split, subunit or whole virion inactivated product, or administered as a 
live attenuated vaccine, most influenza vaccines will continue to be made from 
a live influenza virus. Many cell culture systems that might be used to generate 
influenza vaccines have low permissivity to influenza infection and this is a 
serious problem for production and yield. The most permissive cell culture 
system for amplification of influenza viruses in the laboratory are Madin Darby 
Canine Kidney (MDCK) cells. Solvay has successfully licensed a vaccine grown 
in MDCK cells. The product is known as Influvac©TC (Medema, Wijnands et 
al. 2004). Licensing required rigorous testing to prove that the final purified 
product would not contain any oncogenic or other adventitious agents.  
 
Since African Green Monkey Vero cells have been used for many years for the 
production of vaccines for other viruses such as polio, their use for influenza 
vaccines requires less validation to be licensed. However, Vero cells show 
relatively low permissivity for influenza viruses, although Baxter describe Vero 
cell clones that can yield higher titres of virus under suspension growth 
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conditions (Kistner, Barrett et al. 1998; Audsley and Tannock 2004; Youil, Su et 
al. 2004) and they are the substrate for one of the vaccine for the current 
swine H1N1 pandemic.  
 
An important requirement of the cell line in which influenza vaccine is 
produced is that it supports faithful virus replication, without inducing adapting 
mutations. After all, the vaccine administered should be a close match to strains 
that circulate in humans. The propagation of influenza viruses in eggs is 
associated with changes in the HA protein which can alter antigenicity. 
Therefore human virus HA sequences were analysed following propagation in 
the Vero cell line (Romanova, Katinger et al. 2003), all were identical to that 
of the original clinical isolates. Meanwhile, viruses passaged in MDCK cells 
acquired several different mutations within the HA. Two of the viruses, despite 
having the same sequence as the clinical isolates, displayed differential abilities 
to agglutinate chicken red blood cells suggesting that cell type specific post-
translational modifications can also occur. In this instance, all of the viruses 
passaged in eggs acquired mutations located within the receptor binding site. 
The MDCK-SIAT cell line which over-expresses α2-6 sialic acid, although not 
currently used for vaccine manufacture, are routinely used for the isolation of 
clinical viruses and have been shown to faithfully replicate influenza viruses 
(Oh, Barr et al. 2008). 
 
Sanofi Pasteur, the vaccine arm of Sanofi Aventis, is the largest manufacturer of 
influenza vaccine in the world. Currently, their principal product is a beta-
propiolactone inactivated, split virion influenza vaccine; marketed in the UK as 
Vaxigrip. Sanofi Pasteur manufactured 170 million doses of Vaxigrip in 2008 by 
propagating influenza virus in eggs. Like any large biopharma company, Sanofi 
Pasteur is investing in research and development that will allow them to keep 
abreast of new developments in their relevant market place. This includes the 
investigation of the use of cell lines for influenza vaccine production.  
Crucell N.V. a Dutch company, have developed a human cell line, PER.C6, 
originating from the primary culture of foetal human retinoblasts immortalised 
  
107 
 
with the oncogenic Adenovirus 5 early region 1 (AdE1) gene. These cells have 
been rigorously documented since their conception and comply with all 
regulatory requirements; therefore, they are suitable for the production of 
human biopharmaceuticals. PER.C6 cells can be grown in suspension, which 
eliminates the need for microcarriers and makes scale-up easier (Fallaux, Bout 
et al. 1998). These human cells support growth of a variety of influenza A and 
B strains and can produce high titres (10
10
 TCID50/ml) of virus in 4 days 
following infection in roller bottles or bioreactors. Preliminary data suggests 
that passage of virus to adapt it to this cell line could result in even higher 
yields of HA antigen (Pau, Ophorst et al. 2001).  
 
Sanofi Pasteur has licensed the PER.C6 cell line from Crucell for manufacture of 
human influenza vaccine in Europe and the Americas. The aim of work 
described in the first part of this thesis is to investigate the suitability of PER.C6 
cells for production of influenza vaccines. Since it is likely that future influenza 
vaccines will be generated by the reverse genetics procedure, the first part of 
this work describes the evaluation of PER.C6 cell line to support recombinant 
influenza virus rescue from cDNA. 
 
Although it is not absolutely necessary that the vaccine seed strain be produced 
in the same cell line as the vaccine product, using a single cell line would 
simplify the procedures and regulatory requirements for vaccine production. 
Recognizing this, several groups have already described the application of the 
other two cell lines, MDCK and Vero for recombinant influenza virus rescue 
(Ozaki, Govorkova et al. 2004; Nicolson, Major et al. 2005; Murakami, 
Horimoto et al. 2008). 
 
Thus, a reverse genetics system for use in canine cells, has been developed 
(Murakami, Horimoto et al. 2007). This adaptation from the standard reverse 
genetics systems used widely in research laboratories has required the 
delineation and cloning of the species-specific canine polymerase I promoter to 
drive in situ synthesis of influenza viral RNA in the MDCK cell nuclei. Although 
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MDCK cells are notoriously difficult to transfect, reported titres of rescued 
influenza viruses are typically 10
3-4
 PFU/ml up to a maximum of 10
6
 PFU/ml.  
 
The use of Vero cells for influenza virus rescue has been widely described but 
because of the generally low permissivity of Vero cells for influenza 
amplification, the success of this approach relies on passage of transfection 
products through eggs (Nicolson, Major et al. 2005), or chick embryo 
fibroblasts (CEFs) (Whiteley, Major et al. 2007). Further adaptation of the 
plasmids used for influenza virus rescue has allowed this procedure to be 
performed in chicken cells such as CEFs (Massin, Rodrigues et al. 2005). 
However, virus rescue in CEFs is difficult, inconsistent and unreliable, and 
therefore is unlikely to be utilized routinely for generation of vaccine seeds. 
 
3.2 Establishing a reverse genetics virus rescue system in PER.C6 
 
The development of a reverse genetics system in which influenza viruses can be 
rescued from cloned cDNAs was first described by Palese and co-workers in 
1989 (Luytjes, Krystal et al. 1989). However, in 1999, the Palese group (Fodor 
et al. 1999) refined their methodology and a second group (Neumann, Fujii et 
al. 2005) described a similar approach that enhanced our ability to generate 
recombinant influenza viruses at will. This more recent method is likely to be 
the route for vaccine seed generation in the future. In this procedure (figure 
1.1.1), cells are co-transfected with 8 plasmids encoding each of the viral 
genomic RNAs under the control of an RNA polymerase I (pol I) promoter and 
4 plasmids directing expression of viral mRNAs from a host cell pol II 
promoter. The pol II plasmids encode the three subunits of the viral RNA-
dependent RNA polymerase complex (PB1, PB2, and PA) and the 
nucleoprotein (NP), and are referred to later in this chapter as „helper 
plasmids‟. They comprise the minimal set of viral proteins required for 
encapsidation, transcription and replication of the viral genome (Parvin, Palese 
et al. 1989). In the nucleus of transfected cells, the viral promoters of the 
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negative sense vRNAs produced in situ are recognized by the polymerase 
complex, and then amplified and expressed. Viral gene products and newly 
synthesized genome segments then assemble to form de novo infectious 
influenza virus whose genome sequence has been predetermined by the cDNAs 
that were originally transfected. In order to be a suitable cell line for influenza 
vaccine seed generation, PER.C6 cells must be able to support the procedure to 
generate infectious influenza virus from cDNA.  
 
3.2.1 PER.C6 cells support the rescue of recombinant influenza virus 
 
The first step in assessing the suitability of PER.C6 cells for the generation of 
influenza viruses by reverse genetics was to determine how efficiently they 
could be transfected. Cells were transfected with an expression plasmid 
encoding the reporter gene, eGFP, under a variety of conditions and reagents 
according to the manufacturers‟ instructions. Transfection efficiency was 
measured by monitoring the number of fluorescent cells using fluorescence 
microscopy and the percentage positive cells using FACs (data not shown). 
Adherent PER.C6 cells are readily transfectable. 13.7% PER.C6 cells were 
positive for GFP expression compared to 12.5% achieved with the optimized 
protocol used in the laboratory to transfect the 293T cell line that is routinely 
used for recombinant influenza virus rescue. In contrast, suspension PER.C6 
cells were found not to be transfectable by lipofection.  
 
The optimum transfection conditions established for transfection of a single 
plasmid into adherent PER.C6 cells were achieved using Lipofectamine 2000 
(Invitrogen) at a ratio of 2 µl of reagent: 1 µg DNA. Cells were most 
transfectable when ~95% confluent. This correlates to 2x10
6
 adherent cells in a 
well of a 6 well plate. To achieve this, 1x10
6
 cells were plated the day prior to 
transfection. A 95% confluent monolayer of adherent PER.C6 cells from a T80  
cm
2
 flask split at a 1:2.5 ratio will realize this. 
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Figure 3.2.1 Schematic representing virus rescue procedure by either co-culture 
or PER.C6 
 
For co-culture: 293T cells in 12 well plates are transfected with the 12 plasmids 
for virus rescue using Fugene (Roche). Following an overnight incubation, cells 
are mixed with an MDCK cell suspension in T25 cm
2
 flask. These are allowed 
to adhere for 6 hours at 37°C in 10% DMEM. Media is then replaced with 
serum-free DMEM containing 2.5 µg/ml trypsin, and incubated until cytopathic 
effect was observed (4-6 days).  
 
For rescue in PER.C6 cells: adherent PER.C6 cells in 6 well plates are 
transfected with the 12 plasmids for virus rescue using Lipofectamine 2000 
(Invitrogen). The transfection reagent was removed after 3 hrs and cells 
resuspended in 2 ml virus growth media (2/3 adenovirus expression media-
AEM, 1/3 VPSF) +3 µg/ml trypsin. Cells were then shaken 80 RPM (Shaker flask 
table IKA KS 260). Virus was harvested 6-7 days post transfection. 
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In the laboratory, the established procedure for rescue of recombinant 
influenza virus for research purposes involves the transfection of 293T cells 
with the 12 plasmids for virus rescue, followed by co-culture with MDCK cells 
the following day. Since PER.C6 cells in suspension are more permissive to 
virus growth but are resistant to transfection, a two-step procedure was 
developed. The ratios determined above were applied to the 12 plasmid virus 
rescue in PER.C6 cells. The transfection of 12 plasmids compared to a single 
plasmid means higher concentrations of DNA and accordingly larger volumes 
of reagents will be applied to the transfected cells. Higher quantities of 
transfection reagents are associated with increased cytotoxicity; however, 
PER.C6 cells tolerated these higher concentrations.  
 
Adherent cells were transfected with the 12 plasmids and incubated for 3 hours, 
37°C, 10% CO2. This was deemed sufficient time to allow transfection to 
occur. The media was then removed and cells resuspended in virus growth 
media (2/3 AEM, 1/3 VPSF, Pen/Strep), 1x10
6
 cells/ml (i.e. 2 ml). Using this 
procedure, recombinant influenza virus of PR8 vaccine strain was rescued from 
cDNA and titres of 1x10
6
 PFU/ml were achieved 6-7 days after transfection (fig 
3.2.1). This protocol was written as an SOP for use by national and 
international reference laboratories for the generation of vaccine seeds in the 
PER.C6 cell line. 
 
3.3 Optimising virus rescue conditions 
 
3.3.1 ‘Helper’ plasmids derived from A/Victoria/3/75 virus drive replication 
most efficiently 
 
Having established that the PER.C6 cell line can support virus rescue, it was 
next investigated whether rescue efficiency could be improved by adapting 
rescue conditions. Virus rescue requires transfection of 4 „helper‟ plasmids (PB1,  
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PB2, PA and NP) which express the minimal set of viral proteins required for 
virus RNA replication, (Parvin, Palese et al. 1989). The viral origin of the helper 
plasmids may influence the efficiency of virus rescue because of differences in 
the processivity of the viral polymerases they encode. For example, the 
polymerase of the H3N2 virus A/Victoria/3/75 has been used in the lab to 
efficiently drive minireplicon expression and recombinant virus rescue (Elleman 
and Barclay 2004). Others have described sets of helper plasmids derived from 
influenza PR8 vaccine strain (Schickli, Flandorfer et al. 2001; Whiteley, Major 
et al. 2007; Koudstaal, Hartgroves et al. 2009) or the laboratory adapted 
A/WSN/33 virus (Pleschka, Jaskunas et al. 1996; Fodor, Devenish et al. 1999). 
It is important to emphasise that, since the helper plasmids only encode viral 
proteins, and not vRNA, at no point will the sequences encoding the helper 
polymerases form the genome of the rescued virus. To compare efficiency of 
rescue using different helper polymerases, helper plasmid sets were transfected 
into cells and their ability to drive the replication of an influenza-like 
minireplicon RNA, encoding the non-coding regions of segment 8 flanking a 
luciferase reporter was assessed. Some influenza A virus strains encode a PA 
protein which can be toxic to cells, so a range of concentrations of PA were 
tested. Five helper plasmids sets were compared in their ability to drive 
influenza minireplicon expression (figure 3.3.1), including the polymerases 
cloned from A/Victoria/75, and polymerases cloned from a number of 
different sources of the vaccine strain of influenza A virus, PR8. PR8 
polymerases cloned from a virus supplied by NIBSC were expressed from 
developed bi-directional pol I/II plasmids (Whiteley, Major et al. 2007); these 
direct production in transfected cells of both proteins and vRNA and are used 
in transfection systems described by (Hoffmann, Krauss et al. 2002). A set of 
plasmids encoding PR8 polymerase proteins were also independently cloned 
by Wouter Koudstaal of Crucell N.V. and supplied for testing in this 
experiment and either as 4 separate plasmids or just 2 plasmids expressing 
proteins separated by and IRES (fig 1.1.1 (Koudstaal, Hartgroves et al. 2009).  
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Figure 3.3.1 “Helper” plasmids derived from A/Victoria/3/75 are the most 
efficient at driving replication for influenza virus rescue 
 
The efficiency of different helper plasmid sets was measured by their ability to 
drive the replication of an influenza-like minireplicon RNA, encoding the non-
coding region of segment 8 flanking a luciferase reporter. PER.C6 cells were 
transfected with helper plasmid constellations cloned from A/Victoria/75 and 
A/WSN/33, bi-directional pol I/ pol II A/PR/8/34 and IRES/BGH A/PR/8/34, 
and the luciferase reporter. Since PA from certain strains of influenza can be 
toxic, two concentrations were tested for A/Victoria/75 and A/PR/8 plasmid 
sets. 42 hrs post transfection cells were washed with PBS, lysed in CCLR and 
luciferase activity measured. Means and standard error were calculated for 
duplicate wells. This assay is representative of three repeat experiments. 
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Finally, polymerase expression plasmids for the virus strain A/WSN/33 that are 
routinely used at NIBSC to generate vaccine seeds in Vero cells were provided 
by Ervin Fodor, (SWDSOP, Oxford). The data (figure 3.3.1) shows that the 
most efficient expression of the minireplicon luciferase reporter was driven 
following transfection of helper plasmid encoding the polymerase complex 
cloned from A/Victoria/3/75 virus and 0.05 µg of PA. These are the conditions 
previously optimised for rescue in co-culture and therefore fortuitously the 
conditions used to establish the virus rescue procedure described for PER.C6 
cells above; thus no alterations to this part of the procedure were proscribed.  
 
3.3.2 A single step rescue transfection procedure is most efficient for virus 
rescue in the PER.C6 cell line 
 
Rather than transfecting all 12 plasmids at once, a variation to the procedure 
was made whereby helper plasmids were added on day 1, to allow strong 
expression of viral polymerase proteins before transfection of plasmids 
encoding viral RNAs (figure 3.3.2). Transfection of all plasmids at once resulted 
in >3 logs more virus than a two step procedure (figure 3.3.3). A single step 
transfection is the most efficient and also the most straightforward protocol for 
virus rescue in PER.C6 cells. 
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Figure 3.3.2 Schematic representing rescue procedures for one- or two- step 
transfection protocol 
 
In the one-step procedure cells were transfected with all 4 Victoria helper 
plasmids and 8 RD3 (6:2 PR8 +HA and NA A/Chicken/Italy/1347/99 H7N7) 
rescue plasmids. 3 hours later the transfection reagent was removed and the 
cells resuspended in virus growth media (2/3 AEM, 1/3 VPSF with pen/strep). 
In the two-step procedure cells were transfected with 4 Victoria helper 
plasmids. 16 hours post transfection the media was removed and 8 RD3 rescue 
plasmids were transfected, 3 hours later the transfection reagent was removed 
and the cells resuspended in virus growth media (2/3 AEM, 1/3 VPSF with 
pen/strep). Virus was harvested and clarified 7 days following the first 
transfection. 
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Figure 3.3.3 One-step virus rescue is the most efficient procedure 
 
The efficiency of one- and two- step rescue procedures of the vaccine strain 
RD3 (6:2 A/PR/8 internal gene segments plus HA and NA from 
A/Chicken/Italy/1347/99) were compared in PER.C6 cells. In the one-step 
procedure cells were transfected with all 4 Victoria helper plasmids and 8 RD3 
rescue plasmids and incubated 37°C for 3 hours. The transfection reagent was 
removed and the cells resuspended in virus growth media (2/3 AEM, 1/3 VPSF 
with pen/strep). In the two-step procedure cells were transfected with 4 
Victoria helper plasmids incubated 37°C. 16 hours post transfection the media 
was removed and 8 RD3 rescue plasmids were transfected, incubated 37°C x16 
hours. The transfection reagent was removed and the cells resuspended in virus 
growth media (2/3 AEM, 1/3 VPSF with pen/strep). Virus was harvested and 
clarified 7 days following the first transfection. Virus titres were assayed by 
plaque assay. This assay is representative of two repeat experiments. 
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3.3.3 The kinetics of virus rescue in the PER.C6 cells  
 
In order to establish the optimum day post-transfection to yield the highest 
titre of infectious influenza virus in PER.C6 cells supernatants were taken over 
the course of the rescue. Following the SOP, the 12 plasmids that direct the 
rescue of A/PR/8/34 were transfected on day 0. Cell supernatants were taken 
daily from day 1, clarified by centrifugation (3000 RPM for 3 minutes) and 
stored at -80°C until all samples were collected and could be assayed 
simultaneously for the presence of virus by HA assay using CRBC and plaque 
assay on MDCK cells. The procedure was performed in parallel in PER.C6 cells 
or in 293T/MDCK cell co-culture. Virus was detected on day 2 post 
transfection using the co-culture method or day 3 using PER.C6 cells (figure 
3.3.4). Peak recovery of virus was obtained 6 days after transfection of PER.C6 
cells. Peak titres determined by plaque assay, were similar for each method 
(approximately 1x10
6
 PFU/ml). In PER.C6 an increase in HA units consistently 
occurred towards the end of infection despite a decrease in infectious plaque 
forming units. The reasons for this have not been determined.  
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Figure 3.3.4 Kinetics of virus rescue 
 
Following the SOP for PER.C6 or standard lab procedure for co-culture, cells 
were transfected on day 0 with the 12 plasmids that direct the rescue of 
A/PR/8/34 were. Cell supernatants were taken daily from day 1, clarified by 
centrifugation (3000 RPM x3 min) and stored at -80°C. Samples were assayed 
for the presence of virus by HA assay using CRBC and plaque assay on MDCK 
cells. This data is representative of 2 repeat experiments. 
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3.3.4 PER.C6 cells support rescue of a range of backbones and subtypes 
 
Next, the ability of PER.C6 cells to support the rescue a range of influenza 
viruses and subtypes was assessed. Two complete reverse genetics systems with 
plasmids for the rescue of influenza A/PR/8/34 (H1N1) or A/Victoria/3/75 
(H3N2) were tested. PR8 has been used as the recipient genetic backbone of 
the influenza A virus vaccine for more than 30 years (Kilbourne 1969), and was 
developed particularly for high yields in eggs. A/Victoria/3/75 (H3N2) is more 
representative of a typical human influenza strain. PER.C6 cells were able to 
support the rescue of both PR8 and A/Victoria/3/75 viruses. Moreover, PR8 
based 6+2 reassortants with a wide variety of HA and NA subtypes, 
representing typical vaccine seed strains were reliably rescued in these cells 
(table 3.3.1), yields can be low but are recovered following subsequent 
passage. In general, yields were higher and more reliable in PER.C6 than in the 
licensed alternatives- rescue in Vero cells co-cultured with chick embryo 
fibroblasts. Interestingly rescue of the A PR8-HK97 virus was rather inefficient 
in PER.C6 cells, even though the rescued virus was amplified during one 
additional passage in PER.C6 cells and eventually a model vaccine was 
prepared from this strain (Koudstaal, Hartgroves et al. 2009). 
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Table 3.3.1 PER.C6 cells are able to support the rescue of range of virus 
backbones and subtypes 
 
PER.C6 cells were transfected according to the SOP and assayed 6 days post 
transfection by plaque assay. 
 
Virus Subtype 
Titre 
(PFU/ml) 
A/PR/8/34 H1N1 5x10
6- 
2x10
6
 
A/Victoria/3/75 H3N2 8x10
3
 
B/Beijing/87 B 1x10
4
 
6:2 A/PR/8/34 + A/New Caledonia/20/99 HA & NA H1N1 1x10
2
 
6:2 A/PR/8/34 + A/Victoria/3/75 HA & NA H3N2 2x10
5
 
6:2 A/PR/8/34 + A/Panama/2007/99 HA & NA H3N2 19 
6:2 A/PR/8/34 + A/Wisconsin/67/2005 HA & NA H3N2 5x10
2
 
6:2 A/PR/8/34 + A/Chicken/Italy/1347/99 HA & NA
a
 H7N1 5x10
7
 
6:2 A/PR/8/34 + A/Viet Nam/1194/2004 HA & NA
a
 H5N1 9x10
6
 
6:2 A/PR/8/34 + A/Hong Kong/156/97 HA & NA
a
 H5N1 <10 
a
 Sequence of the HA cleavage site modified to remove pathogenic traits  
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3.3.5 Virus rescue can be performed from a single PER.C6 suspension cell line 
 
Initially the procedure for rescue of influenza virus was established in adherent 
PER.C6 cells because suspension cells were reported to show very low 
transfection efficiency that may preclude virus rescue. On the other hand, virus 
propagation is most efficient in PER.C6 suspension cells (Pau et al. 2005), For 
vaccine generation and production this would require maintenance of both 
adherent and suspension cell lines. It would be preferable to maintain a single 
cell line which could produce recombinant vaccine seed and high titre vaccine 
manufacture. The addition of serum in the growth media rapidly drives PER.C6 
suspension cells to adherence, thus one solution to this would be the 
generation of recombinant virus by transfection in adherent cells that had only 
recently been derived from a suspension culture (fig 3.3.5). The health agencies 
responsible for seed generation (e.g. NIBSC or CDC) would then be required to 
maintain only PER.C6 cells in suspension. Once the rescued virus had been 
generated, it could then be propagated in the same suspension cells from which 
the adherent cells were derived.  
 
We were provided with a line of PER.C6 suspension cells that have been 
adapted by Sanofi Pasteur for influenza propagation and represent the cell line 
they use for vaccine manufacture. In parallel, suspension cells were derived 
from the adherent cell stock originally supplied from Crucell, which has been 
used throughout for the development of virus rescue. To generate the 
suspension cells, the adherent cells were passaged a minimum of six times in 
suspension cell media (AEM +L-glutamine), until stable growth characteristics 
were observed. One day before transfection, the cells were returned to 
adherent state by transfer to serum containing media as before, at a seeding 
density of 2x10
6
 cells. Following the standard SOP, the 12 plasmids that direct 
rescue of PR8 virus were transfected into duplicate dishes of either the 
suspension cells of Sanofi Pasteur or the derived cells of Crucell. Many cells 
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Figure 3.3.5 Schematic representing virus rescue from a single cell line 
 
Adherent PER.C6 cells were reported to show very low transfection efficiency 
that may preclude virus rescue, whilst virus propagation is most efficient in 
PER.C6 suspension cells. It would be preferable to maintain a single cell line 
which could produce both recombinant vaccine seed and high titre vaccine. 
The addition of serum to the growth media rapidly drives PER.C6 suspension 
cells to adherence, so virus can be rescued from adherent cells that have only 
recently been derived from a suspension culture. Rescued virus is then 
propagated in the same suspension cell stock from which the adherent cells 
were derived.  
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Table 3.3.2 Virus rescue can be performed in single PER.C6 cell line in 
suspension 
 
PER.C6 suspension cells were driven to adherence by the addition of serum to 
the growth media. PER.C6 suspension cells adapted by Sanofi Pasteur for 
influenza propagation were compared to suspension cells derived from the 
original adherent PER.C6 cell stock supplied from Crucell, by passage in 
suspension cell media (AEM +L-glutamine) with adherent PER.C6 cells as a 
rescue control. Cells were transfected with 12 plasmids that drive rescue of PR8 
virus, following the SOP. Virus titres 7 days post transfection were determined 
by TCID50/ml in MDCK cells.  
 
Cell origin # TCID50 HA 
Adherent: Crucell 
1 3.2x10
4
 64 
2 3.2x10
1
 0 
Suspension: Crucell 
1 3.2x10
3
 0 
2 5.6x10
4
 32 
Suspension:  Sanofi 
1 1.3x10
4
 16 
2 4.2x10
5
 32 
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 looked granulated and were not well adhered to the well, nonetheless, when 
titres of recombinant viruses at day 7 were compared by TCID50 assay in 
MDCK cells and HA of chicken RBC (table 3.3.2) they were comparable to 
those achieved from rescue in cells fully adapted to adherent growth.  
 
By increasing the total number of cells undergoing transfection, yields might be 
further increased; therefore, cells were also allowed to adhere over night then 
trypsinised and reseeded on day 2 (P1). This did not affect rescue titres (data 
not shown).  
 
3.3.6 Comparison of PR8 backbones 
 
Although the PR8 strain was rescued and propagated efficiently in PER.C6 cells, 
this vaccine backbone has been adapted for high growth in eggs. It may be that 
PR8 is not well adapted for growth in the human cell line and that by further 
passage of a PR8 stock, a derivative could be generated that would more 
efficiently be rescued. The stock of PR8 virus originally obtained from NIBSC 
was passaged 11 times in suspension PER.C6 by Wouter Koudstaal at Crucell. 
The P11 virus did indeed show enhanced growth in the PER.C6 line, and whole 
genome sequencing revealed changes in three viral gene segments, HA, NA and 
NP (L37F and I349F in HA, S349N in NA, I33T and F346S in NP, Wouter 
Koudstaal personal communication). The entire eight segments of P11 PR8 virus 
were cloned into polymerase I rescue plasmids for generation of recombinant 
virus by Wouter Koudstaal. The ability of this set of P11 plasmids to direct virus 
rescue was compared with those generated in the Barclay laboratory as part of 
the FLUPAN EU funded project (Whiteley, Major et al. 2007). The rescue 
efficiency was compared in either PER.C6 or 293T/MDCK co-culture rescue. 
The rescue of three different vaccine strain viruses were assessed; these 
contained plasmids encoding the 6 internal gene segments from either P11 or 
FLUPAN PR8 virus, together with plasmids encoding the surface antigens, HA 
and NA, from either wt PR8 or avian influenza viruses A/HK/97 (H5N1) or 
A/Chicken/Italy/1347/99 (RD3/ H7N1).  
  
125 
 
Table 3.3.3 Comparison of virus rescue backbones 
 
A backbone was generated in house in the Barclay laboratory as part of the 
FLUPAN EU funded project. Another backbone was derived from a stock of 
PR8 virus originally obtained from NIBSC passaged 11 times in suspension 
PER.C6 by Wouter Koudstaal at Crucell. Rescue by co-culture and PER.C6 were 
compared. Cells were transfected with either backbone according to the 
standard SOP, virus titres were assayed by plaque assay in MDCK cells.  
 
backbone transfection method PR8 H5N1 H7N1 
FluPAN Co-culture 3.0x10
7
 1.9x10
7
 1.5x10
5
 
Crucell Co-culture 3.1x10
7
 2.5x10
6
 1.5x10
5
 
FluPAN PER.C6 3.0x10
5
 ND* 5.0x10
7
 
Crucell PER.C6 1.2x10
5
 ND* ND* 
*ND- not detected 
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Wt A/PR8/34 virus of both P11 and FLUPAN derived backbone was rescued 
using either set of cells (table 3.3.3). Interestingly, RD3 H7N1 6:2 recombinant 
virus was only rescued in conjunction with the FLUPAN plasmids. This might 
imply that the sequence changes in the P11 NP gene are incompatible with the 
H7 or N1 genes. The 6:2 PR8 -HK97 H5N1 recombinant virus was not rescued 
under any conditions in PER.C6, although it was rescued using the 
293T/MDCK co-culture protocol. Further work has shown that upon passage 
of transfected cell supernatants through PER.C6 cells the PR8 -HK97 virus can 
be propagated and indeed a vaccine batch has been prepared and tested in 
mice for this strain (Koudstaal, Hartgroves et al. 2009). The data suggests the 
co-culture protocol is more efficient for virus rescue, and that certain 
combination of internal and surface antigens may be more compromised than 
others for rescue and propagation in PER.C6 cells. 
 
3.4 Discussion 
 
Adherent PER.C6 cells are easily transfectable. Furthermore, they support the 
rescue of recombinant viruses by reverse genetics. A rescue procedure has been 
developed and optimised and an SOP has been supplied to NIBSC for 
generation of seed virus for vaccine production in PER.C6.  
 
The procedure has been optimised using the available reverse genetics 
backbone and the current vaccine donor strain PR8, which was originally 
adapted for high growth in eggs. Yields in PER.C6 cells could be increased by 
adapting or improving the backbone of the virus. H5N1 viruses have proved 
difficult to grow to sufficiently high titres. A PR8 based backbone containing a 
chimeric NA was able to increase the yields for a prototype H5N1 vaccine 
(Adamo, Liu et al. 2009). 
 
Following the generation of reassortants for the 2006/7 vaccine season, a 
reassortant of the H3N2 strain, A/Wisconsin/67/2005, was selected (X116) 
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which did not grow well in eggs. An alternative reassortant was then selected 
(X116B) which replicated well in eggs. The passage of these viruses in PER.C6 
cells resulted in the opposite growth kinetics to eggs; X116 grew to high titres 
whilst X116B grew to poor titres. Whilst a 6:2 reassortant is ideally required, 
only the incorporation of surface antigens (HA and NA) and segment 7 into 
the vaccine seed are routinely screened. Subsequent sequencing of both 
reassortants revealed that X116 contained only segment 7 from PR8 and all 
other 7 segments from Wisconsin, whilst X116B was a true 6:2 reassortant. This 
suggests that an H3N2 backbone may be better suited for higher yields of virus 
in PER.C6 cells. However, titres of rescued virus were not higher when the 
A/Victoria/75 (H3N2) backbone was used. A/Victoria/75 is a lab adapted older 
strain of virus; a more modern H3N2 might represent a more suitable donor 
strain for rescue of viruses PER.C6. 
 
PR8 virus has been serially passaged in PER.C6 cells by both Sanofi and Crucell 
in order to adapt the virus to the cell line. Eleven serial passages by Crucell 
resulted in amino acid changes in HA and NA and NP; the mutations in the 
surface antigens are likely to improve the efficiency by which the virus is able 
to enter cells but would confer no additional benefits to PR8 as a vaccine 
donor strain, since only the internal genes are donated. The mutation to NP 
did not seem to increase the rescue efficiency (section 3.3.6). Alternatively, ten 
serial passages by Sanofi resulted in a log increase in virus with yields (Sanofi 
personal communication). Sequencing of the virus revealed two mutations in 
segment 7 (M). Segment 7 encodes two matrix proteins- M1 and M2. M1 is 
involved in assembly and release of the virus. Whilst alternative splicing 
encodes M2 a small ion channel protein, which alters pH of vesicles allowing 
conformational change of HA (Elleman and Barclay 2004) and has also been 
associated with the formation of infectious viral particles (McCown and Pekosz 
2006). One mutation is located in M1, H175D, and the second in M2, V92A. 
However, although inclusion of PER.C6 adapted segment 7 resulted in the 
detection of virus a day earlier than rescue with wt PR8 segment 7 (day 2 
compared to day 3), there was no increase in the final titres of rescued virus 
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(data not shown). Although the addition of PER.C6 adapted segment 7 confers 
no increase in rescued virus titres its inclusion may benefit difficult to rescue 
viruses, and may confer higher titres when propagating the vaccine seed. 
 
PR8 is the approved donor strain currently used in vaccine manufacture. 
Although increases in yields could potentially be obtained with adapted viruses 
and other backbones these will require validation and safety approval. The 
continued use of PR8 as a backbone means seed viruses can be generated by 
reverse genetics in PER.C6 and used for vaccine manufacture in both eggs and 
PER.C6 cell culture.  
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Chapter 4 Rapid generation of a well-matched 
vaccine seed from a modern influenza A virus 
primary isolate without recourse to eggs 
 
4.1 Introduction 
 
The production of influenza vaccines from seed reassortants has relied on 
embryonated chickens eggs for large-scale viral growth for more than 40 years.  
However, the receptor used for cell entry in eggs differs from that in the 
human respiratory tract. As a consequence of host adaptation combined with 
antigenic drift, many recent isolates of influenza A virus have developed 
altered receptor binding characteristics compared to strains that circulated 
shortly after the emergence of the H3 or H1 subtype as pathogens in man more 
than 40 years ago (Medeiros, Escriou et al. 2001; Mochalova, Gambaryan et 
al. 2003; Thompson, Barclay et al. 2004) and now show decreased potential 
to propagate in eggs.  
 
It has long been known that for many human influenza isolates, propagation in 
eggs selects for mutations (Schild, Oxford et al. 1983) some of which give rise 
to a mismatch in antigenicity between the egg-grown virus and the naturally 
circulating virus (Mochalova, Gambaryan et al. 2003). For influenza B viruses, 
this often manifests as changes in the glycosylation patterns of HA during egg 
adaptation that may additionally affect the antigenicity (Schild, Oxford et al. 
1983; Chen, Aspelund et al. 2008). Indeed the positions of egg-adapting 
mutations are key to whether the antigenicity of the vaccine would be 
affected. Egg passage of the H3N2 virus A/Memphis/7/90 resulted in two 
different egg-adapted mutants, containing HA mutations at either G156K or 
S186I. Although the S186I virus induced a protective antibody profile similar to 
that of the wt virus, antibodies induced by the virus with G156K mutation 
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were cross-reactive but did not protect against challenge with a lethal dose of 
unadapted A/Memphis/7/90 virus (Widjaja, Ilyushina et al. 2006).  Thus, 
strains chosen for inclusion in the vaccine should be monitored for the 
occurrence of antigenic mismatches. Moreover, for some viruses, propagation 
in eggs is impossible altogether and in this case, reliance on eggs for vaccine 
manufacture may result in the exclusion of the most suitable strain from 
incorporation into the vaccine or a delay in vaccine manufacture. A recent 
example is the H3N2 influenza A/Fujian/411/02 virus that was predicted to be 
the dominant strain in the 2003/04 season. Since this virus did not grow in 
eggs and an alternative seed had to be sought (A/Wyoming/3/2003) resulting 
in delays to the delivery of the vaccine seed. Subsequent molecular analysis 
revealed that mutations at G186V and V226I were sufficient to confer egg 
adaptation to Fujian and that this had little or no effect on the antigenicity of 
the strain (Lu, Zhou et al. 2005). The G186V mutation alone was also able to 
confer egg adaption to other H3 viruses unable to grow in eggs (Lu, Zhou et al. 
2006).  
 
Several cell lines are currently being explored as alternative substrates for 
influenza vaccine production. These include the MDCK, Vero and PER.C6 cell 
lines (Halperin, Nestruck et al. 1998; Kistner, Barrett et al. 1998; Brands, Visser 
et al. 1999; Pau, Ophorst et al. 2001; Audsley and Tannock 2005). Using cell 
culture systems would add substantial flexibility to the influenza vaccine 
production process, for example in times requiring rapid scale up, such as onset 
of a pandemic. Furthermore, the use of mammalian cell substrates for 
propagation of vaccine strains reduces the likelihood of variants with altered 
antigenicity occurring during propagation since HA mutations are not 
necessarily selected for during replication in cell culture (Minor, Engelhardt et 
al. 2009).  
 
The generation of vaccine seed strains on cell culture has been inhibited by 
concerns about the increased potential for carryover of adventitious agents 
from clinical specimens. Egg propagation has been previously been thought of 
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as a filter for such agents. However, reverse genetics technology (Fodor, 
Devenish et al. 1999; Neumann, Watanabe et al. 1999), allows for the 
generation of recombinant influenza viruses entirely from cDNA, and thus 
eliminates this risk. Moreover, by removing the random aspect of the 
reassortment process, reverse genetics makes it possible to create vaccine seed 
strains at unprecedented speed and even to incorporate desirable safety and 
growth characteristics (Stieneke-Grober, Vey et al. 1992; Li, Liu et al. 1999; 
Subbarao, Chen et al. 2003; Stech, Garn et al. 2005; Horimoto, Takada et al. 
2006).  
 
Technological advances in DNA synthesis mean that long sequences can be 
synthesised de novo, introduced directly into the appropriate plasmids for use 
in reverse genetics, and rescued in a suitable backbone strain. If rescue and 
subsequent propagation does not introduce mutations, this approach should 
provide the best possible antigenic match between vaccine and circulating 
strains. 
 
Previously we showed that PER.C6 cells are suitable for the recovery of 
recombinant influenza viruses by the reverse genetic technique and subsequent 
production of vaccine (chapter 3, (Koudstaal, Hartgroves et al. 2009). Here we 
assess whether the PER.C6 cell line faithfully supports replication of recently 
isolated human influenza strains and facilitates production of appropriate 
vaccine seeds based on their sequence. 
 
However, current manufacturing capacity for the production of influenza 
vaccines on cell culture is insufficient to meet vaccine demand, and some 
proportion of the vaccine quota will require propagation in eggs. Therefore, at 
least for the immediate future, an ideal seed virus should replicate in both cell 
culture and eggs.  
 
Here we investigated whether it was possible to generate a universal seed 
appropriate for both egg and cell culture derived vaccine manufacture for a 
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wild type strain that did not replicate in eggs. As a representative strain to 
demonstrate proof of principle we used A/Eng/611/07 (E611) that is 
antigenically similar to the vaccine strain A/Brisbane/10/07 (the H3 component 
of the 2008/09 vaccine) but whose suitability as a vaccine seed would have 
been precluded by its inability to grow in eggs. Since the G186V mutation has 
been shown to confer egg growth to a number of strains from the first part of 
this decade (2000-2005), we engineered G186V into E611 HA. Additionally, 
we found a novel mutation in the E611 HA gene, L194P, was selected during 
egg passage of the recombinant virus. Therefore, we also directly engineered 
this mutation into the wild type E611 HA gene and compared its ability to 
adapt a virus with E611 HA for growth in eggs with the G186V mutation. We 
found that combination of the wild type HA gene into the PR8 vaccine 
backbone allowed for the generation in PER.C6 cells of a vaccine seed that 
would be capable of efficient propagation in both cell substrates and eggs. 
 
4.2 PER.C6 cells support the faithful propagation of recent clinical 
isolates 
 
Contemporary circulating strains of human influenza A virus are frequently 
isolated in surveillance laboratories on the MDCK-SIAT cell line. These cells 
have been genetically manipulated to over-express the α2-6 sialyltransferase 
enzyme and consequently display a higher level of α2-6 linked SA at the cell 
surface  than do unmanipulated MDCK cells (Matrosovich, Matrosovich et al. 
2003). Recent strains of human influenza A virus that tend to display low SA 
receptor binding affinity are isolated in these cells more efficiently than in 
standard MDCK cells (Oh, Barr et al. 2008). In contrast, inoculation of eggs 
with recent clinical isolates results in sporadic recovery of infectious virus. To 
assess whether recent human influenza viruses were faithfully propagated in 
PER.C6 cells, a small panel of isolates of human influenza A (H3N2 and H1N1) 
and B viruses isolated from clinical cases of influenza like illness in the winters 
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of 2003/04 and 2004/05 were obtained from the Health Protection Agency 
Centre for Infections and had been isolated in the MDCK-SIAT cell line.  
 
The viruses were passaged again once in either MDCK-SIAT cells, in PER.C6 
cells or inoculated into eggs. After 3 days incubation, cell supernatants and 
allantoic fluids were harvested and virus was detected by haemagglutination 
assay using either chicken or turkey red blood cells. Since the 1999/2000 
influenza season, turkey red blood cells have been more sensitive for the 
detection of clinical strains of human influenza viruses than the traditional 
chicken red blood cells. This is most likely because the density of SA on turkey 
RBC is higher than on chicken RBC, and viruses whose HA proteins have low 
affinity for SA maintain the ability to agglutinate them (Kumari, Gulati et al. 
2007). An inability to agglutinate either type of red blood cell was taken as 
absence of virus growth and this was confirmed by plaque assay of undiluted 
samples on both MDCK cells and MDCK-SIAT cells. Table 4.2.1 shows that the 
only viruses to be propagated efficiently in eggs were two strains of influenza B 
virus, B/E/216/05 and B/E/429/05. These isolates had a strong HA titre 
measured with chicken RBC even before passage through eggs suggesting they 
retained a receptor binding phenotype typical of older influenza virus isolates. 
For all the other H3N2, H1N1 and influenza B viruses analysed, no virus 
growth in eggs was detected. Moreover, following passage through either 
PER.C6 cells or SIAT-MDCK cells, this group of viruses did not acquire the 
ability to agglutinate chicken RBCs suggesting that receptor binding profile of 
the original isolate was faithfully maintained. The entire HA gene of a 
representative H3N2 virus (A/Eng/26/05) passaged in PER.C6 and MDCK-SIAT 
cells was sequenced and found to be identical from both cell substrates. 
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Table 4.2.1 PER.C6 cells support the faithful propagation of recent clinical 
isolates 
 
Clinical isolates from the 2004/2005 influenza season were previously 
passaged once on MDCK-SIATs. PER.C6 cells in suspension, MDCK-SIAT cells, 
or 10 day old embryonated chicken eggs were inoculated with virus innoculum 
at equivalent HA units. Supernatants were harvested after 4 days for cell lines 
and 3 days for eggs. Receptor binding characteristics of clarified supernatants or 
allantoic fluid were determined by HA assay with chicken and turkey RBC to 
analyse. 
 
Strain name Virus type 
SIAT PER.C6 Egg 
TRBC CRBC TRBC CRBC TRBC CRBC 
B/E/216/05 
B 
4 >8 4 >8 32 >32 
B/E/429/05 4 >8 4 >8 16 >32 
B/E/319/05 8 >8 4 2 < >32 
B/E/354/05 4 >8 4 2 < < 
B/E/426/05 4 >8 4 2 < < 
A/E/67/04 
H1N1 
8 < 4 < < < 
A/E/82/05 8 < 4 < < < 
A/E/48/04 4 < 4 < < < 
A/E/204/05 4 < 4 < < < 
A/E/208/05 4 < 4 < < < 
A/E/280/05 4 < 4 < < < 
A/E/180/05 
H3N2 
8 < 4 < < < 
A/E/81/05 8 < 4 < < < 
A/E/26/05 4 < 4 < < < 
A/E/13/05 4 < 4 < < < 
A/E/29/05 4 < 4 < < < 
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4.3 A/Eng/611/07 is typical of current circulating strains 
 
The current vaccine strain selection procedure requires growth of viruses in 
eggs before they are put forward for consideration for inclusion in the new 
season‟s vaccine. Since many circulating strains do not grow in eggs, the best 
vaccine candidates may potentially be excluded. In addition, unpredictable 
delays occur while a strain that does grow in eggs is found. Therefore, we 
wanted to assess the feasibility of generating a vaccine seed with the HA 
antigen of a typical circulating influenza A virus that did not grow in eggs. This 
approach is facilitated by two novel technologies: firstly, long sequences of 
DNA can now be generated de-novo and secondly, influenza viruses can be 
generated directly from cDNA. Using this strategy, we reasoned that 
recombinant viruses displaying the surface antigen of circulating viruses could 
be generated directly from sequenced viruses without the need for virus 
propagation in eggs or in cell culture.  
 
From the clinical isolates available through the surveillance programme at the 
HPA, we obtained a sample of a recent H3N2 influenza A virus and deduced 
the complete nucleotide sequence of the HA gene. HAI tests with ferret 
antisera showed that the specific isolate, A/Eng/611/07 (E611), is antigenically 
like A/Brisbane/10/07 (Brisbane), the virus included in the trivalent seasonal 
vaccine for 2008/9 (data not shown). Sequence analysis revealed that the HA 
of E611 differs from that of Brisbane by only two amino acids, one in HA1 at 
residue 194 where E611 has leucine and Brisbane has proline, and the other in 
HA2 at residue 418 where E611 has valine and Brisbane has isoleucine. E611 was 
isolated and propagated on MDCK-SIAT cells and like other very recent 
influenza A H3N2 strains, E611 agglutinated guinea pig RBC but did not 
agglutinate turkey or chicken RBC. Unlike Brisbane virus however, it was not 
possible to attain a primary egg isolate of E611, as this virus did not acquire the 
ability to grow in eggs, even following two blind passages. Absence of virus 
growth in eggs was confirmed by the inability of allantoic fluid to agglutinate 
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guinea pig RBC, and the absence of cytopathic effect or expression of viral 
antigens in MDCK-SIAT cells after inoculation with undiluted allantoic fluid. 
Taken together these data show that E611 is a typical contemporary human 
influenza virus that has highly-adapted human receptor binding characteristics 
and may also be restricted for egg growth by incompatibilities within the 
internal viral genes. Despite the fact that E611 is an antigenic representative of 
the majority of H3N2 clinical isolates of the 2007/08 influenza season, it 
would not have been put forward as a vaccine candidate because the wild type 
E611 virus did not grow in eggs. 
 
4.4 Recombinant viruses with the HA of a recent clinical strain in a 
PR8 backbone can acquire the ability to grow in eggs 
 
The cDNA representing a full length HA gene from E611 flanked at the 3‟UTR 
by a HDV ribozyme and at the 5‟UTR by a human polymerase I promoter was 
synthesised de novo (GENEART) and directly cloned into the pUC19 vector. 
Using our previously described protocols (Koudstaal, Hartgroves et al. 2009), 
recombinant influenza viruses bearing the E611 HA gene in combination with 
the A/Puerto Rico/8/34 (PR8) genetic backbone were rescued in either 293T 
cells with MDCK co culture, or directly in PER.C6 cells. Two different 
recombinant viruses were rescued, combining the E611 HA gene with either a 
modern N2 NA cloned from the H3N2 vaccine strain, A/Sydney/97, or with 
the NA gene of the PR8 vaccine strain. Both viruses were readily rescued in 
both cell systems. The virus containing PR8 NA grew to a high enough titre to 
agglutinate guinea pig RBCs but retained the wt E611 phenotype, being unable 
to agglutinate chicken RBCs (Table 4.4.1). Even passage of rescued viruses in 
MDCK-SIATs, increasing titres above the limit of detection did not affect the 
wild type E611 phenotype. 
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Table 4.4.1 A Synthetic A/Eng/611 HA was rescued by co-culture of 293Ts with 
MDCK-SIATs in a A/PR/8 backbone with NA derived from either A/PR/8 or 
A/Sydney/97 
 
A Synthetic A/Eng/611 HA was rescued by co-culture of 293Ts with MDCK-
SIATs in a A/PR/8 backbone with NA derived from either A/PR/8 or 
A/Sydney/97. Viruses were passaged once in MDCK-SIATs. Virus titres of 
recombinant influenza viruses were determined by plaque assay in MDCK-SIAT 
cells. Receptor binding characteristics of the recombinant viruses were inferred 
by HA assay with either chicken or guinea pig RBC. 
 
  Passage status 
  Rescue Passage 1- SIATs 
HA NA CRBC GPRBC PFU/ml CRBC GPRBC PFU/ml 
611 
PR8 <  16 3.5 x10
5
 < 256 5.8 x10
7
 
Syd <  <  2.5x10
4
 < 256 7.5x10
7
 
< Not detectable 
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Table 4.4.2 Recombinant viruses with the HA of a recent clinical strain in a 
PR8 backbone can acquire the ability to grow in eggs 
 
Rescued recombinant influenza viruses with the HA of A/Eng/611, the NA of 
either PR8 or A/Sydney/97 (Syd) in a A/PR/8 backbone were inoculated into 
the allantoic cavity of three 10 day old embryonated chicken eggs with 
equivalent HA units and incubated for 3 days at 37°C. Allantoic fluid was 
clarified by centrifugation at 2500 RPM for 10 mins, 4°C and stored at -80°C. 
Growth and adaptation in eggs were determined by ability to agglutinate 
chicken and turkey RBC. Virus titres of recombinant influenza viruses were 
determined by immuno-staining of plaques in MDCK-SIAT cells 
 
 
HA NA TRBC CRBC PFU/ml 
E611 PR8 
16 4 8.8x10
4
 
4 4 8.8x10
4
 
8 < 5x10
3
 
E611 Syd 
< < 9x10
3
 
< < 5.5x10
4
 
32 32 2x10
5
 
< Not detectable  
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Therefore, the rescued viruses retain the receptor binding characteristics of wt 
E611. The rescued E611 HA virus containing A/Sydney/97 NA grew to a titre 
below the threshold of detection by HA assay but was detected by immuno-
staining of plaques in MDCK cells. The ability to agglutinate guinea pig RBCs 
was recovered following passage in MDCK-SIATs.  
 
These two recombinant viruses were subsequently inoculated in triplicate in 10-
day-old embryonated chicken eggs. The E611 HA: PR8 NA virus grew to high 
titre in eggs. However, egg grown E611 HA virus displayed an altered receptor 
binding phenotype inferred by the agglutination of chicken and turkey RBCs 
(Table 4.4.2) and attributable to mutation in the HA at L194P. Interestingly, 
proline is the amino acid present at residue 194 in the HA gene of 
Brisbane/10/07 virus, which also grows in eggs. Virus propagated in one of the 
three eggs inoculated with the E611 HA: A/Sydney/97 NA virus also acquired 
the L194P mutation, concurrent with the ability to agglutinate chicken RBCs. 
Although we cannot exclude the possibility that the viruses which do not 
agglutinate chicken RBCs are below the limit of detection since they have 
lower titres. 
 
4.5 G186V is less efficient adapting the growth of more in eggs  
 
We had demonstrated that the introduction of the E611 HA gene into a virus 
background that facilitates replication in eggs had increased the propensity for 
adaptive mutations in the HA gene to be selected. In this genetic background, 
all of the mutations that conferred egg growth were the same, L194P. 
However, it has previously been shown that another mutation, G186V, can 
confer egg adaptation to a range of recent influenza H3N2 viruses so we were 
surprised that this mutation had not arisen in at least some of the viruses with 
egg-adapted E611 HA. We introduced either the G186V or the L194P mutations 
into the synthetic E611 HA cDNA. Viruses containing each of the HA variants 
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Table 4.5.1 A/Eng/611 HA containing mutations thought to improve yields in 
eggs, L194P or G186V, were rescued by co-culture in a A/PR/8 backbone 
 
Amino acid mutations L194P or G186V were introduced into synthetic 
A/Eng/611 HA by QuikChange XL site directed mutagenesis kit (Stratagene). 
Recombinant viruses were rescued by co-culture in a PR8 backbone. Receptor 
binding characteristics of the recombinant viruses were inferred by HA assay 
with either chicken or guinea pig RBC.  
 
HA CRBC GPRBC 
E611 wt < 512 
E611 G186V < 512 
E611 L194P 64 512 
< Not detectable  
 
 
  
  
141 
 
Table 4.5.2 G186V is less efficient adapting more modern viruses for growth in 
eggs 
 
Recombinant influenza viruses containing either the wild type HA of 
A/Eng/611, or G186V or L194P mutation, in a PR8 backbone (including PR8 
NA) were inoculated into the allantoic cavity of three 10 day old embryonated 
chicken eggs with equivalent HA units and incubated for 3 days at 37°C. 
Allantoic fluid was clarified by centrifugation at 2500 RPM for 10 minutes, 4°C 
and stored at -80°C. Adaptation in eggs was determined by ability to 
agglutinate chicken RBC. Virus titres of recombinant influenza viruses were 
determined by plaque assay in MDCK-SIAT cells. 
 
HA CRBC GPRBC PFU/ml 
E611 wt 
1,024 64 3x10
5
 
1,024 64 2x10
5
 
E611 G186V 
< 16 1.4x10
5
 
< < 8x10
4
 
E611 L194P 
1,024 256 3x10
7
  
256 128 6.3x10
6
 
< Not detectable 
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were rescued in a PR8 backbone in conjunction with the PR8 NA gene (7:1 
recombinants) (Table 4.5.1). All viruses were rescued regardless of whether the 
293T MDCK co-culture system or direct rescue in PER.C6 cells was employed. 
Viruses grew in cell culture to equivalent HA titres measured by HA assay with 
guinea pig RBCs. Only the L194P mutation conferred the ability to agglutinate 
chicken RBCs on viruses with E611 HA. Contrary to the implications of previous 
studies, G186V did not confer the ability to agglutinate chicken RBCs. 
Sequencing of the HA genes of each virus confirmed the presence of the 
engineered mutations, and that no other mutations were present. 
 
Eggs were inoculated in duplicate with each of the recombinant viruses (Table 
4.5.2). As before, eggs inoculated with a PR8 based recombinant virus with wt 
E611 HA supported virus replication and the propagated virus gained the 
ability to agglutinate chicken RBCs. HA gene sequencing revealed the 
acquisition of the L194P mutation but not the G186V change. Viruses with the 
G186V mutation engineered into the E611 HA gene grew to slightly lower titres 
in eggs than those with the L194P mutation and did not agglutinate chicken 
RBCs, although we cannot differentiate whether this was due to insufficient 
virus titre or to inability of the HA to bind SA on chicken RBCs. Although the 
recombinant virus with wt E611 HA gained the ability to agglutinate chicken 
RBCs, and the L194P mutation, it grew to lower titres than the virus engineered 
with the same mutation. However, this could be expected, since the virus had 
to acquire this mutation over multi-cycle growth. Of the two eggs inoculated 
with the L194P, the HA titres measured with chicken RBCs differed appreciably 
(1024 vs. 256). Interestingly, the HA gene of the virus with the higher chicken 
RBC HA titre contained an additional mutation G188D that may have 
increased the HA affinity for chicken RBCs. To ensure that these virus are still 
antigenically similar to the clinical isolate, and the mutations do not alter the 
antigenicity and therefore the protection provided if they were to be used as 
vaccines, in the future haemagglutinin inhibition assays (HAI) could be carried 
out with sera raised against the clinical isolate. However, as Brisbane, which 
  
143 
 
has the L194 mutation, has been included in the seasonal trivalent vaccine, this 
mutation is not expected to change the antigenicity. 
 
4.6 PER.C6 cells faithfully support the growth of recombinant viruses 
containing the HA of a recent clinical isolate A/England/611/07 
 
A universal vaccine seed must be able to grow in both eggs and cell culture. 
PER.C6 cells have proven suitable for the rescue a number of subtypes of 
viruses (Koudstaal, Hartgroves et al. 2009) and we have shown here that they 
faithfully support the growth of recent clinical isolates. To ensure that PER.C6 
cells could support the rescue and propagation of proposed universal vaccine 
seeds, E611 wt, G186V and L194P HAs were rescued in the PR8 backbone, and 
passaged through PER.C6 cells. The viruses grew to high titres as measured by 
TCID50 in MDCK cells (Table 4.6.1). The resultant viruses were sequenced, each 
virus was replicated accurately and no sequence changes were observed 
suggesting that each virus was replicated accurately.  
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Table 4.6.1 PER.C6 cells faithfully support the growth of recombinant viruses 
containing the HA of a recent clinical isolate A/England/611/07 
 
Recombinant influenza viruses were rescued in PER.C6 cells, containing either 
the wild type HA of A/Eng/611, or G186V or L194P mutation, in a PR8 
backbone (including PR8 NA). Virus was harvested 7 days post transfection 
and passaged once on PER.C6 cells. Titres of recombinant influenza viruses 
were determined by TCID50 in MDCK cells. 
 
HA TCID50/ml 
E611 wt 3.9x10
8
 
E611 G186V 4.4x10
7
 
E611 L194P 1.9x10
7
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4.7 Discussion 
 
The application of cell culture for the generation of influenza vaccine is widely 
being investigated as a supplement or replacement for egg grown vaccine 
(Minor, Engelhardt et al. 2009). Of particular consequence will be the ease of 
scale-up to produce more vaccine should the need arise (e.g. during an 
epidemic or pandemic). Furthermore, over the last decade, human influenza 
viruses have evolved a decreased capacity for growth in eggs to the extent that 
many recent clinical isolates are unable to grow. Here we show that the 
PER.C6 cell line faithfully supports the growth of recent influenza virus isolates, 
many of which were unable to grow in eggs. Receptor binding changes in the 
HA gene were not incurred during amplification of clinical isolates in PER.C6 
cells. Sequencing corroborated the absence of mutations in PER.C6 passaged 
material. Thus, PER.C6 cells represent a suitable media for the propagation of 
vaccine viruses bearing authentic HA derived from clinical isolates, including 
those which are unable to grow in eggs.  
 
However, since the use of cell culture for influenza vaccine is still in 
development, there is not yet the capacity to comprehensively supply the 
vaccine market with cell grown influenza vaccine. Therefore, a lag period is 
foreseeable, in which both cell culture and egg vaccine are in production. 
Rather than considering the generation of two disparate vaccine seeds, in the 
current study we investigated whether it was possible to generate a seed virus 
appropriate for both egg and cell culture derived vaccine manufacture for a 
typical influenza A virus H3N2 strain that originally did not replicate in eggs.  
We approached this using two different strategies: Firstly, we generated the 
recombinant vaccine virus and passaged it through eggs to assess whether egg-
adapting mutations would be generated. In the second approach we pre-
empted the „random‟ generation of egg-adapting mutations by engineering 
mutations into the HA gene before rescue as recombinant virus. For this 
purpose, we tested two different mutations close to the receptor-binding site of 
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the H3 HA protein to see if they would confer egg adaptation to a virus with 
the H3 HA from a 2007/8 season clinical isolate. The first mutation,  G186V, 
was proposed by others as a universal mutation to confer growth in eggs (Lu, 
Zhou et al. 2005) and was certainly able to do so when engineered into the 
HA gene of viruses from the early half of this decade (Lu, Zhou et al. 2006). 
However, the G186V mutation did not fully confer egg adaptation to the HA 
gene of our very recent (2007) clinical isolate, A/England/611/07 (E611). The 
second mutation we engineered was at position 194 in HA1. This change was 
present in the closely related vaccine strain A/Brisbane/10/07 and was also 
selected during passage of the 7:1 PR8/E611 HA recombinant virus in eggs. As 
expected, the L194P mutation was able to confer egg adaptation to the E611 
HA protein. Thus, it would appear that the very recent human influenza 
isolates of the H3 HA subtype have an altered receptor-binding site in 
comparison with viruses isolated even just 5 years previously, a finding borne 
out by their inability to agglutinate turkey red blood cells in comparison to 
viruses of the Fujian/02 era. It may be difficult to find a universal egg adapting 
mutation for the H3N2 human influenza viruses.  
 
It is noteworthy that the wild type E611 clinical isolate was not propagated in 
eggs even on serial passage. This suggests that its growth in eggs might be 
limited by incompatibilities within several viral genes. On the other hand, 
when the HA gene in isolation was conferred to the egg-adapted PR8 genetic 
backbone, mutants of the 7:1 recombinant virus were readily selected upon 
single passage in eggs. Thus, many clinical isolates whose HAs might be very 
suitable as components of the annual vaccine would not be considered due to 
limitations in the egg growth conferred by internal genes that are irrelevant to 
the vaccine process. 
 
The combination of the HA gene of E611 with the NA gene from the PR8 
vaccine strain may also account for the ability of the recombinant virus to 
grow sufficiently in eggs for adapting mutations to be selected. Influenza virus 
adaption to new hosts can be mediated by mutations in NA (Mitnaul, 
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Matrosovich et al. 2000; Wagner, Matrosovich et al. 2002). The NA enzyme 
activity and/or specificity of recent human influenza viruses may be insufficient 
to accommodate growth in eggs. Indeed, Fujian/02 and later strains acquired 
growth in eggs either with the G186V mutation in HA mentioned above (Lu, 
Zhou et al. 2006) but also through mutations in NA that affect the enzyme 
activity and consequently the balance between HA:SA affinity and receptor 
destroying activity. The most significant of the NA mutations for egg-adaption 
of Fujian-like strains was E119Q, but Q136K and H374Y were also noted (Lu, 
Zhou et al. 2005).  Neither E611 nor Brisbane NA genes possess any of those 
key egg-adapting NA mutations. It is possible that the Brisbane NA gene that 
supports growth in eggs of viruses with Brisbane HA contains its own unique 
egg-adapting motifs. There are seven amino acid differences between the NA 
proteins of A/Eng/611/07 virus and the vaccine strain A/Brisbane/10/07 at 
positions 26, 45, 126, 147, 212, 267 and 312. Whether any of these accounts 
for the high growth properties of viruses with Brisbane HA in eggs has not 
been assessed. As for HA, it may be difficult to elucidate universal mutations to 
be introduced to wild type NA genes for egg-adaptation. 
 
Incorporation of the E611 HA gene into the PR8 backbone and combination 
with PR8 NA was sufficient to allow a virus to acquire egg adaptation, and 
therefore supersedes the need for prior knowledge of the identity of the 
favoured mutation of any virus lineage. This suggests that PR8 NA, which 
shows only 42% identity with NAs of currently circulating viruses such as 
Brisbane, is well adapted to growth in eggs, and that matching HA and NA 
activity for high yield in eggs is not easily predicted.  
 
This approach would mean that vaccines would not be updated with respect 
to the NA component. However, vaccine efficacy is measured by 
haemagglutination inhibition assay (HAI), which only measures the 
haemagglutinin specific antibodies and, vaccine content is largely described in 
quantities of HA. Moreover, recombinant baculovirus vaccines are being 
developed which express HA alone (Treanor, Wilkinson et al. 2001; Wang, 
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Holtz et al. 2006; Huber and McCullers 2008); these have proved to be 
immunogenic and protective. Furthermore, a 7:1 vaccine strategy has been 
described for the generation of H5N1 vaccine and H5 vaccine viruses with PR8 
NA showed improved growth in eggs (Horimoto, Murakami et al. 2007). Thus 
matching with PR8 NA removes potential delays and facilitates timely and 
efficient vaccine production. To determine the contribution of PR8 NA, virus 
could be rescued in the future as a true 6:2 recombinant PR8: E611. 
 
The quantity of HA gene sequences available has grown exponentially over 
recent years. Synthesis of HA genes using the data from sequences derived from 
clinical isolates allows the rapid generation of recombinant vaccine seeds from 
circulating viruses which otherwise might have been excluded from 
consideration as potential vaccine strains due to their inability to grow in eggs, 
and simultaneously eliminates the potential for transfer of adventitious agents 
to the vaccine seed. A 7:1 recombinant virus in a PR8 backbone generates a 
single vaccine seed which is suitable for influenza vaccine culture in both cell 
lines and eggs.  
 
PER.C6 cells are able to support the rescue of vaccine seeds derived from any 
strategy. Furthermore, virus propagation in PER.C6 cells induces no adapting 
mutations, so they provide a highly suitable substrate to produce both vaccine 
seeds and large-scale vaccine which is an exact antigenic match for the chosen 
clinical isolates. 
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Chapter 5 Characterisation of PER.C6 IFN-β 
response 
 
5.1 Introduction 
 
The type I IFN response is a major element of the innate immune system‟s 
antiviral defence (reviewed by (Haller, Kochs et al. 2006), (Randall and 
Goodbourn 2008), and chapter 1). Virus infected cells synthesise and secrete 
type I IFN (IFN-α and -β), these cytokines alert the immune system to the 
invading pathogens and cause cells to express antiviral proteins which inhibit 
viral replication and dissemination. Upon detection of virus by pattern 
recognition receptors (PRR), such as intracellular RNA helicases retinoic 
inducible gene I (RIG-I (Yoneyama, Kikuchi et al. 2004) and melanoma 
differentiation-associated gene-5 (MDA-5 (Andrejeva, Childs et al. 2004), IRF-3 
and NFκB are activated and this leads to the induction of IFN-β (Sato, Tanaka 
et al. 1998; Sato, Suemori et al. 2000).  
 
The induction of IFN-β by influenza viruses could have an adverse effect on the 
ultimate yield of influenza vaccine propagation under multicycle growth 
conditions. African green monkey kidney (Vero) cells, which are licensed for a 
range of human vaccines including poliovirus, rabies and an inactivated 
influenza vaccine from Baxter healthcare corp. vaccines (Kistner, Howard et al. 
2007), are able to respond to IFN-β but lack a functional IFN-β gene and 
therefore do not secrete it. This may contribute to their success as a vaccine 
substrate. The IFN-β response of PER.C6 has yet to be characterised and it is 
unknown whether it is complete and functional. 
 
PER.C6 cells have been shown to support the growth of wild type clinical 
strains of influenza viruses (chapter 3, (Pau, Ophorst et al. 2001). Since growth 
in cell culture does not require the high growth backbone that is needed for 
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vaccine manufacture in eggs, pharmaceutical companies may consider the 
generation of vaccines directly from wild type clinical isolates. In this event, 
with no backbone donor, the internal genes of vaccine strains will vary. 
Influenza viruses have been shown to induce strain dependant levels of IFN-β 
in IFN competent cells lines (e.g. A549 cells (Hayman, Comely et al. 2006), pig 
macrophages (Seo, Hoffmann et al. 2004), and certain strains such as 
A/Sydney/97, a chosen vaccine strain, induce particularly high levels. 
Accordingly, the use of wt viruses as vaccine seeds will be significantly less 
predictable than recombinant or reassortant viruses and the IFN-β induction 
could limit virus propagation.  
 
Also pertinent is the novel strategy for the generation of LAIV from 
recombinant viruses attenuated through the truncation or deletion of the 
influenza encoded IFN antagonist, NS1. Deletion of NS1 results in high IFN-β 
induction by the recombinant virus (Egorov, Brandt et al. 1998; Garcia-Sastre, 
Egorov et al. 1998). LAIV has been developed with either truncated or deleted 
NS1 proteins, that are highly attenuated in both immunologically mature, 
embryonated eggs and mice (Talon, Salvatore et al. 2000; Romanova, Krenn 
et al. 2009). These viruses have been rescued in Vero cells which as stated 
above, lack the ability to secrete IFN-β. They are likely to be attenuated in IFN 
competent cell lines. The strategy of NS1 mutation has also been used to make 
H5N1 vaccine. These were highly attenuated in mice, and reduced growth 
correlated with high levels IFN-β. These viruses protected against challenge 
with HPAI H5N1 viruses in poultry, ferrets and macaques and hold the 
potential for use in mammalian hosts (Romanova, Krenn et al. 2009; Steel, 
Lowen et al. 2009). Vaccines of this design will require propagation in IFN 
incompetent cell lines. 
 
It has already been demonstrated that cell lines which lack an IFN response 
give rise to higher yields for other virus vaccines (Young, Andrejeva et al. 
2003) and this general strategy could be applied to the manufacture of 
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influenza vaccines. Hepatitis C virus (HCV) has been notoriously difficult to 
research due to the lack of permissive cell lines. It was established that a 
hepatoma cell line, Huh-7, could support the replication of HCV replicons 
(Lohmann, ouml et al. 1999; Blight, McKeating et al. 2002). A subline of Huh-
7, Huh-7.5, showed much increased susceptibility and this has been attributed 
to a deficiency in the induction of IFN signalling as a result of a point mutation 
in RIG-I (Sumpter, Loo et al. 2005) in the TRIM25 binding domain (Gack, 
Albrecht et al. 2009). Cells lines have been developed which have artificially 
abrogated IFN responses by transduction with viral antagonists. Many viruses 
encode proteins which antagonise IFN induction. Paramyxovirus 5 encodes V 
protein, which interacts with MDA-5 and targets STAT-1 for degradation, thus 
blocking IFN-α, -β and -γ signalling within infected cells (Didcock, Young et al. 
1999; Andrejeva, Childs et al. 2004). Bovine Viral Diarrhoea virus (BVDV) 
encodes N-pro, which blocks signalling of IRF-3 by preventing translocation to 
the nucleus and targeting it for degradation (Hilton, Moganeradj et al. 2006). 
MDCK and A549 cell lines have been developed by selection of stable 
transfection (Young, Andrejeva et al. 2003; Hayman, Comely et al. 2006; 
Hayman, Comely et al. 2007)) and more recently infection with lentivirus 
encoding these viral proteins (Hale personal communication). The 
development of several negative-strand RNA virus recombinant vaccines that 
lack IFN antagonists, such as respiratory syncytial virus (RSV) and Bunyamwera 
virus, has been compromised by the inability of these viruses to grow to high 
titres in susceptible cell types which are IFN competent. MRC5 and HEp2 cell 
lines were transduced with the V protein of PIV5 (Young, Andrejeva et al. 
2003). The most significant results were seen in the HEp2/SV5-V cells. In this 
cell line there was a 4,000-fold increase in the yield of Bunyamwera ∆NS virus 
compared to wt HEp2 cells. Similarly, there was a ~200-fold increase in the 
yield of RSV ∆NS1 and RSV ∆NS2 in HEp2/SV5-V cells compared to the wt cell 
line. Only a 35-fold increase was seen in Vero cells for the RSV ∆NS viruses. 
Evidently, IFN competent cells have the potential to severely limit viral yields. 
If PER.C6 cells have a vigorous IFN response, then antagonism of the response 
by strategies that ablate the activity of genes involved in IFN activation may 
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help to further improve influenza vaccine yields that may naturally vary in the 
extent to which they trigger an IFN-β response.  
 
The aim of this chapter is therefore to characterise the IFN response in PER.C6 
cells to establish whether antagonism of the IFN response is appropriate and 
whether PER.C6 are a suitable cell line in which to prepare vaccines from 
clinical isolates. 
 
5.2 PER.C6 cells make IFN-β in response to Newcastle disease virus 
 
To ascertain whether PER.C6 cells produce IFN-β in response to virus infection, 
cells were transiently transfected with a reporter construct in which luciferase 
gene expression is driven by IFN-β promoter (IFN-luc). Newcastle disease virus 
(NDV) is a negative sense RNA virus which replicates in the cytoplasm and is a 
potent activator of IFN in mammalian cells (figure 5.2.1). In IFN-β luc 
transiently transfected PER.C6 cells, NDV infection resulted in approximately a 
40-fold activation of the IFN-β promoter. This level was similar to that seen in 
other IFN competent cell lines such as A549s (human lung epithelial cells) and 
293T cells (human epithelial kidney cells). PER.C6 cells must therefore possess 
the upstream components of the IFN signalling pathway to activate the IFN-β 
promoter.  
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Figure 5.2.1 IFN-β promoter is activated in PER.C6 cells following Newcastle 
disease virus infection 
 
Infection with Newcastle disease virus (NDV) induces IFN-β in PER.C6 cells. 
PER.C6 and 293T cells were transiently transfected with IFN-β luc reporter 
plasmid. An A549 cell line stably expressing IFN-β luc was previously generated 
(Hayman, Comely et al. 2006). Cells were infected with NDV (48 hrs post 
transfection for PER.C6 and 293T) for 1 hour, washed in PBS, then incubated 
2% DMEM, for 7 hours at 37°C. Cells were washed PBS, lysed in CCLR, 
clarified 1000 RPM for 1 min and luciferase measured. Data is represented as 
ratio of induction corrected to unchallenged cells. Means and standard error 
were calculated for duplicate wells. This assay is representative of three repeat 
experiments. 
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5.3 Influenza viruses poorly activate the IFN- β promoter in PER.C6 
cells 
 
NDV replicates in the cytoplasm, whilst influenza replicates in the nucleus; the 
IFN response may therefore differ for these viruses. Most influenza viruses are 
able to suppress the IFN response; however, Hayman et al (Hayman, Comely 
et al. 2006) described significant variation in the IFN response induced by 
different strains of influenza in A549 cells. The strain A/Sydney/97 (Syd) 
typified an influenza virus with relatively high IFN-β  inducing properties. 
A/Victoria/3/75 (Vic) is an older H3N2 strain which induces low levels of IFN-
β in A549 cells.  
 
Tested on several occasions with different preparations of virus, A/Sydney/97 
did not activate the IFN-β promoter in PER.C6 cells. In figure 5.3.1, two 
separate preparations of A/Sydney/97 were compared to A/Victoria/75. As 
seen previously in A549 IFN-β luc cells (figure 5.3.1A), A/Sydney/97 activated 
the IFN-β promoter by 20-40 fold. In PER.C6 cells (figure 5.3.1 B), 
A/Sydney/97 activated the IFN-β promoter to insignificant levels similar to the 
negligible activation by A/Victoria/3/75. Even at a higher MOI A/Sydney/97 
did not activate the IFN-β promoter to high levels in PER.C6 (figure 5.3.2). A 
panel of recent clinical isolates from 04/05 season was also tested in this assay, 
these included H1N1 viruses (A/Eng/48/04, (A/Eng/208/05, A/Eng/280/05, 
A/Eng/204/05), H3N2 viruses (A/Eng/26/05, A/Eng/29/05, A/Eng/81/05, 
A/Eng/180/05), influenza B viruses (B/Eng/216/05, B/Eng/319/05). None of 
these viruses activated the IFN-β promoter to significant levels in PER.C6 
(figure 5.3.3).  
 
It was possible that the low IFN-β induction in PER.C6 cells reflected a low 
infectivity of influenza viruses in these cells. This was deemed unlikely since it 
has been shown that influenza viruses grow to high titres in PER.C6 cells 
(chapters 3&4). Moreover, immuno-staining of cells infected with virus (figure   
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Figure 5.3.1 A/Sydney/97 does not induce high levels of IFN-β in PER.C6 
 
A549 cells stably transfected with IFN-β luc (A) were compared to PER.C6 cells 
transiently transfected IFN-β luc (B). 48 hours post transfection, cells were 
infected with two different A/Sydney/97 preparations, or A/Victoria/3/75 MOI 
2, for 1 hour, washed in PBS, then incubated 2% DMEM, for 7 hrs at 37°C. 
Cells were washed PBS, lysed in CCLR, clarified by centrifugation, 13,000 RPM 
for 1 minute and luciferase measured. Data are represented as ratio of 
induction corrected to unchallenged cells. Means and standard error were 
calculated for duplicate wells. Error bars represent standard error. 
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Figure 5.3.2 A high MOI of virus does not activate the IFN-β promoter in 
PER.C6 cells 
 
PER.C6 cells were transiently transfected IFN-β luc and compared to A549 cells 
stably transfected with IFN-β luc. 48 hours post transfection cells were infected 
with virus MOI 5 A/Sydney/97 (Syd) or A/Victoria/3/75 (Vic), for 1 hour, 
washed in PBS, then incubated 2% DMEM, for 7 hrs at 37°C. Cells were 
washed PBS, lysed in CCLR, clarified by centrifugation, 13,000 RPM for 1 
minute and luciferase measured. Data are represented as ratio of induction 
corrected to unchallenged cells. Means and standard error were calculated for 
duplicate wells. This assay is representative of three repeat experiments. Error 
bars represent standard error. 
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Figure 5.3.3 Recent seasonal influenza isolates do not activate the IFN-β 
promoter in PER.C6 cells 
 
PER.C6 cells were transiently transfected IFN-β luc. 48 hrs after transfection 
cells were infected with virus MOI 2, for 1 hour, washed in PBS, then incubated 
2% DMEM, for 7 hours at 37°C. Cells were washed PBS, lysed in CCLR, 
clarified by centrifugation, 13,000 RPM for 1 minute and luciferase measured. 
Data are represented as ratio of induction corrected to unchallenged cells. 
Means and standard error were calculated for duplicate wells. This assay is 
representative of two repeat experiments. Error bars represent standard error. 
 
 
 
  
  
158 
 
5.3.4A) in parallel with the luciferase assay (figure 5.3.2) demonstrate that the 
low IFN-β induction in PER.C6 was not a result of an unproductive infection, 
since most cells express NP. Despite coating the plates with poly-L-lysine, the 
PER.C6 cells do not withstand the repeated wash steps and become easily 
detached, resulting in gaps in the monolayer. The cells also form clumps which 
do not stain well; the clumps are possibly inaccessible to either the virus or the 
antibody. These effects may arise because PER.C6 cells are essentially a 
suspension cell line which can be driven to adherence by the addition of serum 
to the media. To use an alternative method for assessing infection of PER.C6 
cells by influenza, the generation of vRNA was measured using qRT PCR to 
determine the number of copies of segment 7 (M) vRNA/ml. This data also 
showed that viral replication was occurring to at least equivalent levels in 
PER.C6 cells and A549 cells (figure 5.3.4B). In accordance with data to be 
presented in chapter 6, following infection with A/Sydney/97 in either cell line 
more vRNA is generated than infection with A/Victoria/75, suggesting faster 
replication. Furthermore, both viruses generate more vRNA in PER.C6 cells 
suggesting that PER.C6 cells are more permissive for RNA replication than 
A549 cells. Thus, the low IFN-β induction in PER.C6 cells is not a result of 
either reduced viral infection or replication. 
 
The luciferase assay does not measure secreted IFN-β, rather the activation of 
the IFN-β promoter. A complete and functioning set of upstream signalling 
proteins will activate the IFN-β promoter but may not correlate with synthesis 
of IFN-β. However, the induction of the IFN-β promoter measured by the 
luciferase reporter assay correlated with IFN-β RNA measured by qRT PCR 
(figure 5.3.5). In A549 cells A/Sydney/97 induced very high levels IFN-β 
mRNA which correlate to ~65 fold induction over A/Victoria/75, in line with 
results seen using the reporter assay. In PER.C6 cells neither A/Victoria/75 nor 
A/Sydney/97 virus infection results in induction of IFN-β mRNA. An IFN-β 
ELISA (R&D systems) was used to determine whether luciferase expression 
corresponded to secreted IFN-β. 
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Figure 5.3.4 The low IFN-β induction by influenza viruses in PER.C6 cells is not 
a result of unproductive infection 
 
A) A549 cells and PER.C6 cells were infected with A/Victoria/75 or 
A/Sydney/97 virus at an MOI 5 for 1 hour, washed in PBS, then incubated 2% 
DMEM, for 7 hours at 37°C. Cells were fixed and permeabilised using ice-cold 
methanol: acetone (50:50 v/v) for 10 minutes. NP was detected by incubation 
with mouse -NP antibody (1/300) for 1 hour at RT, washed 3x PBS, followed 
by goat -mouse antibody conjugated to -galactosidase (1/400) for 1 hour at 
RT. Infected cells were visualised by incubation overnight at 37C with CN 
buffer (X-Gal substrate) which changes from yellow to blue in the presence of 
-galactosidase. 
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B) A549 cells and PER.C6 cells were infected with A/Victoria/75 or 
A/Sydney/97 virus at an MOI 2 for 1 hour, washed in PBS, then incubated 2% 
DMEM, for 7 hours at 37°C. RNA was extracted with TRIzol, and cDNA 
generated with QuantiTect RT (Qiagen) using random hexamer primers. cDNA 
was amplified by qRT PCR, using primers specific for H3N2 influenza matrix 
protein. Copies/ml were normalised to GAPDH 
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Figure 5.3.5 Luciferase expression correlates with IFN-β expression and 
secretion 
 
A) A549 cells and PER.C6 cells were infected with A/Victoria/75 or 
A/Sydney/97 virus at an MOI 2 for 1 hour, washed in PBS, then incubated 2% 
DMEM, for 7 hours at 37°C. RNA was extracted with TRIzol, and cDNA 
generated with QuantiTect RT kit, Qiagen. cDNA was amplified by qRT PCR, 
using primers specific for human IFN-β. Copies/ml were normalised to 18s 
ribosomal RNA. Overleaf, A549 cells (B) and PER.C6 cells (C) were infected 
with influenza virus A/England/41/96 (4196) at an MOI 2, and PER.C6 cells 
with NDV as a positive control, for 16 hours. Supernatants were removed, 
clarified by centrifugation 13,000 RPM for 1 min and then applied to an ELISA 
which employs streptavidin-conjugated horseradish peroxidase (HRP) and 
Tetramethyl-benzidine (TMB) as the substrate, to measure IFN-β secretion. This 
assay is representative of two repeat experiments. 
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Cells were infected with A/England/41/96 (4196) an alternative high IFN-β 
inducing strain of influenza (Hayman, Comely et al. 2006), which resulted in 
IFN-β secretion in A549 cells (figure 5.3.5B). In contrast, infection of PER.C6 
cells with A/England/41/96 virus did not result in secretion of IFN-β. This 
correlated with both the activation of the IFN-β promoter measured by the 
luciferase assay and the number of RNA copies measured by qRT PCR (figure 
5.3.4C). However, infection with NDV does result in the secretion of IFN-β in 
PER.C6 cells, albeit to a low level. Taken together the data suggests that the 
mechanisms involved in IFN-β induction by influenza viruses may be defective 
in PER.C6 cells. 
 
5.4 PER.C6 cells respond to IFN-β 
 
Paracrine IFN signalling results in the formation of signalling complexes which 
translocate to the nucleus and bind to the IFN stimulated response element 
(ISRE promoter) leading to the expression of many antiviral genes. Infection of 
Vero cells, which lack a functional IFNAR, suggest that positive feedback 
enhances IFN-β induction by influenza viruses (Johnson et al manuscript in 
preparation). The ISRE promoter has been cloned upstream of a luciferase gene 
by Steve Goodbourn (St. Georges, University of London) to provide a simple 
quantification of ISRE promoter activation. To assess whether PER.C6 cells 
were able to respond to IFN-β they were transiently transfected with an IFN 
stimulating response element upstream of a luciferase reporter gene (ISRE-luc) 
and stimulated with 1U/ml of IFN-β for 16 hours (figure 5.4.1). Priming of 
PER.C6 ISRE-luc cells resulted in a 10-fold activation of the ISRE promoter. 
Although the response was not as marked as in 293T ISRE-luc cells transfected 
with the same reporter, this could be due to a less efficient IFN-β induction in 
PER.C6 or less transfected cells since β-gal assay was not performed for this 
assay. However, data shown in chapter 3 indicates little difference in the 
transfection efficiency between PER.C6 and 293T cell lines (section 3.2.1) 
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Figure 5.4.1 PER.C6 cells respond to IFN-β 
 
293T cells and PER.C6 cells were transiently transfected with ISRE-luc. 24 hours 
post transfection cells stimulated with 1U/ml IFN-β for 16 hours. Cells were 
washed PBS, lysed in CCLR, clarified by centrifugation, 13,000 RPM for 1 
minute and luciferase measured. Data are represented as ratio of induction 
corrected to unchallenged cells. Means and standard error were calculated for 
duplicate wells. This assay is representative of three repeat experiments. Error 
bars represent standard error. 
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In summary, PER.C6 cells respond to IFN-β and secrete it following NDV 
infection, but respond only poorly to influenza viruses.  
 
5.5 IFN-β promoter is activated in PER.C6 cells in response to poly IC 
but not to in vitro transcribed viral-like dsRNA 
 
It is intriguing that PER.C6 cells do not secrete IFN-β in response to infection 
by influenza virus. It is possible that they lack the ability to detect the influenza 
RNA PAMP. In order to identify the possible PAMPs that PER.C6 cells can 
recognise and thus further characterise the IFN response in PER.C6, cells were 
stimulated with three different RNA based PAMPs. Poly IC is a synthetic dsRNA 
analogue thought to activate the MDA-5 pathway (Kato, Takeuchi et al. 
2006). Poly IC was obtained from a commercial source (GE healthcare, 
formerly Pharmacia). In vitro transcribed dsRNA with 5‟ triphosphate is 
thought to activate the RIG-I pathway. A particularly relevant dsRNA would 
contain influenza sequences. Influenza-like dsRNA was synthesised from 
plasmids encoding short defective viral RNAs. These short RNAs result from 
spontaneously occurring deletions in full-length viral RNAs during RNA 
synthesis. The short RNAs are incorporated into virions, often called defective 
interfering particles (DIs) which are able to infect cells, but are unable to 
replicate without the assistance of an intact helper virus. dsRNA representing 
influenza DI RNA was generated by in vitro transcription from appropriate 
cDNA that contained a T7 promoter upstream of influenza sequences (figure 
5.5.1). RNPs are the packaged state of influenza viral genomes and consist of 
influenza viral RNA complexed with nucleoproteins. RNPs represent a form of 
viral RNA which is known to exist in cells during viral replication, although it 
has yet to be determined if RNPs induce IFN-β. RNPs were obtained by 
purifying the NP rich fraction of egg derived virus particles through CsCl 
gradient ultracentrifugation purification (Parvin, Palese et al. 1989) 
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Fig 5.5.1 Schematic representation of in vitro transcribed dsRNA synthesis 
 
Influenza-like dsRNA was synthesised from plasmids encoding defective 
interfering RNAs. T7 RNA polymerase promoters are added at the 5´ ends of 
both DNA strands with amplification by PCR with primers containing the T7 
promoter sequence at the 5´ end. Generation of the two DNA templates 
requires two separate PCR amplifications, each containing one gene specific 
primers, and the converse T7 primers. Two complementary RNA strands are 
then synthesized from the DNA templates using T7 RiboMAX Express RNAi 
System (Promega). The resulting RNA strands are annealed to form dsRNA. 
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Figure 5.5.1 Schematic representation of in vitro transcribed dsRNA synthesis 
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Figure 5.5.2 IFN-β promoter is activated in PER.C6 cells in response to poly IC 
but not dsRNA 
 
A549-luc cells (A) or PER.C6 cells transiently transfected with IFN-β luc (B) 
were stimulated with a panel of stimuli. Poly IC (pI:C), in vitro transcribed 
dsRNA and RNPs were transfected into cells 48 hours post IFN-β luc 
transfection. 6 hours post transfection cells were washed PBS, lysed in CCLR, 
clarified by centrifugation, 13,000 RPM for 1 minute and luciferase measured. 
Data are represented as ratio of induction corrected to unchallenged cells. 
Means and standard error were calculated for duplicate wells. This assay is 
representative of two repeat experiments. Error bars represent standard error. 
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A549s stably expressing the IFN-luc reporter or PER.C6 cells transiently 
transfected with IFN-luc reporter plasmid, were stimulated with poly IC, in 
vitro transcribed dsRNA, RNPs or NDV (figure 5.5.2). All three RNA based 
PAMPs activated the IFN-β promoter in A549 cells (figure 5.5.2 A). However, 
only poly IC was able to activate the IFN-β promoter in PER.C6 cells (figure 
5.5.2 B). This implies that PER.C6 cells have an intact MDA-5 pathway but are 
impaired in RIG-I signalling. Alternatively poly IC may be detected by TLR-3 
and both MDA-5 and RIG-I could be defective in PER.C6 cells.  
 
5.6 PER.C6 cells respond to IFN-β priming 
 
RIG-I and MDA-5 are IFN stimulated genes (ISGs), their expression is 
upregulated by IFN-β (Yoneyama, Kikuchi et al. 2004; Siren, Imaizumi et al. 
2006). In order to test whether IFN-β primed PER.C6 cells would respond 
more robustly to challenge with influenza viruses or viral like dsRNA, after up-
regulation of PRRs, cells were transiently transfected with IFN-β luc plasmid 
and pre-treated with exogenous IFN-β overnight. Cells were stimulated as 
before with influenza virus, poly IC or dsRNA (figure 5.6.1). Following 
stimulation with virus and dsRNA a two-fold greater activation of IFN-β 
promoter is seen in IFN-β primed cells than in naïve cells. This could be the 
result of up-regulation of RIG-I following IFNAR signalling. IFN-β promoter 
activation by poly IC transfection was unaffected by IFN-β pre-treatment. Poly 
IC IFN-β activation was much greater than for other stimuli. The amount of 
poly IC added could be in excess and may have already saturated the response. 
Alternatively, the high levels of IFN-β could be a result of very high or even 
constitutive expression of the poly IC PRR.  
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Figure 5.6.1 PER.C6 cells respond to IFN-β priming 
 
PER.C6 cells were transiently transfected with IFN-β luc plasmid. 48 hours post 
transfection cells were primed with 0.5 U/ml IFN-β, for 16 hours. Cells were 
subsequently infected with virus MOI 2 A/Sydney/97 (Syd) and 
A/Victoria/3/75 (Vic), or transfected with 10 µg/ml poly IC or dsRNA. 7 hours 
post transfection/infection cells were washed PBS, lysed in CCLR, clarified by 
centrifugation, 13,000 RPM for 1 minute and luciferase measured. Data are 
represented as ratio of induction corrected to unchallenged cells. Means and 
standard error were calculated for duplicate wells. This assay is representative 
of two repeat experiments. Error bars represent standard error. 
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5.7 Expression of PRR differs in PER.C6 cells to IFN-β competent 
A549 cells 
 
Semi-quantitative RT-PCR was used to determine the levels of expression of 
MDA-5 and RIG-I mRNAs, pre and post-IFN-β treatment. Cells were primed 
with 0.5U/ml IFN overnight and lysed in TRIzol according to manufacturer‟s 
instructions. Total cellular RNA was quantified by spectrophotometer. 
Equivalent amounts of RNA were used to generate cDNA and then equal 
volumes of cDNA were used in the PCR reaction to render the PCR 
quantitative. The PCR was limited to 25 cycles to maintain the proportional 
relationship between amplification and input RNA. Expression of RIG-I, MDA-
5, SOCS3 and GAPDH mRNA as a loading control, were evaluated (figure 
5.7.1). As expected in A549 cells RIG-I and MDA-5 mRNAs are present in low 
amounts in untreated cells, and were up-regulated following priming with IFN-
β (Siren, Imaizumi et al. 2006). SOCS3 is moderately upregulated. Although 
total signals for SOCS3 are low, SOCS3 expression has been shown to peak 3 
hours p.i. in A549 cells (Pauli, Schmolke et al. 2008), therefore it is possible 
that expression of SOCS3 had already peaked after overnight IFN-β treatment. 
In a human bronchial epithelial cell line, BEAS-2B SOCS3 expression peaks after 
14 hours (Pothlichet, Chignard et al. 2008). In PER.C6 cells both RIG-I and 
MDA-5 were upregulated following IFN-β pre-treatment. Interestingly, MDA-5 
was constitutively expressed prior to IFN-β treatment; this may contribute to 
the high reactivity to poly IC. Since no standards were used, it is not possible to 
compare the levels of expression from gene to gene; the levels of MDA-5 
might not be higher, rather its primers may be more efficient than those of 
SOCS-3 for example. If either PRR are functionally competent in un-primed 
cells, their residual expression could certainly have an adverse effect vaccine 
yields for viruses that are IFN-β sensitive.  
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Figure 5.7.1 Expression of PRR differs in PER.C6 cells to IFN-β competent A549 
cells 
 
Cells were primed with IFN-β  for 16 hours. Cells were lysed in TRIzol 
(Invitrogen) and RNA extracted according to instructions. 2 µg RNA was used 
in an RT reaction to synthesize cDNA. 2 µl of this reaction was used in a 25 µl 
PCR reaction using primers against RIG-I, MDA-5, SOCS-3, GAPDH was used as 
loading control. 
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5.8 Viruses do not upregulate PRR RIG-I and MDA-5 
 
IFN-β priming moderately enhanced the sensitivity of PER.C6 cells to PAMPs, 
but this would only be relevant to vaccine production if it were to occur 
during multicycle virus growth in response to virus infection. Therefore, 
expression levels of PRRs were also analysed following infection with a panel 
of high inducing viruses A/Sydney/97 (Syd) and A/England/41/96 (4196), or 
low inducing viruses (A/Victoria/3/75 (Vic) and A/England/919/99 (919) (figure 
5.8.1). Cells were infected with the viruses and treated as previously described 
(section 5.7). As before, MDA-5 expression is constitutive in PER.C6 cells and 
priming with IFN-β or infection with NDV both up-regulated expression of the 
PRR mRNAs in both A549s cells (data not shown) and PER.C6 cells. However, 
infection with influenza virus did not elicit induction of PRR expression. 
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Figure 5.8.1 Viruses do not upregulate PRR RIG-I and MDA-5 
 
PER.C6 cells were infected with influenza virus for 8 hours MOI 2 
A/Victoria/3/75 (Vic), A/Sydney/97 (Syd) A/England/919/99 (919) and 
A/England/41/96 (4196), or infected with NDV for 8 hours, or were primed 
with IFN-β for 16 hours. Cells were lysed in TRIzol (Invitrogen) and RNA 
extracted according to instructions. 2 µg RNA was used in an RT reaction to 
synthesize cDNA. 2 µl of this reaction was used in a 25 µl PCR reaction. 
Screened with primers against MDA-5, RIG-I and GAPDH as a loading control. 
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5.9 Discussion 
 
Vaccine manufacturers are investigating the potential of cell culture for the next 
generation of influenza vaccines. Most laboratory based cell lines available are 
unpermissive, unlicensable or low yielding, hence the need to test new lines 
such as PER.C6. PER.C6 cells are also able to support the growth of both 
clinical isolates and vaccine strains (chapter 3 and chapter 4). There exists great 
variation in the levels of IFN-β induction from clinical isolates from year to 
year and even within a single season, which could lead to inconsistency in 
yields (Hayman, Comely et al. 2006). 
 
PER.C6 cells appear to be IFN-β competent; the IFN-β promoter is activated 
and IFN-β protein is secreted in response to poly IC or NDV. They also 
respond to exogenous IFN-β by activation of the IFN-β responsive promoter, 
ISRE. However, infection of PER.C6 cells by influenza virus results only in low 
activation of IFN-β promoter, suggesting a defect in either the detection of the 
influenza PAMP or the downstream signalling pathway. As such, PER.C6 cells  
represent a good cell line for the propagation of clinical influenza isolates 
which may vary in their ability to induce IFN-β. 
 
The key PRRs involved in detection of RNA PAMPs are MDA-5 and RIG-I. 
Previously MDA-5 has been associated with detection of poly IC and positive 
sense RNA viruses whilst RIG-I has been associated with influenza virus (Kato, 
Takeuchi et al. 2006) and in particular the presence of 5‟ triphosphate RNA 
(Pichlmair, Schulz et al. 2006). However, recent research suggests that rather 
than being related to the nature of the nucleic acids, the recognition by each 
PRR is associated to its length; RIG-I and MDA-5 selectively recognize short 
(<1kb) and long (>1kb) dsRNAs, respectively (Kato, Takeuchi et al. 2008). The 
DI dsRNAs used here (DI 316) was 585 nucleotides long (Duhaut and Dimmock 
2002) and the poly IC (GE healthcare (formerly Pharmacia) ranges between 
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4,000 and 6,000 nucleotides. These therefore represent distinct activators of 
RIG-I and MDA-5 respectively.  
 
The constitutive expression of the PRR MDA-5 may explain why PER.C6 cells 
respond more robustly to poly IC. Alternatively, the response to poly IC in 
PER.C6 may also be transduced by TLR-3. More accurate and sensitive 
techniques, such as quantitative RT PCR, would allow comparisons between 
the levels of gene expression in different cell lines and give further indication of 
any irregularities in genes associated with IFN induction. Following activation 
of RIG-I, expression of an inactive splice variant (SV) is up-regulated (Gack, 
Kirchhofer et al. 2008). Analysis of MDA-5 has yet to be performed but 
inactive splice variants may also be generated following IFN induction. Full 
length RT PCR of PRRs could determine potential defects in PRR splice variant 
expression in PER.C6. Furthermore, application of a micro-array would detect 
difference in expression of the full range of proteins involved in IFN signalling 
and clarify precisely if the induction or expression of any proteins is defective. 
Sequencing of both MDA-5 and RIG-I, and proteins flagged in the micro array 
might indicate where the defects lie. However, since PER.C6 cells are able to 
support the propagation of influenza virus, further characterisation of these 
genes may not be necessary. 
 
On the other hand, antagonism of the residual IFN response albeit low may 
increase yields further. Cell lines expressing virally encoded antagonists have 
improved yields for viruses which induce high levels of IFN e.g. MDCK cells 
that express PIV5 V protein (Young, Andrejeva et al. 2003). No significant 
increase in yield was noted for viruses which do not induce significant levels of 
IFN-β (unpublished observation Anna Hayman). However, since very little 
IFN-β has been detected following infection of PER.C6 with influenza with 
either  vaccine strains made by reverse genetics, clinical isolates or reassortant 
viruses, no significant benefit is likely to be gained by growth in an IFN 
antagonised cell line. Furthermore, an altered cell line would also require re-
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validation to ensure the antagonism has no ensuing adverse side effects on the 
safety, composition and efficacy of the vaccine.  
 
The constitutive expression of MDA-5 may be a concern for the propagation 
and vaccine development for positive sense RNA viruses such as members of 
the Picornaviridae family, e.g. Encephalomyocarditis (EMCV) (Gitlin, Barchet et 
al. 2006) or the negative sense paramyxoviruses (PIV5) (Childs, Stock et al. 
2007) which are known to induce IFN-β expression in an MDA-5 dependant 
manner. In this instance, antagonism of the IFN response by transduction of 
the cells with viral antagonist proteins such as PIV5-V may be appropriate for 
the propagation of these viruses. 
 
Further characterisation is required to describe the irregularities in IFN response 
in PER.C6 cells. However, since the secreted IFN-β following infection with 
influenza is lower than for other IFN competent cell lines and the cell line is 
able to support the growth of clinical isolates, it may not generate any further 
constructive data. As such, PER.C6 cells represent a highly suitable cell line for 
the generation of influenza vaccine. 
 
  
178 
 
Chapter 6 Characterising viral IFN induction, 
implications for vaccine manufacture 
 
6.1 Introduction 
 
Comparisons in the induction of IFN-β by a panel of human H1N1 and H3N2 
clinical isolates found considerable variation in their ability to induce IFN-β in 
A549 lung epithelial cells. A number of strains induced high levels of IFN-β, 
exemplified by the H3N2 strain A/Sydney/5/97. Although the PER.C6 cell line 
elicits only a very limited IFN-β response to influenza virus infection (chapter 
5), other cell lines used in vaccine manufacture may still be IFN competent. 
Should vaccines be made directly from clinical isolates in IFN competent cell 
lines, IFN induction may be of consequence. Although high IFN-β induction in 
immortalised cell culture has yet to be correlated with high cytokine induction 
in vivo, the variation in IFN-β induction by different strains of influenza A 
viruses is likely to contribute to the biological consequences of infection 
including the pathology, pathogenicity and outcome of disease. 
 
The concept that the cytokine response, including IFN, might contribute to the 
disease process following influenza infection is most recognised following 
infection with H5N1 virus. Since 2003, the H5N1 virus has caused devastating 
outbreaks in poultry in Asia, Africa and Europe, and resulted in 438 human 
infections, with 262 fatalities thus an overall case fatality rate of 60%, 
(according to the WHO 5th Feb. 2009  
(http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_0
8_11/en/index.html). Thankfully, human-to-human transmission so far remains 
restricted. Post mortem analysis showed elevated levels of the inflammatory 
cytokines interleukin-6 (IL-6), TNF- α and IFN-γ (To, Chan et al. 2001). This 
correlates with H5N1-infected ferret lungs, where IFN stimulated genes were 
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more strongly expressed than in lungs from ferrets infected with the less 
pathogenic H3N2 subtypes (Cameron, Cameron et al. 2008).  
 
The 1918 “Spanish flu” pandemic was unusually severe, resulting in 
approximately 50 million deaths. Analysis of the 1918 pandemic virus was not 
possible until RT-PCR of viral RNA isolated from preserved tissue obtained 
from formalin-fixed pathology specimens and a cadaver buried in permafrost 
at the time of the pandemic, allowed the sequencing and subsequent 
reconstruction of the virus (Taubenberger, Reid et al. 1997; Basler, Reid et al. 
2001; Tumpey, Basler et al. 2005; Tumpey, Garcia-Sastre et al. 2005). Infection 
of macaques with 1918 virus caused an ultimately lethal, highly pathogenic 
respiratory disease (Kobasa, Jones et al. 2007). Infected animals mounted an 
immune response, characterized by dysregulation of the antiviral response that 
was insufficient for protection. Several key cytokines (including IL-6, IL-8), were 
expressed at a high level in 1918-virus-infected animals but not in low 
pathogenic H1N1 infected animals. The dysregulation of IFN induction by 
H5N1 and 1918 have been reviewed by (Basler and Aguilar 2008). The IFN 
response clearly plays an important role in pathogenesis and understanding the 
mechanisms will enable more co-ordinated treatment of viral infection. 
 
Some high IFN-β inducing strains of influenza virus, in some cell lines seem to 
be resistant to the IFN they induce. For example the replication of the H5N1 
strain, A/HK/97, in pig epithelial cells was not affected by pre-treatment of 
cells with a number of cytokines including, IFN-α, IFN-γ or TNF-α. In this 
instance, resistance was shown to map to glutamic acid at position 92 on the 
non-structural protein, NS1, replacing the usual aspartic acid (Seo, Hoffmann et 
al. 2002; Seo, Hoffmann et al. 2004). The seasonal strain A/Sydney/97 which 
induces a high level of IFN-β, was less affected by the presence of exogenous 
IFN-β in A549 cells; whilst viruses which induced lower levels of IFN-β, e.g. 
A/Victoria/75, were more susceptible (Hayman, Comely et al. 2006). Since 
A/Sydney/97 does not possess the D92E mutation, there must also exist 
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alternative mechanisms of IFN-β resistance. Furthermore, the mechanisms 
behind high IFN-β induction are also yet to be established.  
 
Many viruses encode immunomodulatory proteins that interfere with the 
induction, response to, or action of host cytokines. The influenza NS1 protein 
antagonises the innate immune response in several ways (Egorov, Brandt et al. 
1998; Garcia-Sastre, Egorov et al. 1998; Hale, Randall et al. 2008). NS1 has 
two domains involved in suppression of the IFN response. The mechanisms are 
strain-dependent since not all strains retain all functions, and are likely to be 
determined by the amino acid sequence of NS1. NS1 has been shown to 
interact with both the PAMP (currently believed to double stranded structures 
within 5‟ triphosphate ssRNA (Pichlmair, Schulz et al. 2006) mediated via an 
RNA binding domain within residues 38 and 41 (Hatada and Fukuda 1992; 
Wang, Riedel et al. 1999; Donelan, Basler et al. 2003), and PRR such as  RIG-I 
(Garcia-Sastre, Egorov et al. 1998; Talon, Horvath et al. 2000; Wang, Li et al. 
2000; Pichlmair, Schulz et al. 2006). It also interacts with many other proteins 
involved in IFN induction such as protein kinase R (PKR) (Wang, Riedel et al. 
1999), and the p85β regulatory subunit of host-cell phosphoinositide 3-kinase 
(PI3K) which activates signalling (Hale, Batty et al. 2008). The NS1 from some 
strains of influenza A virus have been shown to bind to the 30 kDa subunit of 
the cellular processivity and specificity factor (CPSF-30) and poly (A)-binding 
protein II (PABII), thus abrogating the export of cellular mRNA, including those 
that encode anti-viral genes and IFN-β (Nemeroff, Barabino et al. 1998; Chen, 
Li et al. 1999; Wang, Riedel et al. 1999; Noah, Twu et al. 2003). 
 
As part of the investigation into the role IFN may play in the ultimate yield of 
vaccine strains and the extent to which antagonism can be beneficial, the 
mechanism by which viruses induce IFN-β, and the reasons for the disparity in 
levels of IFN-β induction between virus strains, needs to be understood. This 
supplements research done by two previous lab members: initially Anna 
Hayman and subsequently Ben Johnson. 
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6.2 IFN-β induction does not map to HA, NA, NS 
 
Since the NS1 protein has been shown to antagonise IFN-β induction by 
multiple mechanisms it is the obvious candidate to account for the variation in 
IFN-β induction. Using reverse genetics, a panel of recombinant influenza 
viruses that differed only in the origin of segment 8 RNAs, was generated 
(Hayman, Comely et al. 2006). Initially this was done in the A/Victoria/75 
background (Anna Hayman, figure 6.2.1). To exclude the possibility that an 
additional gene(s) of A/Victoria/75 was acting to suppress IFN-β induction and 
thus mask a defect in NS1 function, a selection of viruses were also rescued in 
PR8P background (a 6:2 recombinant virus with six internal genes of 
A/PR/8/34 and surface antigens HA and NA of A/Panama/2007/99, 
representative of a typical vaccine seed). Using the A549 IFN-β reporter cell 
line, recombinant viruses with NS1s derived from human viruses with both low 
and high IFN-β inducing phenotypes, all only activated the IFN-β promoter to 
low amounts, similar to that induced by the parental strains. Moreover, 
endogenous expression of high inducing virus NS1 proteins in the context of 
virus infection, were able to control IFN-β induction by Sendai and influenza 
virus (Johnson et al manuscript in preparation). Thus, the high induction of 
IFN-β in human cells by wild-type influenza viruses was not accounted for by a 
deficiency in their NS genes. 
 
Besides NS1, the surface glycoproteins HA and NA of influenza have also been 
implicated in the high cytokine induction of the 1918 “Spanish” pandemic virus 
and high TNF-α induction by Sydney in porcine macrophages in vitro (Seo, 
Webby et al. 2004). For vaccine manufacture, the properties of the surface 
antigens are the most significant since the vaccine is a 6:2 recombinant. 
Recombinant viruses in both A/Victoria/75 and PR8P backgrounds, containing 
constellations of HA, NA and NS derived from A/Sydney/97, all induced low 
amounts of IFN-β, similar to that induced by the parental strains in the A549 
IFN-β reporter cell line (figure 6.2.1), suggesting that high IFN-β induction in 
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A549 cells is not conferred by either the influenza surface glycoproteins or NS1. 
If vaccine seeds are 6:2 reassortants derived from a low inducing donor strains 
then IFN-β induction should not be an issue for vaccine manufacture. 
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Figure 6.2.1. IFN induction by wild type A/Sydney/97 virus does not map to 
HA, NA, NS 
 
Figure 6.2 The A549 IFN-β luc reporter cell line was infected with recombinant 
viruses containing constellations of HA, NA and NS genes from A/Sydney/97 in 
stable human genetic backgrounds (A/Victoria/3/75 or A/PR8/) at an MOI of 3 
PFU/cell. 8 hours post infections cells were washed PBS, lysed in CCLR, clarified 
by centrifugation, 13,000 RPM for 1 minute and luciferase measured. Data are 
represented as ratio of induction corrected to unchallenged cells. Means and 
standard error were calculated for duplicate wells. This assay is representative 
of two repeat experiments. Error bars represent standard error. 
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6.3 High IFN-β inducing viruses exhibit dysregulation of protein 
expression 
 
Although it had been shown that A/Sydney/97 virus NS1 protein was 
functional and able to antagonise IFN-β induction, it was possible that its 
expression could be dysregulated in the context of wild type virus infection 
such that when PAMP is generated insufficient NS1 protein has accumulated to 
antagonise IFN-β induction. To assess this possibility protein levels over the 
course of infection were measured by Western blot. Expression of A/Sydney/97 
viral proteins were compared to a low IFN-β inducing virus A/Victoria/75. A 
recombinant virus containing A/Sydney/97 NS in the A/Victoria/75 background 
was used as a second, low IFN-β inducing virus for comparison. 
 
A dose of virus was established that infected an equal number of cells. The 
expression of viral proteins, NS1, M1 and NP, were assessed by Western blot 
(figure 6.3.1). JAK/STAT signalling following IFNAR stimulation by IFN-β 
results in the phosphorylation of STAT-1, so phosphorylated STAT-1 was used 
as a marker for the induction of IFN-β.  
 
Infection with A/Sydney/97 was found to be synchronized differently than for 
A/Victoria/75 based viruses. Viral proteins in A/Sydney/97 infection 
accumulated much earlier in infection than did proteins expressed by the two 
low inducing viruses. Viral proteins (NP, M and NS1) were detected as early as 
2 hours post infection with A/Sydney/97 and this correlated with earlier STAT-1 
phosphorylation. Furthermore, the expression of A/Sydney/97 NS1 protein 
appeared to lag behind the other viral proteins. Although differences in the 
affinity of the antibodies to each of the viral proteins cannot be excluded, the 
data suggests that viral replication resulting in the synthesis of certain viral 
proteins, and the accumulation of PAMP, occurred earlier during infection with 
A/Sydney/97 without a corresponding increase in the levels of NS1 to 
antagonise the IFN-β induction 
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Viral proteins also accumulated, to a lesser extent, earlier following infection 
with the recombinant virus containing A/Sydney/97 NS1 in the A/Victoria/75 
background, than during infection with wild type A/Victoria/75. However, this 
was associated with much higher relative levels of NS1. The increased 
expression of NS1 can antagonise the IFN-β induced by the increased levels of 
PAMP and thus results in much reduced levels of phosphorylated STAT-1; 
which do not accumulate until later in infection. The NS1 protein has been 
shown to mediate the temporal regulation of viral RNA synthesis via 
interactions with the viral polymerase (Min, Li et al. 2007) and also enhance 
the rate of translation of certain viral proteins (Enami, Sato et al. 1994; de la 
Luna, Fortes et al. 1995) and this could in part explain the differences in viral 
protein expression of the recombinant virus. 
 
Viral proteins associated with infection with A/Victoria/75 accumulated slowly 
and did not even reach equivalent levels to those expressed by the other two 
viruses. However, this does not correlate with outcome of infection; 
A/Victoria/75 is an extremely “fit” virus and can achieve titres of 108 PFU/ml 
following propagation in cell culture whilst A/Sydney/97 usually attains a log 
less.  
 
Furthermore, the earlier phosphorylation of STAT-1 correlates with early IFN-β 
induction by A/Sydney/97 virus (figure 6.3.2). A549 cells harbouring the IFN-β 
luciferase reporter were infected with the same panel of viruses. IFN-β 
induction was detected as early as 2 hours post infection by A/Sydney/97. 
Infection with the recombinant virus in the A/Victoria/75 background with 
A/Sydney/97 NS resulted in a slight induction of IFN-β which correlates to the 
lower levels of phosphorylated STAT-1 noted by Western blot. 
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Figure 6.3.1. A/Sydney/97 proteins accumulate early in infection 
 
A/Sydney/97 proteins are synthesised earlier in infection than those of 
A/Victoria/75. A549 cells were infected with viruses (A/Victoria/75- V, 
A/Sydney/97- S, and a recombinant containing NS from A/Sydney/97 in the 
A/Victoria/75 background- NS) at a dose twice that required for every cell to 
express antigen, cells were lysed in RIPA buffer containing iDOC at 2, 4, 6, and 
8 hours post infection. Cell lysates were run on 10% or 15% SDS PAGE gels 
and Western blotted on to PVDF membrane. Membranes were probed with 
antibodies and detected with ECL reagent. Vinculin was used as a loading 
control. (Antibody concentrations were Vinculin 1/1000, Stat-1 1/500, NP 
1/400, M 1/1000, NS 1/300, secondary antibodies 1/2000). 
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Figure 6.3.2 A/Sydney/97 induces IFN-β early in infection 
 
The A549 IFN-β luc reporter cell line was infected with A/Sydney/97, 
A/Victoria/75 and a recombinant containing NS from A/Sydney/97 in the 
A/Victoria/75 background at a dose twice that required for every cell to 
express antigen. At 2, 4, 6, 8, 12 and 24 hours post infection cells were washed 
PBS, lysed in CCLR, clarified by centrifugation, 13,000 RPM for 1 minute and 
luciferase measured. Data are represented as ratio of induction corrected to 
unchallenged cells. Means and standard error were calculated for duplicate 
wells. This assay is representative of three repeat experiments. Error bars 
represent standard error. 
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To normalise infections, the infectivity of viruses in the A549 cell line was 
measured by “blue cell” assay, where expression of the viral protein, NP was 
immuno-detected. Interestingly, it was observed that not all viruses expressed 
the same levels of NP in infected cells. Infection with some strains resulted in 
cells which stained very weakly whilst for others staining was more intense. 
The "blue cell" assay standardises the volume of virus required to infect an 
equal number of cells regardless of intensity. In some instances, Western blots 
of virus proteins have been used to standardise assays and ensure equivalent 
levels of infectivity. The results of both the Western blot and the blue cell assay 
highlight the need to be aware when comparing some virus strains that the 
levels of virus protein from different strains are not absolute. 
 
6.4 High IFN-β induction requires expression of RIG-I 
 
Work in section 6.3 suggested that the higher levels of IFN-β induced by 
A/Sydney/97 may be due to a dysregulation in the levels of PAMP relative to 
the levels of NS1 protein. Alternatively, A/Sydney/97 may also generate a 
different kind of PAMP which NS1 is unable to control. The PRR, RIG-I, has 
been shown to mediate the IFN-β response to influenza viruses (Pichlmair, 
Schulz et al. 2006; Le Goffic, Pothlichet et al. 2007; Loo, Fornek et al. 2007; 
Pothlichet, Chignard et al. 2008), however, these experiments have largely 
been performed with lab strains of viruses which tend to have a low IFN-β 
inducing phenotype.  
 
Huh-7.5 cells have a point mutation the PRR, RIG-I (Sumpter, Loo et al. 2005) 
in the TRIM25 binding domain (Gack, Albrecht et al. 2009) and are believed 
to be unable to respond to RIG-I activating PAMPs. Huh-7.5s were used to 
determine whether the high IFN-β  induction by A/Sydney/97 virus was 
mediated via the RIG-I dependant PRR pathway. 
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Figure 6.4.1. High IFN-β induction by influenza viruses is mediated by RIG-I 
 
High IFN induction is mediated by RIG-I. Huh-7 and the RIG-I deficient subline 
Huh-7.5 cells were transiently transfected with the IFN-β luc reporter construct, 
and infected 48 hours post transfection at a dose twice that required for every 
cell to express antigen with a panel of high and low inducing viruses and a 
recombinant in the A/Victoria/75 background containing A/Sydney/97 NS. 8 
hours post infection cells were washed PBS, lysed in CCLR, clarified by 
centrifugation, 13,000 RPM for 1 minute and luciferase measured. Data are 
normalized to β-galactosidase activity for each transfection to account for 
differences in translation and transfection efficiencies and are represented as 
ratio of induction corrected to unchallenged cells. Means and standard error 
were calculated for duplicate wells. This assay is representative of two repeat 
experiments. Error bars represent standard error. 
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Huh-7 and Huh-7.5 cells were transiently transfected with the IFN-β luc 
reporter construct, and infected with a panel of high and low inducing WT 
viruses and the recombinant virus containing A/Sydney/97 NS in the 
A/Victoria/75 background (figure 6.4.1). Huh-7 cells with intact RIG-I pathway 
displayed a similar pattern of IFN-β induction upon infection had been seen 
following as infection of A549 cells. In contrast, only low amounts of IFN-β 
were induced following infection of Huh-7.5 cells irrespective of the virus 
strain. This suggests that the high induction of IFN-β by wild-type influenza 
viruses, such as A/Sydney/97, is mediated via RIG-I. 
 
6.5 RIG-I and MDA-5 mRNAs are upregulated during influenza 
infection 
 
PRR such as MDA-5 and RIG-I, are IFN stimulated genes (ISGs) which are 
upregulated by IFN-β induction. To determine whether the high IFN-β 
induction by some strains of influenza viruses elicited a typical upregulation of 
ISG, semi-quantitative RT-PCR was used to determine the levels of expression 
of MDA-5 and RIG-I, in response to virus infection of A549 cells. Total RNA 
was extracted from infected cells at various times post infection. Equal amounts 
of RNA, quantified by spectrophotometer, were used to generate cDNA, then 
equivalent volumes used to generate cDNA. Only 25 cycles of PCR were 
performed to ensure the reaction was terminated in the exponential phase. 
mRNA expression of RIG-I, MDA-5 and GAPDH as a loading control, were 
analysed (fig 6.5.1). In A/Sydney/97 infected A549 cells RIG-I and MDA-5 were 
up-regulated early in infection; RIG-I mRNA signal increased as early as 2 hours 
post infection. Both PRR are upregulated by positive feedback in a typical 
autocrine manner as a consequence of IFN-β induction during infection with 
A/Sydney/97. 
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Figure 6.5.1 PRR are upregulated by IFN-β induction by influenza viruses 
 
MDA-5 and RIG-I are upregulated earlier in infection in cells infected with 
A/Sydney/97. A549 cells were infected with virus at a dose twice that required 
for every cell to express antigen and lysed in TRIzol (Invitrogen) according to 
manufacturer‟s instructions at the given time points. Purified RNA was 
quantified by spectrophotometer. Equivalent amounts of RNA were used to 
generate cDNA. Equivalent volumes of cDNA were used in the PCR reaction, 
for 25 cycles to ensure PCR was in the quantitative phase. Expression of RIG-I, 
MDA-5, and GAPDH as a loading control, were evaluated. 
 
 
 
  
  
192 
 
6.6 High IFN-β inducing viruses are prone to making more defective 
RNA 
 
UV treatment denatures nucleic acids, but viral proteins are undamaged and 
the virion particles remain intact. UV treatment abrogated IFN-β induction by 
influenza viruses including A/Sydney/97 (Johnson et al manuscript in 
preparation). Therefore, IFN-β induction is not activated by virus cell binding 
or entry but rather must be reliant on RNA replication. The most systematic 
way to dissect the mechanisms for high IFN-β induction would be to test the 
contribution of each RNA segment in the phenotype by generating 
recombinant viruses containing constellations of segments from high and low 
inducing viruses; this approach had eliminated HA, NA and NS genes (figure 
6.2.1). However, we do not possess a full reverse genetics system for a high 
inducing virus. While attempting to clone the remaining genes of A/Sydney/97, 
using primer pairs complementary to the 5‟ and 3‟ termini of each viral RNA, a 
number of shorter products were consistently generated and for some viral 
RNA segments the full-length band was not even detectable. This occurred 
frequently during attempts to clone segments from viruses which induced high 
levels of IFN-β, and although these short products could be PCR artefacts, they 
were rarely seen in low inducing viruses. A number of these bands were 
sequenced and had the properties of defective interfering RNAs (figure 6.6.1 
and table 6.6.1). Defective RNAs result from spontaneously occurring deletions 
within the full-length viral RNAs during RNA synthesis. These shorter RNAs 
retain the 3‟ and 5‟ non coding regions which encode the packaging signals. 
This means they can be incorporated into virions to generate defective 
interfering particles (DIs) which are able to infect cells but since they lack a 
complete genome are unable to replicate without the assistance of an intact 
helper virus. In this event, as a result of the small size of the defective RNAs the 
shorter RNAs are replicated to much higher levels than full-length segments, so  
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Figure 6.6.1 Schematic representation of defective interfering RNA 
 
Defective RNAs result from spontaneously occurring deletions within the full-length viral RNAs during RNA synthesis. These 
RNAs are incorporated into virions to generate defective interfering particles which are able to infect cells but due to the lack 
of a complete genome are unable to replicate without the assistance of an intact helper virus. As a result of the small size of 
defective interfering RNA it is replicated to much higher levels than full-length segments, so the cell produces defective virions 
in place of infectious progeny (Duhaut and Dimmock 2000; Duhaut and Dimmock 2002). 
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Table 6.6.1 Defective RNAs accumulate during infection with A/Sydney/97 
virus 
 
Sequence analysis of shorter PCR products generated from amplification of 
A/Sydney/97 virus show signatures of defective RNAs. Alignment against the 
full length sequence allows the junctions of the DI to be determined. 
 
Segment 
of origin 
Approx. PCR 
product size 
Full Length 
of segment 
5' 
junction  
3' 
junction  
Deduced 
length of 
RNA  
PB2 600 2280 259 2010 529 
PB1 900 2274 275 1943 606 
PB1  600 2274 204 2025 453 
PA 900 2183 115 1586 712 
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Figure 6.6.2 High IFN-β inducing viruses have a propensity to make short 
RNAs 
 
32
P
 labelled oligos complimentary to PB2 gene segment 3‟UTR were used in an 
extension assay with total RNA from infected cells as a template. Cells were 
infected at an MOI 0.01 and harvested 40 hours post infection. RNA was 
extracted with TRIzol according to manufacturers‟ instructions. Equivalent 
amounts of RNA were used in each reaction. Only the lower part of the gel is 
shown. Data provided by Matt Smith. 
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the cell produces defective virions in place of infectious progeny (Duhaut and 
Dimmock 2000; Duhaut and Dimmock 2002). DIs usually occur late in 
infection or when a high MOI is used (Odagiri and Tobita 1990), preparations 
that contain them are known to induce high levels of IFN-β (Johnston 1981). 
The amplification of short products suggests that A/Sydney/97, and other high 
IFN-β inducing viruses, have a propensity to make defective RNAs. Primer 
extension analysis was used to quantify the RNA species in virus infected cells 
(fig 6.6.2). 32P labelled oligos complimentary to viral gene segments were 
used in an extension assay with total RNA as a template. In this case, primers 
specific to the 3' UTR of vRNA were used. Shorter RNAs were produced during 
infection with A/Sydney/97 or A/England/370/02 again suggesting that viruses 
that induce high IFN-β have a propensity to make defective RNAs. Although 
these short RNAs could be the result of mispriming, this is unlikely because they 
did not occur when RNA from cells infected with A/Victoria/75. Analysis 
showed that the primer sequence is unique and specific for the 3‟UTR of the 
PB2 segment 1. Plaque picking removes DIs which accumulate during an 
infection, because virus isolated from a plaque will be derived only from a 
single infectious event. Bearing in mind Ben Johnson showed the high IFN-β 
inducing phenotype was carried over in plaqued picked viruses and was also 
genetically determined (Johnson et al, manuscript in preparation) this suggests 
that the DIs are generated spontaneously during infection with viruses which 
induce high levels IFN-β.  
 
6.7 A/Sydney/97 virus drives replication early in infection 
 
Taken together the data suggested that the high IFN-β inducing phenotype 
maybe inherent to the polymerase complex. To assess this the rate of viral 
replication was measured using a luciferase reporter assay. The principal 
involves transfection of cells with a plasmid encoding the non-coding regions 
of segment 8 flanking a luciferase reporter gene. The amount of luciferase 
expression driven by viral polymerase allows replication to be quantified. This 
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Figure 6.7.1 Schematic of up-luc assay (overleaf) 
 
In a minireplicon assay it is sufficient to transfect cells with the polymerase 
subunits, PB2, PB1, PA and NP together with a minireplicon reporter construct 
of viral like RNA containing a luciferase gene flanked by the 5‟ and 3‟ UTR of 
segment 8. However, in virus infection the viral polymerases are unable to 
drive the replication of such a reporter, mutation of nucleotides 3, 5 and 8 in 
3‟ UTR, to generate a so-called “up-promoter, are able to restore this capacity. 
Cells are transfected with the up-luc reporter construct, then infected with 
virus. Viral polymerases drive the amplification and expression of the viral like 
RNA. Quantification of the luciferase signal allows the rate of virus replication 
to be determined. 
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Figure 6.7.1 Schematic of the “up-luc” assay 
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Figure 6.7.2 A/Sydney/97 virus drives replication early in infection 
 
Cells were transfected with the up-luc reporter construct. After 48 hours, cells 
were infected with virus. 8hours post infection cells were washed PBS, lysed in 
CCLR, clarified by centrifugation, 13,000 RPM for 1 minute and luciferase 
measured. Data are represented as ratio of induction corrected to unchallenged 
cells. Means and standard error were calculated for duplicate wells. This assay 
is representative of three repeat experiments. Error bars represent standard 
error. 
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is apt for minireplicon assays, however, the polymerases, in the context of virus 
infection, seem unable to recognise and replicate „naked‟ vRNA present inside 
a cell to detectable levels (Lutz et al., 2005) unless three nucleotide changes at 
positions 3, 5 and 8 in the 3‟ non-coding region are present. This mutation 
appears to increase viral polymerase transcription of a synthetic viral-like RNA 
(Neumann & Hobom, 1995). Therefore these three point mutations were 
engineered into a minireplicon containing the luciferase reporter gene (Dan 
Brookes), and function as an „up-promoter‟ enhancing recognition of the 
reporter gene by virus polymerases (here on called the “up-luc” reporter) 
(figure 6.7.1).  
 
The extent to which the virus polymerase of A/Sydney/97, A/Victoria/75 or 
recombinant, in the A/Victoria/75 background containing A/Sydney/97 NS 
drove RNA replication and expression were compared. Huh-7 cells were 
transiently transfected with the up-luc reporter construct and infected with 
twice the volume of virus required to infect every cell. Luciferase production 
was measured at various times post-infection (figure 6.7.2). A/Sydney/97 virus 
drove expression of the up-luc reporter very early in infection. Luciferase was 
measured at the earliest time point; just 2 hours post infection. The low 
inducing viruses A/Victoria/75 or the A/Victoria/75 +A/Sydney/97 NS 
recombinant eventually attained similar or higher levels of luc expression, but 
not until much later in infection at 12 hours. These data imply that the 
polymerases of A/Sydney/97 virus are particularly active and initiated 
replication very early in infection. 
 
6.8 Total RNA from infected cells induces similar levels of IFN-β 
irrespective of strain 
 
The increased rate of replication of A/Sydney/97 appears to correlate 
kinetically with its high IFN-β induction. However, the nature of the PAMP 
which drives the high IFN-β induction is as yet undetermined. 5‟ triphosphate 
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RNA has been shown to mediate IFN-β induction for laboratory strains of 
influenza virus but this has yet to be associated with the high IFN-β phenotype. 
The earlier replication observed in A/Sydney/97 virus infection may result in 
the generation of vRNAs, possessing 5‟3P, which accumulate in the infected 
cells in the absence of sufficient NS1 protein to antagonise IFN-β induction. To 
investigate the ability of RNAs generated in infected cells to trigger IFN-β 
induction, total RNA was extracted from cells infected over the course of 
infection with RNA extracted from uninfected cells serving as a control. The 
RNA was then applied to the same cell type expressing the IFN-β luc reporter, 
and its ability to induce activation of the IFN-β promoter was assessed (figure 
6.8.1). 
 
RNA from uninfected cells did not activate the IFN-β promoter. RNA from 
infected cells induced no IFN-β until 4 hours post infection after which up to 
20 fold induction of IFN-β was observed, irrespective of strain. This was higher 
than the 5 fold induction measured by infection with A/Sydney/97 virus and 
transpired at a later time during infection. The data suggest that virus infection 
causes accumulation of a PAMP from 4 hours post infection which is not strain 
dependant, perhaps via a general modification to RNAs present in the cells 
which renders them immuno-stimulatory.  
 
It is surprising that IFN-β induction by RNA extracted from A/Sydney/97 
infected cells was not detected earlier since A/Sydney/97 polymerases were 
active as early 2 hours post infection (section 6.3 and 6.7) and IFN-β induction 
was also seen at that time (figure 6.3.2). The assay may not be sufficiently 
sensitive to respond to the levels of PAMP present in the total RNA extraction 
at the earlier time points. 500 ng of RNA extracted from virions was able to 
induce IFN-β promoter induction, yet 100 ng of this RNA could not (data not 
shown). In the present assay, 250 µg of total RNA from infected cells was 
applied to IFN-β luc reporter cells. 
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6.8.1 RNA from infected cells induces similar levels of IFN-β irrespective of 
strain 
 
Total cellular RNA from infected cells induces similar levels of IFN-β, 
irrespective of IFN inducing phenotype of virus. Cells were infected at a dose 
twice that required for every cell to express antigen. Total cellular RNA was 
extracted with TRIzol (Invitrogen) according to manufacturer‟s instructions, 
from infected Huh-7 cells at given times (1, 2, 3, 4, 6, 7 hours) post infection. 
250 µg RNA was then transfected onto Huh-7 cells transiently transfected with 
IFN- luc and β-galactosidase, 48 hours post transfection. After 8 hours post 
transfection cells were washed PBS, lysed in CCLR and clarified by 
centrifugation, 13,000 RPM for 1 minute. Luciferase activity was measured and 
normalized to β-galactosidase activity for each transfection to account for 
differences in transfection efficiencies. Data are represented as ratio of 
induction corrected to unchallenged cells. Means and standard error were 
calculated for duplicate wells. This assay is representative of two repeat 
experiments. Error bars represent standard error. 
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Should the proportion of viral RNA contained within the total RNA fall below 
the threshold of detection (between 500 ng and 100 ng vRNA), IFN-β 
induction would not be measured. Increasing the amount of total RNA applied 
to cells and thereby increasing the proportion of PAMP or increasing the 
amount of time the RNA is incubated on the cells before taking measurements 
may improve the sensitivity.  
 
6.9 Leptomycin B, inhibits the export of luciferase mRNA from the 
nucleus and activates IRF-3 
 
It seemed likely that A/Sydney/97 induced IFN when replicated RNA reached 
the cytoplasm, where it would be detected by RIG-I. If this were the case it was 
reasoned that inhibition of the export of viral RNAs from the nucleus would 
prevent IFN-β induction. Leptomycin B is a specific nuclear export inhibitor, 
which alkylates and thus inhibits CRM-1 (chromosomal region maintenance) 
mediated nuclear export of proteins containing nuclear export sequences 
(NES). Addition of LMB has been shown to prevent the export of viral RNPs 
(Elton, Simpson-Holley et al. 2001). A549 IFN-β luc reporter cells infected with 
virus were incubated in the presence of 10 nM LMB. Luciferase activity, 
reflecting activation of the IFN-β promoter, was measured after 8 hours (figure 
6.9.1). IFN-β promoter induction by A/Sydney/97 was greatly reduced 
although not completely prevented. However, LMB also reduced IFN-β 
induction by NDV infection. Since NDV replicates in the cytoplasm it is not 
dependant on nuclear export of its PAMP to mediate an IFN-β response. This 
result suggests that LMB treatment retains luciferase mRNA in the nucleus and 
that the luciferase mRNA is also exported from the nucleus in a CRM-1 
dependant manner. The abrogation of IFN-β induction by A/Sydney/97 virus 
was not complete, and some induction of the IFN-β promoter was measured. 
LMB was shown to be effective at retaining NP in the nucleus when added 3 
hours post infection at a concentration of 11 nM (Elton, Simpson-Holley et al. 
2001). Other groups have used a similar range of concentrations (2-40 nM) 
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and addition as late as 6 hours post infection to inhibit export of vRNA and 
RNPs from the nucleus (Ma, Roy et al. 2001; Watanabe, Takizawa et al. 2001; 
Wu and Pante 2009).Typical virus infection procedures allows 1 hour for the 
virus to enter the cells, after which the media is replaced with serum free 
DMEM. This minimises the carryover of artefacts in the virus preps which are 
able to induce IFN-β. The LMB was therefore added to the replacement serum 
free media. Since it has been demonstrated that virus replication and IFN-β 
induction occurs early during A/Sydney/97 virus infection, the IFN-β luc 
measured could have been induced during the hour prior to the addition of 
LMB and whilst the later addition of LMB is appropriate for other virus strains, 
addition from the onset of infection is required for viruses such as A/Sydney/97 
to completely block export from the nucleus.  
 
Because LMB inhibits the export of luciferase messenger RNA from the nucleus, 
the luciferase reporter assay is not an appropriate assay to determine whether 
nuclear export is required for influenza mediated IFN-β induction. 
Immunofluorescence was used as an alternative assay; the activation of the 
IFN-β promoter can be inferred by the translocation of IRF-3 from the 
cytoplasm to the nucleus. Cells were infected as above but fixed at 7 hours 
post infection and immunostained for viral antigen (NP) and IRF-3. 
Surprisingly, however, even in uninfected cells treated with LMB, IRF-3 was 
predominantly nuclear (figure 6.9.2 top right panel). Thus, the addition of 
LMB seems to activate IRF-3 and this precluded an assessment of the 
relationship between RNP localisation during influenza infection and RIG-I 
activation. Interestingly, in A/Sydney/97 untreated infected cells treated with 
LMB, IRF-3 translocation to the nucleus was still more substantial than in 
infected cells. This again could be due to IRF-3 activation during the first hour 
of infection when LMB is not present. Alternatively, IFN-β induction by 
A/Sydney/97 virus could indeed occur in the absence of nuclear export. NP 
was also more nuclear in LMB treated cells confirming NP required CRM-1 for 
export from the nucleus, and that inhibition of CRM-1 by LMB had occurred. 
In conclusion, it is not possible to equivocally establish the importance of vRNP   
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Figure 6.9.1 Inhibition of nuclear export with Leptomycin B 
 
The A549 IFN-β Luc reporter cell line was infected with a high IFN inducing 
virus A/Sydney/97, a low inducing viruses A/Eng/99/00 at a dose twice that 
required for every cell to express antigen and NDV. 10 nM Leptomycin B was 
added 1 hours p.i. 8 hours post infection cells were washed PBS, lysed in CCLR, 
clarified by centrifugation, 13,000 RPM for 1 minute and luciferase measured. 
Data are represented as ratio of induction corrected to unchallenged cells. 
Means and standard error were calculated for duplicate wells. This assay is 
representative of three repeat experiments. Error bars represent standard error. 
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Figure 6.9.2 Leptomycin B immunofluorescence of NP and IRF-3 
 
A549 cells were infected with A/Sydney/97 at a dose twice that required for 
every cell to express antigen. 10 nM Leptomycin B was added 1 hours post 
infection. 7 hours post infection cells were washed PBS, then fixed 4% PFA/PBS 
for 10 minutes, RT. Coverslips were blocked 3% BSA for 30 minutes RT. 
Proteins were immunodetected (top left panel- goat IRF-3 1/300, anti goat 
FITC 1/500, bottom left panel- mouse NP 1/300, anti mouse Texas red 1/500, 
top right panel- phase contrast, bottom right panel- overlay). 
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nuclear export in the A/Sydney/97 high IFN-β inducing phenotype because 
the drug used to inhibit CRM-1 had unexpected albeit interesting effects.  
6.10 Cells infected with A/Sydney/97 do not have early nor greater 
translocation of NP to the cytoplasm 
 
Viral proteins, particularly NEP (Neumann, Hughes et al. 2000; Robb, Smith et 
al. 2009) and M1 (Liu and Ye 2002) are involved in the export of vRNA and 
RNPs from the nucleus. The accumulation of viral proteins earlier in 
A/Sydney/97 (figure 6.3.1) infection may have promoted the export of vRNAs 
and RNPs from the nucleus before sufficient NS accumulated to antagonise the 
IFN-β response. It has been noted previously that following infection with 
A/Sydney/97 virus, a portion of virus infected cells have IRF-3 in the nucleus. 
Typically such cells showed increased levels of NP (and by inference, RNPs) in 
the cytoplasm (Hayman, Comely et al. 2006). In this instance, the cells were 
fixed 8 hours post infection, however, data presented in this chapter (sections 
6.3.1 and 6.5.2) indicates that IFN-β promoter activation occurs already at 
earlier time points. Therefore, the location of NP and IRF-3 in virus infected 
A549 cells were determined by IF at 4, 5, 6 and 7 hours p.i. (figure 6.6.1). 
Since IFN-β was induced as early as 2 hours post infection (figure 6.3.2) and 
STAT-1 was phosphorylated 4 hours post infection (figure 6.3.1), IRF-3 
translocation to the nucleus ought to occur early in infection and be detectable 
by 4 hours post infection. The number of A/Sydney/97 infected cells with 
nuclear IRF-3 was expected to be higher than in cells infected with either 
A/Victoria/75 or the recombinant. As previously observed, infection with 
A/Sydney/97 virus resulted in an increase in the number of cells in which IRF-3 
had translocated to the nucleus (figure 6.10.1), corresponding to induction of 
IFN-β. Activated IRF-3 had translocated to the nucleus even at the earliest time 
point, 4 hours. At 7 hours post infection, the latest time point examined, 40% 
of A/Sydney/97 infected cells had IRF-3 in the nucleus, compared to just 14% 
for the recombinant with A/Victoria/75 with A/Sydney/97 NS and none for 
WT A/Victoria/75.  
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Figure 6.10.1 Cells infected with A/Sydney/97 do not have early nor greater 
translocation of NP to the cytoplasm 
 
A549 cells were infected with A/Victoria/75, A/Sydney/97 or a recombinant 
A/Victoria/75 with A/Sydney/97 NS at a dose twice that required for every cell 
to express antigen. A) At the times indicated post infection cells were washed 
PBS, then fixed 4% PFA/PBS 10 minutes, RT. Coverslips were blocked with 3% 
BSA for 30 minutes, RT. Proteins were immunodetected (top left panel- rabbit 
IRF-3 1/300, anti rabbit FITC 1/500, bottom left panel- mouse NP 1/300, anti 
mouse Texas red 1/500, top right panel- phase contrast, bottom right panel- 
overlay). 
 
A) On this page uninfected cells, on the following pages virus infected cells at 
4, 5, 6 and 7 hours post infection. 
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B) Three fields were stained for each virus and each time point. Cells were 
scored on expression of NP exclusively in the nucleus or expression in both the 
nucleus and the cytoplasm, and cells with nuclear IRF-3 and those with both 
nuclear IRF-3 and cytoplasmic NP. Three fields stained for NP were counted, 
the percentage of cells with nuclear NP are shown by blue bars, the percentage 
of cells with nuclear and cytoplasmic NP are shown by the pink hashed bars. 
Three fields stained for IRF-3 were counted, the percentage of cells with 
nuclear IRF-3 are shown by green hashed bars, for three fields the number of 
cells with cytoplasmic NP as a percentage of cells with nuclear IRF-3 are shown 
in grey bars. 
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However, at the same time point 65% cells infected with either of the low 
inducing viruses expressed NP in the cytoplasm; compared to only 40% cells 
infected with A/Sydney/97. Thus, there was no evidence for an early or greater 
translocation of NP to the cytoplasm in cells infected with A/Sydney/97. 
Moreover, more of the infected cells in which IRF-3 was nuclear had 
cytoplasmic NP after infection with the recombinant virus than after 
A/Sydney/97 infection, 36% compared to 26%). An increase in the expression 
of NP, based on the intensity of the antibody staining, in A/Sydney/97 infected 
cells was not observed. The experiment was carried out in the same cell line, 
with the same virus preparations and equivalent innoculum as the Western 
blot. Since the Western blots have been repeated a number of times, this 
suggests that immunofluorescence is a less quantitative technique. At optimised 
concentrations digitonin can selectively lyse the plasma membrane leaving the 
nuclear membrane intact allowing the cytoplasm to be separated from the 
nuclear fraction. Western blots of cell fractions could be used in the future to 
quantify the amount of NP export from the nucleus. However, it should be 
noted that IRF-3 translocation is transient and the dimer shuttles in and out of 
the nucleus (Reich 2002).  
 
6.11 Discussion  
 
Ongoing work in the lab has attempted to establish the mechanisms 
responsible for the variation in IFN-β induction between influenza strains. This 
body of work has not been fully resolved the issue but has alluded to the viral 
genes involved. In human strains of influenza, high IFN-β induction does not 
map to segments 4, 5 and 8; those of the surface antigens HA and NA nor 
surprisingly the IFN-β antagonist, NS. 
 
These experiments have shown that the IFN-β induction profile is set very early 
in induction. Polymerases from high IFN-β inducing viruses initiate RNA 
synthesis and viral replication within 2 hours of infection. This has a knock on 
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effect of increased protein expression early in infection. Thus, viral proteins are 
synthesised early and ultimately accumulate to greater abundance over the 
course of infection. Surprisingly, this does not correlate with increased viral 
yields or indeed increased virus fitness in immortalised cell lines. It could 
however, result in the dysregulation of viral RNA or protein targeting within 
the infected cells. The experiments designed thus far were not able to 
demonstrate this. Since the high IFN-β induction requires replication, the early 
start by A/Sydney/97 could be due to very quick entry and uncoating. The 
viral inhibitor, Amantadine, inhibits formation of M2 mediated pores in the 
virion whilst within endosomes and thus prevents virus uncoating. Its use 
would provide further evidence that input virus does not induce IFN-β. Its 
addition at staggered times post infection might demonstrate that A/Sydney/97 
infects and uncoats earlier in infection than viruses such as A/Victoria/75. 
Whilst the use of RNA dependant RNA polymerase specific inhibitor such as 
Ribavirin would corroborate that viral replication is required. 
 
The ideal way to assay the molecular basis for high IFN-β induction would be 
to employ a reverse genetics system. Recombinant viruses could be used to 
determine the contribution of each gene segment and subsequently which 
motifs within these genes are required to elicit the high IFN-β induction. 
However, difficulties have been encountered trying to obtain full length PCR 
products. Two laboratories have published the use of a A/Sydney/97 virus 
reverse genetics system (Parks, Latham et al. 2007). They were approached for 
access, but unfortunately, did not respond.  
 
The attempt to establish a reverse genetics system revealed further irregularities 
in the activity of A/Sydney/97 polymerase. RNA analysis and the generation of 
smaller PCR products amplified while attempting to clone each segment, 
suggest these viruses have a propensity to make short defective RNAs which 
are known to induce high levels of IFN-β in virus preparations. Thus far, 
primer extensions have only been performed using the PB2 gene as a template. 
Although DIs most frequently occur within the longer segments, using the mid-
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range or smaller segments of the influenza genome may infer whether the 
phenomenon is the result of an unstable polymerase complex for example or a 
result of genetic encoding within the RNA sequence. A mutation in PA, R638A 
of A/WSN/33 virus has been shown to drive the synthesis of DIs (Fodor, 
Mingay et al. 2003). The mutation in PA was proposed to destabilize 
polymerase-RNA template interactions during elongation which results in the 
release of the RNA template, the polymerase then reinitiates downstream on 
the template and completes elongation. These viruses were severely attenuated 
in MDBK cells, but were rescued by a compensating mutation in PA, C453R 
(Fodor, Mingay et al. 2003). It is interesting to speculate that the attenuation is 
due to the IFN-β induction, although this was not investigated. A mutation in 
NEP, I32T of A/Aichi/2/68 virus was also shown to drive the aberrant synthesis 
of RNAs derived from the PA vRNA segment (Odagiri and Tobita 1990; 
Odagiri, Tominaga et al. 1994); thus there seem to be multiple mechanisms 
which can lead to the generation of DIs. A/Sydney/97 virus does not encode 
either of the mutations described above (neither R638 in its PA, nor T32 NEP), 
but it and other high IFN-β inducing virus could encode other mutations which 
are compensated through mutations which drive resistance to IFN-β induction 
caused by DIs, rather than mutations which repair the destabilisation of the 
polymerase. 
 
Pichlmair et al, (Pichlmair, Schulz et al. 2006) showed 5‟3P RNA to be 
involved in influenza virus driven IFN-β induction since CIP treatment of vRNA 
abrogated the response. This work was all performed using the laboratory 
strains A/PR/8, and high inducing viruses may make another PAMP which has 
yet to be determined. RIG-I thus far seems to be the most important transducer 
of IFN-β induction in influenza infection, and although MDA-5 was found to 
be upregulated in influenza virus infected cells in an autocrine manner, it is not 
involved in viral PAMP recognition. Short doubled stranded secondary 
structures within single stranded RNA, such as the proposed pan handle of 
influenza vRNA (Brownlee and Sharps 2002), have also been shown important 
for RIG-I detection of PAMP (Schlee, Roth et al. 2009; Schmidt, Schwerd et al. 
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2009). In order to understand the nature and localisation of the influenza 
PAMP, an antagonist of CRM-1 dependant nuclear export, LMB was used. It 
was hoped this would demonstrate whether the PAMPs presumably produced 
during viral RNA replication in the nucleus, required transport into the 
cytoplasm. Unfortunately, LMB also blocked export of the reporter luciferase 
mRNA and so IFN-β induction could not be measured. Intriguingly, LMB also 
seemed to activate IRF-3 and this masked the ability to detect influenza 
activated IRF-3 translocation by immunofluorescence. The situation may be 
resolved in the future by isolating RNA from nuclear and cytoplasmic extracts 
from infected cells, to help determine the location of the PAMP.  
 
Increased expression of viral proteins particularly NEP (Neumann, Hughes et 
al. 2000; Robb, Smith et al. 2009) and M (Liu and Ye 2002) which are 
involved in nuclear export, could result in dysregulation in protein and RNP 
targeting. FISH can be used to determine the localisation of influenza RNA 
species (Hutchinson, Curran et al. 2008), but has yet to used to investigate 
differences in RNA localisation between high and low IFN-β inducing viruses. It 
would be interesting to determine whether high inducing viruses yield more 
RNAs in the cytoplasm, whether this correlates to all segments or is segment 
specific and NP localisation. An increase in the export of RNAs or another 
PAMP, either by increased expression or more efficient protein function, could 
account for A/Sydney/97 high IFN-β induction phenotype.  
 
The mechanisms and consequences of high IFN induction have yet to be 
determined. Experiments to investigate the consequences of high IFN induction 
are to be carried out in the ferret model and in redifferentiated human airway 
epithelial (HAE) cells. Preliminary experiments in the ferret model, suggest that 
animals infected with A/Sydney/97 showed more severe symptoms, they had 
audible respiratory infection and wheezing, they were less interactive and more 
lethargic (personal communication Kim Roberts). To determine whether this 
correlates with high IFN-β induction by A/Sydney/97 virus, cytokine levels, 
measured by qRT-PCR are in progress on both ferret tissue samples and human 
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airway epithelial cells cultures. Infection of HAE cells resulted in high cytokine 
induction (personal communication Holly Shelton) and also resulted in more 
cell death- a phenotype not seen in immortalised cell lines.  
 
Through understanding the mechanisms of high IFN-β induction by 
A/Sydney/97, improvements and modifications can be made to virus 
antagonism, prophylaxis and vaccine design. Furthermore, this could have 
implications for other viruses which induce high levels IFN but have more 
severe pathology, such as HPAI H5N1. 
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Chapter 7 General discussion 
 
7.1 Emergence of a new pandemic- swine origin H1N1 influenza 
 
March 2009 saw the emergence of the first pandemic of the 21st century. The 
work in this thesis has concerned two aspects of influenza research that are 
pertinent to the emergence of this pandemic. Firstly, the acknowledgment that 
novel vaccine substrates are required in order to meet the global needs for 
pandemic vaccination policy. The PER.C6 cell line is one of a number of cell 
lines that might be part of this new wave of vaccine substrates  and it has been 
important to evaluate their usefulness for the propagation of a range of 
influenza strains, also as a vehicle in which recombinant influenza vaccine seeds 
might be generated quickly and efficiently. Secondly, we need to understand 
how severe the consequence of the new pandemic will be. The viral factors 
that determine pathogenicity of influenza strains are not completely elucidated 
but the induction of host cytokine response is one of the foremost mechanisms 
by which some viruses appear to display increased virulence. The second part 
of this thesis aimed towards understanding the molecular basis of high cytokine 
induction by naturally occurring variants of influenza virus and may indeed be 
directly relevant for predicting the biological outcome of the H1N1 swine 
influenza viruses. 
 
The new H1N1 2009 pandemic virus originated not from the much anticipated 
highly pathogenic H5N1 avian influenza, but from a classical swine influenza 
virus. Thanks to extensive prepandemic planning, the UK has a large stockpile 
of the antiviral drug oseltamivir (Tamiflu) and despite several isolated cases the 
virus largely remains sensitive to this drug (http://www.thelancet.com/H1N1-
flu/egmn/0c03a65d). However, prophylaxis is clearly preferable to treatment. 
In contrast to previous pandemics, we possess the knowledge and technology 
to respond quickly and an H1N1 vaccine will hopefully be available before the 
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winter season (in the northern hemisphere) when the potential for more 
sustained transmission will increase (Lipsitch and Viboud 2009). The threat of 
an HPAI pandemic has lead to the foundation of sleeping contracts with 
vaccine manufacturers by many governments worldwide. However, these 
agreements are complex and may only be activated once WHO pandemic alert 
level 6 is reached. Furthermore, the ability to deliver the vaccine to a country 
will be dependent on the number of other countries which activate their 
contracts and the relative scale of each. This, and the desire to assuage public 
anxiety, may explain why WHO was reticent to raise the pandemic alert level 
to 6 despite widespread transmission in several countries on different 
continents in late May and early June. The UK has two, now active, contracts 
for 72 million doses from Baxter of a whole, inactivated Vero cell culture 
derived vaccine, and 60 million doses from GSK of egg grown, split vaccine 
(http://www.thelancet.com/H1N1-flu/egmn/0c03a65d). Both vaccines will be 
given as a 2 dose regime of a prime followed by boost, since the main target 
groups (under 60 years of age) are expected to be immunologically naive to 
the H1 antigen. In addition, the immunogenicity of the vaccines will be 
enhanced by their formulation. Whole virion preparations have an 
immunostimulatory effect compared to split vaccine (Geeraedts, Bungener et 
al. 2008). Otherwise they will be given in conjunction with novel adjuvants 
such as MF59 (Radosevic, Rodriguez et al. 2008; Banzhoff, Gasparini et al. 
2009) or AS03 (Leroux-Roels, Borkowski et al. 2007; Sambhara and Poland 
2007). In our own work with an H5 vaccine prepared in the PER.C6 cell line, 
the immune response was greatly enhanced by a proprietary adjuvant (a 
double oil emulsion of 2% Montanox-80) (Koudstaal, Hartgroves et al. 2009). 
In human trials with an H7N1 prepandemic vaccine prepared in the PER.C6 
cell line, the use of alum adjuvant was essential to enhance the otherwise 
rather low response in naive volunteers (Cox, Madhun et al. 2009). Influenza 
vaccines generated in the PER.C6 cell line are still at the clinical trial stage, so 
the cell line was not certified for vaccine production during the current 
pandemic. The ability of PER.C6 to generate vaccine seed in the same substrate 
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as vaccine production and the high vaccine yields, shown in this thesis, would 
have made them an ideal substrate. 
 
7.2 Swine-origin influenza flu vaccine  
 
Once the severity of the current outbreak became clear, reference labs across 
the globe began generating vaccine seeds. Five seeds have, as of August 09, 
been approved by WHO. These have been generated by both classical 
reassortment (IVR-153, NYMC X-179a) and by reverse genetics, (IDCDC-RG15, 
NIBRG-121, CBER-RG2) 
(http://www.who.int/immunization/sage/4.Zhang_SAGE_vaccine_virus_reagen
ts_-_Final.pdf). NIBSC, the UK institute responsible for generating vaccine seeds 
for Europe, along with the other labs attempting to make vaccine candidates 
encountered some technical difficulties with the gene cloning step 
(http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1245138053330). The 
use of synthetically derived sequences (as discussed in chapter 4) could 
potentially have overcome the problems encountered with cloning. In the 
present outbreak, our lab encountered delays in the delivery of ordered 
sequences due to the sudden high demand for the service, however reference 
laboratories might in the future hold sleeping contracts with gene synthesis 
companies, whereby the required sequences can be prioritised, and synthesised 
within days of submission.  
 
7.3 Poor growth of vaccine seeds  
 
Some of the reassortant and recombinant swine influenza strains vaccine seeds 
generated (x179a, CBER-RG2, NIBRG-121) were reported to grow poorly in 
either eggs or cell culture; yields were approximately 50% less than expected 
for H1N1 component of the seasonal vaccine  
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(http://www.who.int/immunization/sage/4.Zhang_SAGE_vaccine_virus_reagen
ts_-_Final.pdf). A serial passage derivative of NIBRG-121, NIBRG-121xp, has 
shown a 4 fold improvement in yields. Since we have shown that vaccine seeds 
can be generated and propagated in PER.C6 this adaption may not have been 
required, meaning high growth recombinants might have been available for 
production pipelines earlier.  
 
The most commonly used donor strain for inactivated influenza vaccine is 
A/PR/8, which was selected for its high growth characteristics in eggs. Recent 
clinical trial data (Kistner, Howard et al. 2007) and unpublished data for a 
wild type swine origin influenza vaccine (A/California/7/09)  
(http://www.who.int/immunization/sage/4.Zhang_SAGE_vaccine_virus_reagen
ts_-_Final.pdf) suggest that yields with wild type strains can be higher than 6:2 
recombinants in Vero cells. The use of wild type strains for seasonal vaccine 
manufacture is being investigated. However, these are subject to seasonal 
variability in growth characteristics, and will also require more rigorous 
containment. An alternative would be to develop a high growth strain adapted 
for high growth in cell culture, based either on a cell passaged derivative of 
A/PR/8 or an entirely different strain. Indeed, experience with PER.C6 cells 
suggests that an H3N2 virus may be a more suitable backbone (as discussed in 
chapter 3). During the 2006/7 vaccine season, the reassortant of the H3N2 
strain, A/Wisconsin/67/2005 which grew best in PER.C6 cell culture (X116) 
actually contained 7 genes from the seasonal strain and only one gene, (M), 
from the A/PR/8 donor. Reverse genetics could be used in the future to map 
which „wild type‟ genes confer the increased growth advantage to X116 in 
PER.C6 and perhaps stably utilize their genotypes as a novel vaccine backbone. 
The chief obstacle in developing a cell culture adapted donor strain is the wide 
selection of cell culture substrates that are being developed. It is unlikely that 
the reference labs would be willing to generate more than one reference strain, 
nor the pharma companies willing to incur the costs of having their preferred 
donor incorporated. Furthermore, regulatory bodies may also be reticent to 
approve multiple reference strains. However, improvements in vaccine yield 
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will not only be more cost effective for the manufacturer but also allow more 
doses of vaccine to be generated. This is still more important during a 
pandemic, when vaccine is in high demand. The choice of the „universal 
backbone‟ for influenza vaccine seeds in the future will require careful 
negotiations and open mindedness from manufacturers and regulators alike. 
 
7.4 Pathology of disease 
 
There are now more than 150,000 confirmed cases and more than 1,000 
deaths, in 168 countries resulting from infection with swine origin H1N1 virus, 
and all continents are affected (WHO). The infection is associated with mild or 
moderate clinical signs but an increase in morbidity has been noted compared 
to seasonal influenza  
(http://www.ecdc.europa.eu/en/files/pdf/Health_topics/090731_Influenza_A(H
1N1)_Analysis_of_individual_data_EU_EEA-EFTA.pdf). Virus shedding in ferrets 
was equal (Maines, Jayaraman et al. 2009) or slightly higher (1.5 fold) 
(Munster, de Wit et al. 2009) than seasonal influenza depending on the study. 
However, in all cases the virus replicated efficiently in both the upper and 
lower respiratory tract of ferrets. The disease was associated with lesions in the 
lower respiratory tract and virus was detectable in the lungs (Munster, de Wit 
et al. 2009) which correlates with a cough as a prevalent symptom in human 
infection (Novel Swine-Origin Influenza A Virus Investigation Team 2009). 
Although the virus is currently not as virulent, one of the possible contributions 
to the severity of the 1918 virus was the tropism to both the upper and lower 
respiratory tract. Infection of the upper respiratory tract facilitated 
transmission; it has been suggested lack of replication in the upper respiratory 
tract is a factor contributing to the restriction of H5N1 virus transmission 
(Shinya, Ebina et al. 2006; van Riel, Munster et al. 2006). However, 
replication in the lower respiratory tract has been correlated with higher 
pathogenicity (Watanabe, Watanabe et al. 2009).  
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In Britain, the number of cases has increased such that testing of all influenza 
like illness (ILI) is impossible and deemed unnecessary, and has now been 
superseded by estimates based upon the numbers of people consulting their 
GPs. There is no information relating the proportion of pandemic (H1N1) 2009 
cases who consult their GP. A telephone helpline The National Pandemic Flu 
Service (NPFS) will have reduced the proportion of pandemic (H1N1) 2009 
cases who consulted their GP. However, it is thought, that this proportion is 
likely to lie within the range 20% to 50% based on seasonal influenza 
(http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1248940851283), and 
a website set up to monitor the activity of ILI in the population through the 
internet (www.flusurvey.co.uk) also generates estimates within this range. 
Interestingly reporting levels are still lower than the peak during the winter 
08/09. 
 
Bearing this in mind 110,000 new cases per week were estimated in England at 
the beginning of August 2009. Children and young adults still seem to be the 
most affected and this is a profile that has been noted for previous pandemics‟ 
of the 20
th
 century including the notorious 1918 (Lipsitch and Viboud 2009). 
To date in the UK, there have been more than 30 deaths, ~800 hospitalised 
patients. It is too early for information on human pathology, particularly 
cytokine profiles to be published but initial accounts suggest that swine origin 
pandemic H1N1 virus is not particularly virulent and does not elicit extreme 
responses such as the cytokine storm induced by H5N1 and 1918 type viruses. 
Cytokine arrays are to be performed on hospitalised patients with severe 
disease; this may provide information on the pathology of the virus, but may 
also be skewed by variability in patients‟ immune response. Hospitalisation can 
be caused by two factors, patients may be either genetically predisposed or 
have pre-existing conditions such as asthma or pregnancy, which can result in 
severe illness; alternatively they may become infected with a more virulent 
strain of the virus. Sequencing is being performed on all  cases admitted to St. 
Mary‟s hospital, London. Aside from mutations universally occurring in severe 
cases, virally encoded virulence markers will be anticipated. Of the sequences 
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available to date, the virus does not contain these markers which could infer 
the emergence of a more dangerous strain. Using the knowledge acquired from 
virulent strains, particularly 1918 and HPAI (H5N1, H7N1), as benchmarks key 
virulence factors have been identified. These viruses often displayed both 
increased viral titres in vitro and in vivo (Hatta, Gao et al. 2001; Tumpey, 
Basler et al. 2005; Watanabe, Watanabe et al. 2009) that  have been 
associated with the polymerase complex (Rolling, Koerner et al. 2009). In 
H5N1, this has been attributed to the presence of a lysine at position 627 in 
place of glutamic acid on PB2. Another virulence factor associated with 1918 
influenza, is the presence of a full length protein from an alternative reading 
frame of PB1, PB1-F2, encoding the mutation in N66S (Conenello, Zamarin et 
al. 2007). 1918 PB1-F2 has also been associated with increased inflammation 
which rendered the patient more susceptible to secondary bacterial infections 
which were particularly prevalent in the 1918 pandemic (McAuley, Hornung et 
al. 2007). Secondary bacterial infection has been proposed as a factor for the 
increased severity seen in Mexico (Perez-Padilla, de la Rosa-Zamboni et al. 
2009). The increased replication of 1918 virus in the lungs, which appears to 
have been a contributing factor to the pathogenicity of the virus has also been 
linked to the polymerases (Watanabe, Watanabe et al. 2009). Fortunately, 
sequencing gazing suggests that the circulating 2009 pandemic  H1N1 swine 
influenza has a very truncated F2, and requires the reversion of 2 stop codons 
for full length protein expression to be regained, thus the likelihood of it 
acquiring a more virulent form through mutation alone is low. However, this 
virus could equally reassort with other circulating human seasonal viruses, and 
pick up more virulent polymerase genes.  
 
HPAI and 1918 viruses display high virulence associated with hypercytokinemia, 
(Tumpey, Garcia-Sastre et al. 2005; de Jong, Simmons et al. 2006; Kobasa, 
Jones et al. 2007; Basler and Aguilar 2008). Although no information relating 
to cytokine storms and their role in the severity of disease associated with the 
current pandemic has been published, infection of pigs with swine origin H1N1 
influenza suggest that the IFN response may play a role in the pathology 
  
227 
 
(Barbé, Saelens et al. 2009). Work presented in this thesis suggests that there is 
a correlation between increased polymerase activity and cytokine induction, 
and this has also been associated with severe pathology by H5N1 in the avian 
model (Suzuki, Okada et al. 2009). Although the mechanism have yet to be 
fully clarified, the data suggests that destabilisation of the polymerase genes 
may result in the generation of defective RNAs which induce cytokines to 
which the viruses have evolved resistance.  
 
The mutation in swine origin H1N1 that could have the most impact on our 
public health policies is the acquisition of resistance to Tamiflu. Previously the 
resistance acquired through mutation of amino acid 275 from histidine to 
tryptophan, has been associated with attenuation of the virus (Meijer, 
Lackenby et al. 2009). However, recent seasonal H1N1 viruses have acquired 
subsequent mutations which compensate this and they replicate as well as 
Tamiflu susceptible viruses. Worryingly, although the majority of the swine flu 
isolates do not have the Tamiflu resistance mutation they do have the 
associated mutations which suggest that the virus will not be attenuated if they 
are acquired (Rameix-Welti, Enouf et al. 2008). 
 
These virulence determinants can be picked up by pyrosequencing. However, 
other unknown mutations may also arise which result in a similar phenotype. 
The techniques described in this thesis provide a useful panel with which to 
analyse viruses isolated from severe and fatal cases and determine quickly and 
easily whether any viruses display a different phenotype. Moreover, the 
techniques could be adapted to could include analysis of other important 
cytokines such as TNF-α, IL-6 and those associated with apoptosis such as 
CCLR5 (RANTES) (To, Chan et al. 2001; Tyner, Uchida et al. 2005; Zhou, Law 
et al. 2006) and caspase-1 (Allen, Scull et al. 2009). Monitoring of these 
features may help to reveal whether the virus is evolving and whether this 
correlates with a shift from the current mild symptoms to more severe 
pathology. 
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Use of reverse genetic will allow the contribution of each gene segment to the 
severity of disease to be assessed, and  clarify why this virus is different to 
either the TRIG (triple reassortant) swine influenza which has circulated in pigs 
for the last decade (Shinde, Bridges et al. 2009) or other virus which 
transmitted from pigs to humans (Yassine, Khatri et al. ; Vincent, Swenson et al. 
2009) but did not results in sustained human to human transmission.  
 
The pathology of disease can be considered a balance between transmissibility 
and pathogenicity, a virus that kills its hosts or incapacitates them may not be 
optimally transmissible (Morens, Taubenberger et al. 2009). Some viruses such 
as A/Sydney/97 virus are somewhat resistant to the IFN-β they induce 
(Hayman, Comely et al. 2006), whilst other strains rely on antagonism. These 
differences could have important implications for the pathology of disease. 
 
The consequences of globalisation; increased air travel and free movement 
between countries and continents mean viruses are able to spread with 
increased ease throughout the world. Nevertheless, we are also better 
equipped than ever before to deal with the effects of a pandemic. It is too 
early to say whether sufficient vaccine doses will be produced in time or 
indeed whether the pandemic will reach the scale that has been forecast 
(Fraser, Donnelly et al. 2009). However, a new era of influenza vaccine 
production in cell culture is coming to the fore which means together with 
reverse genetic derived seeds, in the future vaccines will be available more 
readily and the terrible consequences of previous pandemics may be averted.  
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